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Abstract 
Introduction: Neural degeneration of the retina has been demonstrated in diabetes 
mellitus (DM). Several studies have focused on retinal neural function in diabetic 
retinopathy (DR) but few have assessed function in diabetic maculopathy, the 
leading cause of visual disturbance in DM. 
Aim: To correlate, cross-sectionally and longitudinally, central macular function to 
diabetic maculopathy. 
Methods: Treatment-naïve subjects with DM were recruited to three groups: i) 
diabetic controls (no visible signs of DR); ii) early maculopathy (maculopathy not 
meeting criteria for clinically significant macular oedema (CSMO)); and iii) sight-
threatening maculopathy (presence of CSMO and/or ischaemic maculopathy). A 
group of healthy controls was also recruited. Subjects underwent assessment of 
best correct visual acuity (BCVA), contrast sensitivity (CS), optical coherence 
tomography (OCT), microperimetry (MP), multifocal electroretinography (mfERG), 
oscillatory potential (OP) and systemic risk factors (HbA1c, serum cholesterol and 
blood pressure). Subjects with DM were invited to follow-up at 6 months and 12 
months where assessments were repeated. One-way ANOVA and ANCOVA were 
used for cross-sectional and longitudinal analysis, respectively (SPSS, Version 22). 
Results: Eighty-nine subjects with DM (diabetic controls, n=24; early maculopathy, 
n=24; sight-threatening maculopathy, n=41) and 29 healthy controls were recruited. 
Compared to both healthy and diabetic controls, subjects with sight-threatening 
maculopathy showed significant worsening in CS (10-15% reduction, p<0.01), MP 
central ring sensitivity (23-29% reduction, p<0.01), mfERG central ring amplitude 
(45% reduction, p<0.01), mfERG implicit time (7% prolongation, p<0.01) and OP sum 
amplitude (35% reduction, p≤0.01), and a 20-25% increase in mean central subfield 
thickness(CSFT) on OCT (p<0.01). Subjects with early maculopathy showed a trend 
towards worsening in mfERG amplitude (23% reduction, p<0.05), CS (7% reduction, 
p<0.05) and MP sensitivity (p=0.06) compared to healthy controls. Function was 
non-significantly reduced in diabetic controls compared to healthy controls. Sixty-
one subjects were invited for follow-up, with 39 and 31 subjects attending at 6 and 
12 months respectively. At 12 months, there was a trend towards worsening OP 
sum amplitude (p=0.03); conversely, MP sensitivity improved (p<0.01). There were 
no significant or trend associations with other assessments, most notably best 
corrected distance visual acuity. There was no correlation between change in mean 
central subfield thickness on OCT and change in mfERG, MP and OP (p>0.10 for all 
comparisons). 
Conclusions: Central macular function is reduced in diabetic maculopathy despite 
reasonable visual acuity. Assessment of neural function alongside clinical 
examination may provide the clinician with a clearer picture of central macular 
status and aid in clinical decision making.
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Chapter 1 - An introduction to 
diabetes mellitus and diabetic eye 
disease 
Diabetes mellitus refers to a group of conditions where impairment in glucose 
metabolism results in elevated blood glucose levels. This results in micro- and 
macrovascular complications affecting multiple organs, one of them being the 
retina. In this introductory chapter I will review the history behind diagnosing 
diabetes mellitus and the features of diabetic eye disease. 
1.1 History of diabetes mellitus pre-17th century 
The earliest recorded description of diabetes mellitus (DM) appears to come from 
Ancient Egypt.1 A physician named Hesy-Ra produced the Ebers Papyrus, a treatise 
on therapeutics, somewhere between 300 and 1500BC. He refers to a ‘sugar 
disease’ in which polyuria appears to be a common symptom.1,2 The Ebers Papyrus 
mentions a specific treatment of polyuria:  
‘A measuring glass filled with Water from the Bird pond, Elderberry, 
Fibres of the asit plant, Fresh Milk, Beer-Swill, Flower of the Cucumber, 
and Green Dates. Urinary troubles in the adult were also corrected with 
rectal injections of olive oil, honey, sweet beer, sea salt, and seeds of the 
wonderfruit’.3  
Susruta, a physician from India, appeared to make the first clinical diagnosis of DM 
when he reported honey urine, madhumea, seen in stout Hindu patients in India.1,4 
However the date of this description ranges from anywhere between 1000 BC and 
6th Century AD.1 Another Indian name for a condition resembling DM was ‘prameha’ 
meaning urinary flux.5 Other Hindu physicians, including Charaka and Vaghbata, 
described these findings along with observing how ants and flies were attracted to 
the urine of patients with these symptoms.3 
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In ancient Greece, Hippocrates described some signs and symptoms suggestive of 
DM, mentioning a disease of excessive urinary flow and wasting of the body.3 A 
disciple of his, Galen, described a condition with features of “diarrhoea of the urine” 
and “the thirsty disease”, and hypothesised this condition originated from the 
kidney.1,3 His compatriot, Aretaeus of Cappadocia, an eminent physician of the 
Pneumatic School, introduced the term ‘diabetes’, δίαβnrηs, adapted from the 
Greek word δίαβαίvω, the verb for passer through.1,2,6 He recognised the chronicity 
of this condition and he provides a comprehensive description of a condition where 
there is   
‘...a moist and cold wasting of the flesh and limbs into urine...The 
patients never cease making water...The disease is chronic in nature, 
and is slowly engendered, though the patient does not survive long when 
it is completely established...’ 1,3 
Though ancient practitioners noted that insects were attracted to the urine of some 
individuals they never linked this finding to the other features of polydypsia and 
polyuria.1,2 Avicenna, the Arabian ‘Prince of Physicians’, and Rhazes described the 
condition, its features and its treatment in their books Canon and Liber Continens, 
respectively. They recognised that the urine smelt and tasted sweet through the 
observation that wasps, flies and ants were attracted to the urine of sufferers.2,4 
Indeed ‘water tasters’ were used to taste the urine of individuals suspected of 
having diabetes. The discovery of the sweetness of urine led to the Latin word 
‘mellitus’ (meaning honey) being added to the term diabetes.1,5 At a similar time, 
Moses Maimonides, a rabbi, physician and philosopher, hypothesised that the 
‘sweet waters of the Nile and the prevailing heat’ caused DM.3 
Other features established in ancient times included excessive dry skin, reduced 
secretions and repeated infections (boils, carbuncles) with children dying quickly 
and adults developing devastating complications.1  
Initial remedies were based around dietary recommendations (bear meat, diluted 
wine, herbs and grains) with no obvious basis for their implementation. Venesection 
was performed to reduce blood flow to the kidneys and so reduce their burden of 
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work. Other methods employed included avoidance of sex (to suppress 
overabundance of urine), bareback horse riding (as recommended by Avicenna in 
the 10th-11th Century AD to ‘employ friction and alleviate excess urination’), and the 
use of opiates, tepid baths and drinking wine in the later stages of the disease. In 
the 1300s purgatives and astringents were prescribed by physicians to relieve 
polyuria and strain on the kidneys.1 
The causative organ in DM was elusive in the first half of the second millennium 
with the kidneys, blood, liver and the stomach deemed as the culprits. It was only in 
the 16th century when Paracelsus, a Basel Physician, recognised DM to be a serious 
general disorder, though the cause remained uncertain. He evaporated urine to 
leave behind a substance he thought was salt but was likely to be glucose.2 
Paracelsus led the Renaissance physicians who introduced science into the 
understanding of medicine. They challenged authority and undertook scientific 
studies to understand anatomy and bodily functions.3 However, the management of 
DM underwent little progress; for example dietary suggestions included foods high 
in fat and carbohydrate content, reflecting the poor understanding of the 
condition.1 
1.2 Diabetes mellitus between the 17th and early 19th century 
The first mention in European medical literature of ‘sugar in urine’ was in the 17th 
Century.1 A British physician, and sometime Sedleian Professor of Natural 
Philosophy at Oxford, Thomas Willis (1621-1715), tasted the urine of a patient and 
noted its sweetness in his celebrated book ‘Pissing Evil’.1,2,4,5 He also proposed that 
glycaemia, the presence of glucose in blood, preceded glycosuria in DM.3 He 
recommended a diet consisting of milk, bread and barley water, i.e. one that was 
high in carbohydrates but low in calories. Twenty years later he appears to have 
changed his mind and suggested a high fat, high protein and low carbohydrate diet. 
However there was once again little progress for another century.1 
In the 1770s Dr Matthew Dobson of Liverpool Infirmary confirmed Willis’ findings 
and theories by discovering the presence of sugar in the bloodstream, suggesting a 
systemic disease.2 He heated ‘two quarts of urine to dryness’ and noted a 
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granulated residue that smelt like brown sugar.3 He also noted that in patients with 
diabetes their kidneys appeared to filter a considerable amount of “saccharine 
matter”.2 He presented his findings to the Medical Society of London in 1776.3 
Twelve years later a researcher called Thomas Cawley correlated the presence of 
DM with the discovery of a ‘shrivelled pancreas’ when performing an autopsy on a 
patient with DM. This finding, however, went unheeded and a general surgeon, 
John Rollo, placed further emphasis on the stomach being the culprit in 1796. His 
theory was based on his observations of a diet high in meat being associated with 
reduced glycaemia, whilst bread, fruits and grain resulted in increased sugar 
production. These findings were corroborated by French Physician, Apollinaire 
Bouchardat, in 1870 who noted that soldiers with DM had reduced glycosuria when 
food was rationed during the Franco-Prussian War.1 Other causes of DM suggested 
at the time included drinking cold water when one was hot, drinking excess alcohol, 
suffering from excessive anxiety, or as a direct result of a physical assault. 
During the 19th Century the management of DM was based on the stringent 
attention to diet. The aim was to avoid foods containing sugars and starch and 
consuming meat and green vegetables. Unfortunate individuals were denied staple 
foods such as potatoes, carrots, peas, bread and pasta. Some were allowed bran 
cakes in place of bread. They were allowed non-stimulating beverages such as tea, 
coffee, soda and water, but were denied lemonade, sweet wines and sweet ales. It 
was also suggested that drinks were to be taken warm to alleviate the craving for 
liquids. Other treatments included the use of opium given as compound soap pills 
to reduce urine production, phosphoric acid, bromide of potassium and nitrate of 
uranium. Extract of ergot was offered, and so was a skimmed milk diet which 
consisted of six pints of skimmed milk per day as the only form of nourishment for 
six consecutive weeks with animal food allowed after that. Relief from this strict 
diet included a warm bath once or twice weekly or a Turkish bath.1 
1.3 Diabetes mellitus from the mid-19th century onwards 
The understanding of the pathophysiology of DM developed rapidly in the latter 
half of the 19th Century. Claude Bernard hypothesised the role of the liver in 
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glycogen storage and glucose production early in that century through his work on 
animal glucogenesis. He isolated ‘glycogen’ from the liver, thus paving the 
understanding of the role of the liver in DM. He considered the overproduction of 
glucose to be the cause of DM.1-3  
In 1880 a French physician, Lancereaux, identified two variants of DM. He labelled 
them as ‘maigre’ (thin) and ‘gras’ (fat). This paved the way to linking obesity to 
excess sugar intake and the identification of type 2 DM.5  
In 1869 Paul Langerhans identified the presence of islet cells in the pancreas whilst 
still a medical student.1,2 However he died in 1888 before he could explain their 
significance. The following year two Germans, Joseph von Mering and Oscar 
Minkowski, identified the pancreas as the essential organ in glucose metabolism 
and thus to be the major organ in DM. They showed that a dog developed DM 
following removal of the pancreas.2 In 1893 a French doctor, Gustave Laguesse, 
suggested the role of the islet cells of the pancreas in DM and named them the 
‘Islets of Langerhans’ after their discoverer. He hypothesised that the product 
released by these cells is important in controlling blood glucose levels and a lack of 
this product leads to DM. Thus the concept of type 1 DM was realised. 
Clinicians were also gaining a greater understanding of the disease. The ‘great loud 
breathing’ was identified by Kussmaul to be an indicator of severe metabolic 
imbalance due to uncontrolled blood sugar levels.2 Following this knowledge, 
Naunyn and Magnus Levy insisted that in the absence of carbohydrates the body 
imperfectly metabolised fats resulting in the formation of ketones and acids that 
are now synonymous with the life-threatening condition of diabetic ketoacidosis.2 
Naunyn recognised that sugar-free urine was associated with greater sugar 
tolerance and so recommended a diet that was reduced in carbohydrates and 
calories.2  
1.4 The discovery of insulin 
Across the Atlantic Ocean, an American vivisectionist, Moses Barron, identified that 
the islet cells were damaged in patients with DM and suggested the product 
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secreted from these cells could be used for treatment.1 This product was named 
‘insuline’ after the Latin word insula, meaning island, by the English physiologist, Sir 
Edward Albert Sharpey-Schafer, in 1910.1 After several failed attempts to extract 
insulin, Zuelzer isolated insulin and used it to treat humans. However he had 
encountered several alarming side-effects and so abandoned treatment.2  
Eventually a group from the University of Toronto achieved success. In 1922 
Frederick Banting, Charles Best and John Macleod isolated insulin from dogs and 
they were able to inject it into dogs with diabetes to control their 
hyperglycaemia.1,2 However this insulin was not suitable for human use. They 
recruited a biochemist, James Collip, and together were able to extract a suitable 
sample of insulin from cattle. The first individual to receive this treatment was a 14 
year old boy named Leonard Thompson, who lived a reasonable life until his early 
death from pneumonia at the age of 27. Their hard work culminated in the Nobel 
Prize in 1923 in Physiology and Medicine.1 
Once isolated, the structure of insulin was studied. John Jacob Abel identified its 
crystalline structure in 1926, contributing to the understanding of protein 
chemistry.3 In 1958 Frederick Sanger was awarded the Nobel Prize in Medicine for 
his work in defining the exact amino acid sequence of insulin. 
1.5 The insulin revolution 
Prior to insulin, the only treatment was a diet with limited carbohydrates. Mortality 
was high amongst these patients with few surviving to marriage or procreation.2 
Insulin offered sufferers hope in their fight against this wasting disease. A nurse 
describes the atmosphere at the time: 
‘...the mere illusion of new hope cajoled patient after patient into new 
life...it was a resurrection, a crawling stirring, as of some vague 
springtime’ 7 
Insulin was first produced in Britain in 1923 after several trials and risk assessments. 
Animal insulin was the mainstay of insulin treatment till the 1980s when 
synthetically manufactured human insulin was made available.1,3 The 20th Century 
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revolutionised the management of DM through a greater understanding of the 
pathophysiology of DM, the introduction of various types of insulin, the 
introduction of oral hypoglycaemic agents and greater flexibility available to 
patients in managing their DM.7 With more sufferers living to an older age and an 
increasing prevalence of DM, future treatments are being aimed towards the early 
identification of the disease and eventually towards its elimination. 
1.6 Early association between diabetes mellitus and eye disease 
The first clinician to link eye disease to DM was the French ophthalmologist and 
Professor of Hygiene in Paris, Appolinaire Bouchardat, in 1846.6,8 He noted that 
patients with diabetes complained of visual symptoms in the absence of anterior 
segment pathology or cataract and their symptoms improved with better control of 
their blood sugar levels. His observations were also described by François Tavignot. 
Neither clinician was able to corroborate their observations to clinical findings or 
histopathological specimens.6,8 
The invention of the ophthalmoscope aided clinicians in assessing the posterior 
segment of the eye.6 Early ophthalmoscopes were complicated and were difficult to 
use in examining the fundus. In 1855, Jaeger (1818-1884) observed abnormalities in 
the macula that he attributed to DM and used a meticulous approach to recording 
the smallest details in his clinical findings (Figure 1.1). 
In one patient he identified “roundish or oval, yellowish spots and extravasations 
that permeated part or the whole thickness of the retina”.8 His diagrams were used 
to produce a colour atlas of 21 fundus paintings, taking 20 to 40 clinical sessions per 
patient to detail his illustrations.6 However Albrecht von Graefe (1828-1870) and his 
contemporaries disputed these findings, citing that there was no proof of a cause-
effect relationship between DM and retinal complications. Jaeger’s one supporter 
was Louis Desmarres who published a small report in 1858.6,8 
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Figure 1.1: (a) The first fundus drawing of diabetic macular changes was published 
by Eduard Jaeger in the middle of the 19th century. (b) Vascular sheathing and 
dilatation, intraretinal haemorrhages as well as “hard” and “soft” exudates can be 
observed. (From: Jaeger E. Beitr zur Pathol des Auges. Wien: 1856, p. 33 Fig. 12).8 
 
 
 
 
 
 
 
 
 
 
 
A decade later, in 1869, Henry Noyes (1832-1900) published an article (‘Retinitis in 
glycosuria’) supporting the link between DM and abnormalities in the macula.6,8 In 
1872, Edward Nettleship (1845-1913) provided further strength to the role of DM in 
the development of eye disease when he presented histological proof of cystoid 
macular degeneration in diabetic patients in his seminal paper ‘On oedema or cystic 
disease of the retina’.6 In 1877 he published further findings in collaboration with Sir 
Steven Mackenzie on the abnormal retinal changes in diabetes in the report 
‘Glycosuric retinitis’ (Figure 1.2).8  
Around the same time Bouchardat published his book ‘De la glycosurie ou diabète 
sucré’, in which he described the presence of fluid and lipid accumulation within the 
macula resulting in ‘glucose-induced amblyopia’ (Figure 1.3).8 In addition a German 
ophthalmologist, Theodor Leber, published a series of his clinical observations 
which he termed ‘glycosuric retinitis’.8  
The diagnosis of proliferative diabetic retinopathy (PDR) appeared at a similar time. 
Wilhelm Manz published his seminal paper, ‘Retinitis Proliferans’ in 1876. He 
Fig 1.1b Fig 1.1a 
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presented drawings of vitreoretinal adhesions, fibrovascular proliferation and 
degeneration of the optic disc (Figure 1.4).  
Figure 1.2: (a) First published drawing by Sir Steven Mackenzie and Edward 
Nettleship of a retinal microaneurysm in a histopathological specimen from a 
diabetic patient (From Mackenzie and Nettleship, Roy Ophthal Lond Hosp Rep, 
1877). (b) Edward Nettleship F.R.S. (1845–1913) published the first report with 
histopathological proof of diabetic changes in the retina in 1872. (From: The History 
of Moorfields Eye Hospital, London, 1929).8 
 
 
 
 
 
 
 
 
 
Figure 1.3: Fundus drawing of a right eye showing advanced diabetic maculopathy. 
Note the presence of a large plaque of exudates (B,C) in the macula as well as 
several small haemorrhages (C). (From: A Bouchardat “De la glycosurie ou diabète 
sucré”, Paris, 1875).8 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.2a Fig 1.2b 
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Figure 1.4: First published drawings of fibrovascular proliferations along the blood 
vessels in a case of proliferative diabetic retinopathy by the German 
ophthalmologist Wilhelm Manz. (From W. Manz, Retinitis proliferans, Graefes Arch 
für Ophthalmol, 1876;22, 229). 8 
 
 
 
 
 
 
 
The earliest classification of PDR appeared in 1890 with Julius Hirschberg dividing it 
into four broad groups: retinitis centralis punctuate, haemorrhagic form, retinal 
infarction and haemorrhagic glaucoma.6,8  
The link between clinical findings and pathology was advanced by Arthur James 
Ballantyne (1876-1954) in the early part of the 20th Century (Figure 1.5).6,8 Upon 
retirement he dedicated his time to understanding the microvascular changes 
associated with diabetes. He demonstrated abnormalities in the capillary wall, 
which we recognise today as loss of the inner blood retinal barrier, that result in the 
leakage of fluid and exudates into the various layers of the retina.8 This paved the 
way in our understanding of diabetic maculopathy. I explore this further in Chapter 
2. 
 
 
 
 
 
 11 
 
Figure 1.5: Arthur James Ballantyne (1876–1954) chaired the ophthalmology 
department of the University of Glasgow. He published his most important work 
very late in his academic career. 
 
 
 
 
 
 
1.7 Use of lasers in managing diabetic eye disease 
With the identification of diabetic retinopathy and maculopathy, focus turned to 
the treatment of these conditions. Paradoxically, the discovery of insulin led to 
improved survival and increased numbers of patients developing diabetic eye 
complications.8 The observation of the damaging effects of a solar eclipse on the 
retina prompted the German ophthalmologist, Gerhard Meyer-Schwickerath (1920-
1992), to research the role of light in the treatment of retinal disorders (Figure 
1.6a).6,8  He noted that the retinal scars produced were useful in treating retinal 
holes and tears. 
In 1949 he designed a device that was able to concentrate sunlight to a focal point 
on the retina, a photocoagulator. However there was limited control of delivery of 
treatment resulting in several excessively treated eyes and worsening vision. 
Eventually he was able to replace sunlight with xenon lasers developed by Zeiss 
Laboratories (Figure 1.6b).  
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Figure 1.6: (a) Gerhard Meyer-Schwickerath introduced the xenon coagulator to 
treat retinal diseases and thus laid the basis for the current use of laser therapy for 
diabetic retinopathy. (b) One of the first xenon coagulators used in the treatment of 
retinal disorders.  
 
 
 
 
 
 
 
Paul Wetzig and colleagues were the first to utilise light in a clinical setting in 
diabetic eye disease, using the xenon photocoagulator to destroy retinal blood 
vessels. However the wide beam of the xenon laser was not useful for treating small 
lesions and was often associated with poor outcomes. This was in part because in 
this period the common practice was to directly treat the proliferating vessels. Ruby 
lasers were then introduced into clinical practice by Christian Zweng and colleagues 
with some success.6 Once again these lasers were found to be useful for retinal 
tears but lacked the precision in treating diabetic vascular changes.  
1.7.1 Argon laser  
In 1966 Zweng and Francis L’Esperance recognised that argon laser was absorbed by 
blood vessels, unlike ruby lasers. Photocoagulation using argon lasers showed 
excellent results with up to 90% of patients maintaining vision in small clinical 
studies.9 Several years later the clinical effectiveness of these lasers in treating PDR 
was confirmed by William Beetham and Lloyd Aiello as they led a pivotal 
multicentre study, the Diabetic Retinopathy Study (see Chapter 3). One of the key 
breakthroughs was the recognition that indirect treatment to the retina produced 
better results compared to direct treatment of retinal vessels. 
Fig 1.6a Fig 1.6b 
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During this period ophthalmologists recognised that argon laser was useful in 
treating diabetic maculopathy though photocoagulation often resulted in poor 
outcomes due to foveal damage. As techniques were refined, several case reports 
and case series were published that demonstrated the beneficial effects of argon 
laser photocoagulation in treating diabetic macular oedema. In the early 1980’s, 
another multicentre study performed by the Early Treatment Diabetic Retinopathy 
Study (ETDRS) Research Group provided clinicians with conclusive evidence and 
guidance on using lasers in treating diabetic macular oedema (see Chapter 3).6,8  
1.8 Surgical treatment strategies 
The surgical treatment of PDR lagged behind laser treatment. Following the 
observation that the progression of PDR appeared to be delayed following pituitary 
necrosis in a patient, empirical hypophysectomy was performed in such patients in 
the late 1950’s.6 Though the operation was effective in 30% of cases, it was 
abandoned in favour of laser therapy.8 Robert Machemer introduced pars plana 
vitrectomy (PPV) for the treatment of vitreous haemorrhage secondary to PDR.6 The 
role of PPV was expanded to include the delamination of fibrovascular membranes 
which resulted from the proliferation of retinal neovascularisation into the vitreous 
humour.8 However no surgical strategies have been identified to successfully 
manage diabetic maculopathy.  
1.9 Summary 
I have briefly reviewed the history of DM and diabetic retinopathy. The rapid 
advances in our understanding of diabetic retinopathy and maculopathy have paved 
the way for developing treatment strategies that aim to minimise visual loss in 
individuals with this condition. In the next chapter I demonstrate the impact of 
diabetic maculopathy, summarise knowledge of macular anatomy and introduce 
the theories underpinning my research objectives. 
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Chapter 2 The impact of diabetes 
mellitus  
In this chapter I describe the socioeconomic impact of diabetes mellitus and 
diabetic eye disease. I describe the anatomy of the retina and the pathophysiology 
of diabetic eye disease, in particular diabetic maculopathy. I also introduce the 
neurodegenerative theory of diabetic retinopathy. 
2.1 The burden of disease 
Diabetes mellitus (DM) is a metabolic disorder affecting approximately 220 million 
people worldwide.10 It is estimated that the numbers affected will reach 365 million 
by 2030.11 In the UK there are 2.4 million people with DM with prevalence likely to 
exceed 4 million by 2025.12,13 
A cross-sectional study of subjects with DM, who attended the Liverpool screening 
programme, was performed to determine rates of diabetic eye disease in the local 
population.14 Point prevalence of DM was 12.4/1000. There were 149 subjects with 
type 1 DM, 40 with type 2 insulin requiring DM and 268 with type 2 non-insulin 
requiring DM. Rates of CSMO were 2.3%, 16.2% and 5.7% respectively, with an 
overall prevalence of 6.4%. Furthermore, 9.2% of subjects had exudates within 1 
disc diameter of the fovea or significant circinate maculopathy.   
Longitudinal studies have demonstrated that nearly all patients with type 1 DM and 
60% of those with type 2 DM develop some degree of diabetic retinopathy (DR) 
within 20 years of diagnosis.15 The prevalence of diabetic macular oedema (DMO) 
was low in the first five years following diagnosis of DM (0% and 3% in Type I and 
Type II respectively).16 This increased to between 20% and 30% of all patients with 
DM after 20 years.15-17 A longitudinal, prospective study of 133 subjects recently 
diagnosed with type 2 DM demonstrated that 21% of them developed signs of 
diabetic maculopathy and this was associated with a decrease in visual acuity 
(VA).18 Poor glycaemic control appeared to be the most important predictor.  
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Despite established screening programmes DR remains the leading cause of 
blindness amongst the working population.17-19 Approximately 2% of patients 
developed blindness after 15 years of suffering from DM, with another 10% 
developing visual impairment.20 Unfortunately this visual impairment is usually 
irreversible.21 
Diabetic eye disease can be divided into two broad groups – diabetic retinopathy 
(DR) and diabetic maculopathy. Diabetic maculopathy is the leading cause of visual 
impairment in patient with DM.15,18 Approximately half of all patients with diabetic 
maculopathy lose ≥2 Snellen lines of visual acuity (VA).22 Chronic maculopathy 
results in irreversible anatomical changes to the neurosensory retina and retinal 
pigment epithelium resulting in permanent visual impairment.22 
Quality of life studies have demonstrated the negative impact diabetic maculopathy 
has on the individual’s general and mental health.17 A population-based study in 
Sweden10 estimated the costs of treating DMO without and with proliferative 
diabetic retinopathy (PDR) to be €216 and €433 per patient per year, respectively, 
highlighting the economic burden of this condition. Hence the ability to diagnose 
and manage diabetic maculopathy prior to visual loss will benefit both the 
individual and the state. 
2.2 The normal macula 
The macula is the region of the retina designed for central vision, colour perception 
and visualising fine details.23,24 It comprises of the central 6mm of the posterior pole 
of the retina centred on the fovea. Histologically it is distinct from the surrounding 
retina by the presence of two layers of ganglion cells in the neurosensory retina. 
The macula can be divided into three zones. The central zone is the fovea, measures 
1500µm in diameter, and consists of the foveola (measuring 350µm in diameter). 
The fovea is designed for highest visual acuity. Surrounding the fovea is the 
parafovea which measures 2500µm in diameter. The zone from the outer edge of 
the parafovea to the outer edge of the macula is the perifovea.24 
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Cross-sectional imaging of the macula reveals a depression in the centre of the 
fovea, the foveal pit. In this unique structure the photoreceptors are tightly packed 
and their axons run obliquely. They connect to ganglion cells located around the 
foveola which themselves are arranged into a layer 6-8 cells thick. This arrangement 
ensures that light is not scattered by passing through other retinal layers and so 
maximal acuity is reached.25,26 
At the nasal edge of the macula lies the optic disc, a cross-sectional view of the 
distal end of the optic nerve. The optic disc measures on average 1800µm in 
diameter vertically and 1500µm horizontally, though post-mortem studies have 
shown the diameter of a normal optic disc to range from 900µm to 2600µm. The 
temporal edge of the optic disc lies approximately 3000µm nasal to the centre of 
the fovea.24 A more consistent measure of anatomical relationship is the distance 
between the centre of the fovea and the centre of the optic disc, which measures 
on average 3800µm, with a range of 3000 to 4500µm.  
2.3 Histology of the macula 
The retina can be histologically divided into the neurosensory retina and the retinal 
pigment epithelial layer. The neurosensory layer is composed of a network of neural 
cells that are responsible for transforming light energy into ‘electrical’ energy 
(photoreceptors) and then transmitting these electrical signals to the optic nerve 
(bipolar, horizontal, amacrine and ganglion cells) via the nerve fibre layer (NFL).25 
The neurosensory retina may be further subdivided into five layers reflecting the 
structures included within them. The outer nuclear layer (ONL) consists of the 
photoreceptors, i.e. the rods and cones, in particular their inner segments. The 
inner nuclear layer (INL) consists of horizontal cells, bipolar cells, amacrine cells and 
Müller cells. The ganglion cell layer (GCL) consists of ganglion cells and displaced 
amacrine cells. The outer plexiform layer (OPL) consists of the neural connections 
between photoreceptors and horizontal and bipolar cells. The inner plexiform layer 
(IPL) consists of neural connections between the bipolar and amacrine cells and 
ganglion cells.25 Optical coherence tomography (OCT) allows for visualisation of 
these retinal layers (Figure 2.1). 
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Figure 2.1: Cross-sectional image of the macula through the centre of the fovea, as 
generated by optical coherence tomography, to demonstrate the different retinal 
layers. The photoreceptor layers are now referred to as the ellipsoid zone (Image 
from Heidelberg website) 
 
Within the neurosensory layer are two capillary networks that supply the neural 
cells. In the human central retina, the innermost capillary plexus lies within the NFL 
and the outer plexus lies within the GCL. At the foveal slope there is only one 
capillary plexus which is located at the border of the GCL and IPL.27 These vascular 
networks are essential for meeting the metabolic requirements of the retina.25  
2.4 Physiology of the macula 
The role of the retina is for vision. It is designed to convert light into electrical signal 
through the photoreceptors.23 Upon stimulation by light the chromophore, retinal, 
undergoes changes in structure which leads to a cascade of events resulting in 
activation of an enzyme, phosphodiesterase. Activation of this enzyme results in 
reduction in levels of cyclic guanosine monophosphate (cGMP) and then the closure 
of sodium channels. The resulting hyperpolarisation of the photoreceptor leads to 
decrease in glutamate. This decrease results in depolarisation of the on-bipolar cells 
and hyperpolarisation of the off-bipolar cells. The electrical signal then travels 
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through the neural cells to the ganglion cells and the visual pathway to visual cortex 
of the brain. 
For the neural cells to function effectively, along with meeting demanding 
metabolic requirements, the retinal capillary network has to maintain a “highly 
defined microenvironment conducive to neurotransmission, phototransduction and 
the complex interaction of metabolites, growth factors and vasoactive agents”.26 
Retinal homeostasis is maintained by the integrity of the inner and outer blood-
retinal barriers (BRB).28 The inner BRB is composed of the tight junctions between 
the endothelial cells of the retinal capillaries. This is supplemented by the pericytes 
that encircle capillaries.29 The inner BRB controls the permeation of products 
through the retinal vasculature whilst anionic pumps located within the endothelial 
layer assist in the removal of excess fluid and waste product from the extracellular 
space.26  
The outer BRB is formed by tight junctions between the retinal pigment epithelial 
(RPE) cells.29 The RPE is involved in maintaining the normal physiological process of 
the retina, especially the renewal and maintenance of the photoreceptors and 
removal of excess fluid from the subretinal space.29 In a study comparing retinal 
vasculature between patients with DM, there appeared to be no significant 
difference in the perifoveal capillary network and the foveal avascular zone 
between patients with and without diabetic macular oedema.30 The author 
hypothesised that the RPE and the choroid may be implicated in the development 
of DMO and that choroidal ischaemia may be associated with fluid leakage. It is 
likely that both the inner retina and the choroid are implicated in the development 
of DMO. 
2.5 Microvascular pathology of diabetic maculopathy 
The commonest accepted theory for the development of diabetic retinopathy (DR) 
is the microvascular theory which attributes visual loss to changes in the retinal 
microvasculature, especially the capillaries.31 These changes are also noted in the 
macula and results in diabetic maculopathy.  
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Diabetic maculopathy consists of two principal components, retinal ischaemia and 
retinal oedema. Retinal ischaemia results from capillary and arteriolar non-
perfusion; retinal oedema is due to the breakdown of the inner or outer blood-
retinal barrier resulting in a reduced ability to clear fluid transudate.29,32 Laboratory 
studies have shown that there is a reduction in the quantity and quality of the tight 
junction proteins described above, resulting in DMO.33 Retinal oedema may be 
associated with exudates, plasma lipoproteins released from damaged capillaries, 
and are usually located in the OPL and ONL.32 
DM is associated with an increased inflammatory response.34 Leukocyte release, 
and subsequent adherence to the endothelium, results in cell death, vascular 
obstruction and vascular leakage. In addition there is an increased release of 
vascular endothelial growth factor (VEGF) which results in increased vascular 
permeability. The superficial inner retinal capillary network appears to be the most 
susceptible vascular pathway to elevated levels of VEGF. Other vasoactive factors 
implicated include protein kinase C (which is associated with decreased retinal 
blood flow by inducing vasoconstriction), angiotensin II, vasopressin and bradykinin. 
Matrix metalloproteinases have been shown to influence the endothelial cell 
junctions and participate in endothelial and pericyte cell death.28,34 
The oedema in diabetic macular oedema (DMO) comprises intracellular swelling of 
the Müller cells, the OPL or the Henle layer and the accumulation of extracellular 
fluid in cystoid macular oedema (CMO) mainly in the OPL and INL of the retina 
within the fovea.35,36 CMO appears on fluorescein angiography (FA) as petalloid 
hyperfluorescence in the region of fovea in the late images. Persistent retinal 
oedema may result in apoptosis of Müller cells and formation of cystic cavities,37 
which involves the whole retina and may result in loss of identifiable structures, 
such as the fovea.30 Several studies have demonstrated that not all patients recover 
vision despite adequate treatment and resolution of maculopathy and suggest this 
is caused by the loss of these retinal neuronal cells. 
Increased blood glucose, presumed hypoxia and systemic hypertension are 
associated with arterial dilatation.33 There is an increase in hydrostatic pressure 
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which contributes to small vessel dilatation and transudation of fluid and 
macromolecules, such as proteins and lipids, into the retinal interstitial spaces. 
These lipoprotein complexes are called exudates and are indication of either active 
or recent increased vascular permeability or leakage. 
In addition to ischaemia and oedema, there are other features associated with 
diabetic maculopathy. Vitreomacular interface abnormalities (VMIA) refer to the 
attachment of the posterior hyaloid membrane of the vitreous to the retinal nerve 
fibre layer resulting in macular abnormalities. VMIA has been noted in 2.8 to 3.6% 
of cases of DMO38 and the risk of developing DMO was 3.4-fold lower in those 
individuals in whom there was complete detachment of the posterior hyaloid 
surface.39 Serous foveal detachment describes the presence of leaked fluid between 
the ONL and the RPE layer, has been found in up to 15% of patients with diabetes 
and is associated with dysfunction of the RPE.35  
2.6 Types of diabetic maculopathy 
Diabetic maculopathy may be subdivided into four types: focal exudative, diffuse, 
ischaemic, and mixed. Focal exudative maculopathy refers to the presence of a well 
circumscribed area of retinal thickening with associated exudates, usually due to 
leakage from microaneurysm(s) (MA) from an intraretinal vessel or dilated capillary 
segments at the level of the outer nuclear layer.32,38,40,41 Diffuse maculopathy is the 
presence of a poorly circumscribed area of retinal thickening with possible areas of 
retinal tissue non-perfusion, functional dilatation of the capillaries and cystoid 
changes; the leakage usually results from a generalised breakdown of the inner BRB 
with the absence of exudates reflecting the leakage of smaller molecules.22,32,39,41 
Ischaemic maculopathy is the constriction or loss of the terminal arterioles of the 
perifoveal capillary network resulting in reduced oxygen and nutrient supply and 
thus visual loss.22  Mixed maculopathy refers to the presence of diffuse oedema and 
ischaemia concurrently;39 the term has been falling out of use in recent years. 
The different types of maculopathy are determined by combining findings of clinical 
examination and FA. Focal exudative and diffuse maculopathy are usually described 
clinically though FA aids in determining involvement of the fovea. Ischaemic 
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maculopathy may be suspected on clinical examination through the presence of 
blot haemorrhages and cotton wool spots in the perifoveal region. However FA is 
essential for identifying any disruption to the perifoveal capillary network and FAZ. 
2.7 Management of diabetic maculopathy 
There are various treatment modalities available for managing diabetic 
maculopathy. The first line of treatment is usually laser photocoagulation, either in 
a targeted fashion (focal) or in a pattern of spaced burns (grid) around the FAZ, as 
established by the Early Treatment Diabetic Retinopathy Study (ETDRS) Group.35 
Application of laser is thought to reduce macular oedema through closure of the 
adjacent microaneurysms and the proliferation of the RPE cells and thus re-
establishment of the outer BRB. Other possible theories are the photocoagulative 
debridement of unhealthy RPE cells, to be replaced by healthier cells, and the 
reduction of oxygen demand by the retina through the reduction in active 
photoreceptors.32 
Focal laser is beneficial in reducing the rate of moderate vision loss by ~50% (from 
24% to 12%) but offers little benefit in improving VA.22,35,42 Despite treatment 12% 
may still lose vision.22,35 Also, photocoagulation may be of no benefit in up to 50% 
of cases.43 I describe these results in more detail in Chapter 3. 
The use of peri-ocular or intra-ocular injection of steroid, such as triamcinolone, 
have shown benefit in reducing macular oedema and improving visual acuity. They 
produce anti-inflammatory effects that modify the blood-ocular barrier and inhibit 
vascular endothelial growth factor (VEGF) resulting in modulation of the vascular 
permeability. However the benefits are often short-lived, multiple treatment are 
often required, and an associated increased risk of adverse events including 
infection, glaucoma and cataract.15,22 
Since starting my research, newer treatment strategies for diabetic maculopathy 
are now available with many receiving approval as first-line agents. These 
intraocular agents have shown benefits in reducing oedema and improving vision 
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and include ranibizumab, aflibercept, bevacizumab, dexamethasone and 
flucinolone. 
Ranibizumab (RZB) is an anti-VEGF agent that has been shown to reduce DMO and 
deliver sustainable visual improvement.44 The Ranibizumab for Edema of the 
mAcula in Diabetes-2 (READ-2) study demonstrated a significant improvement in VA 
compared to laser alone45 and this improvement was sustained for up to three 
years with repeated injections.46 The RESOLVE study confirmed the advantage of 
RZB over sham injections.47 Further studies, such as the DRCR.net (Protocol I), 
RESTORE, REVEAL, RIDE and RISE have shown RBZ to be superior to laser, 
triamcinolone and sham treatments with early treatment demonstrating greater 
improvement in VA.48-51 The LUCIDATE study demonstrated improvement in 
microperimetry and electrophysiology outcomes when treating DMO with RBZ.52 
Aflibercept (AFL) is an anti-VEGF agent that binds all isoforms of VEGF.44 The DA 
VINCI study demonstrated AFL to be significantly better than laser in the treatment 
of DMO.53 The VIVID and VISTA confirmed these findings, as well as demonstrating 
that eight weekly injections were statistically as efficacious as four weekly 
injections.54   
Bevacizumab (BZB) is another anti-VEGF agent that binds all isoforms of VEGF. 
Randomised controlled trials, such as DRCR.net (Protocol H) and BOLT, have 
demonstrated BZB to be superior to sham treatment or laser in the treatment of 
DMO.55,56 However, unlike RZB and AFL, BZB does not have approval for use in 
treatment of DMO and so is used off-label, predominantly due to it being 
substantially cheaper than RZB and AFL.44 
One disadvantage of anti-VEGF agents is the need for treatment on a monthly or 
two-monthly basis. Use of a single dexamethasone implant has shown to be 
effective for up to six months.44 Prospective studies have shown dexamethasone to 
be significantly better than sham or laser treatment in both VA and in anatomical 
improvement.57,58 The BEVORDEX study identified similar rates of improvement in 
VA between dexamethasone implant and BZB.59 The MEAD study demonstrated a 
mean of only 4.1 injections were required over three years; however over half of 
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the patients underwent cataract surgery and quarter developed secondary ocular 
hypertension.60 
Another corticosteroid implant that is approved for use in the treatment of DMO is 
flucinolone acetonide. The FAMOUS study demonstrated improvement in VA in 
persistent DMO that was sustained for over one year.61  The FAME A and FAME B 
studies demonstrated a significant improvement in VA compared to sham 
injections, lower rates of glaucoma as compared to dexamethasone and 
improvement in VA in patients with chronic DMO (≥3 year duration).62  
Newer treatments offer more hope to patients in maintaining, or even improving, 
VA in the presence of DMO. However this requires regular clinical appointments 
and carries risk of complications, and some patients are still at risk of losing vision. 
2.8 The neurodegenerative theory of diabetic maculopathy 
As described above the microvascular theory is commonly accepted as the most 
significant factor behind the visual loss associated with diabetic maculopathy. 
However over 50 years ago post-mortem studies of human eyes described 
degeneration of retinal ganglion cells and other neurons prior to the onset of 
vascular lesions.63 In addition, atrophy of the inner retina has been described, 
attributed predominantly to the reduction in the number of ganglion cells in 
addition to the number of amacrine, horizontal, Müller and photoreceptor cells.31,33 
FA has not been useful in identifying these features, though the improved 
resolution of newer OCT systems has demonstrated inner retinal thinning in 
patients with DM but no maculopathy.64  
Therefore it is possible that patients with DM develop sub-clinical retinal changes, 
i.e. changes within the neuronal network which clinicians are unable to detect. This 
suggests that deficits in visual function may occur before the patient notices any 
changes in their daily life. If we, as clinicians, are able to identify these sub-clinical 
deficits then it may be possible to identify those patients who are at most risk of 
developing visual loss. This would allow for early and targeted treatment for this ‘at-
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risk’ group. Ultimately we may be able to reduce the rates of visual loss in patients 
with DM. 
2.9 Discussion 
In summary diabetic maculopathy is a significant cause of visual loss with obvious 
impact on an individuals’ physical and mental well-being. As our understanding of 
the pathology behind diabetic maculopathy improves, newer treatment solutions 
are being investigated. However current treatment is based on preserving vision 
with many individuals continuing to lose vision. The identification of 
neurodegeneration of the retina prior to the development of microvasculopathy 
has been described previously and newer investigative techniques have made it 
possible to study the macula. By assessing the neuronal function of the macula in 
diabetic maculopathy it may be possible to determine severity of dysfunction. By 
correlating dysfunction to clinical severity it could be possible to identify subjects at 
risk of developing visual impairment and therefore be targeted for early 
intervention. In Chapter 3 I review the literature on current clinical techniques in 
the assessment of diabetic maculopathy and the current understanding of 
functional assessments of the macula in diabetes mellitus. 
2.10 Aims of thesis 
My aim is to correlate macular function to severity of diabetic maculopathy, and 
determine the potential role of functional investigations in the assessment of 
diabetic maculopathy. I will achieve this by assessing macular function using both 
objective (multifocal electroretinogram and oscillatory potentials) and subjective 
investigations (contrast sensitivity and microperimetry) to determine whether 
increasing severity of diabetic maculopathy is associated with decreasing macular 
function. I will compare these investigations to current clinical investigations (visual 
acuity and optical coherence tomography) to determine whether the former 
investigations provide more information on the state of retinal function before 
visual function is significantly reduced. 
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My secondary aim is to determine change in macular function longitudinally. I will 
achieve this by using the above investigations to assess whether retinal function 
decreases over time, and whether increasing severity of disease is associated with a 
greater decrease in retinal function. I will also assess whether these investigations 
may provide further information to identify those patients more likely to require 
treatment. 
I hypothesise that increasing severity of diabetic maculopathy is associated with 
decreasing retinal function and that these investigations may help identify those 
with reduced function prior to development of visual impairment. I also hypothesise 
that subjects with more severe diabetic maculopathy will develop a greater 
reduction in retinal function than those with early or no diabetic maculopathy.  
 26 
 
Chapter 3 Literature review  
In this chapter I will review the key literature on the epidemiology, diagnosis and 
management of diabetic maculopathy. Using PubMed I searched for terms related 
to diabetes mellitus (DM), in particular diabetic maculopathy.  These terms 
included: 
 diabetic macular oedema (DMO) 
 clinically significant macular oedema (CSMO) 
 exudates in diabetic maculopathy 
 ischaemic maculopathy 
 enlarged foveal avascular zone (FAZ) 
 hypertension in DM 
 hyperlipidaemia in DM 
 contrast sensitivity in DM 
 fluorescein angiography in DM 
 optical coherence tomography in DM 
 multifocal electroretinogram in DM 
 microperimetry in DM 
 oscillatory potential in DM 
From these searches, I selected landmark studies that have shaped our 
understanding of diabetic maculopathy. I have also selected papers that have been 
frequently referenced or whose results are comparable to my aims. I have critically 
appraised these papers, highlighted their strengths and weaknesses and then, for 
each of the following sections (and sub-sections), I have explained how I plan to 
incorporate them into my study to improve the strength of my results. Finally, I set 
the scene for the aims of my study.  
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3.1 Landmark studies in diabetic maculopathy 
3.1.1 The Diabetic Retinopathy Study (DRS) 
In the 1970’s a randomised, controlled, prospective trial evaluated the efficacy of 
laser photocoagulation in the treatment of proliferative diabetic retinopathy 
(PDR).65  In a three year period 1758 patients were recruited and randomised to 
either no treatment or treatment; the latter group were further randomised to 
treatment with either the argon or xenon laser photocoagulator. Patients were 
followed on a 4 monthly basis. The primary outcome was the risk of developing 
severe visual loss (SVL, Snellen acuity ≤5/200). At 1 year the treated group 
demonstrated a statistically significant reduction in risk of developing severe visual 
loss as compared to the control group (2.3% vs 3.6%, z=2.2). By 6 years the 
treatment group were less than half as likely to develop severe visual loss (16.6% vs 
36.7%, z=9.0). 
The DRS identified that a proportion of patients developed SVL despite laser 
treatment with diabetic maculopathy being identified as one of the factors. The 
authors proposed a further trial to determine the role of photocoagulation in the 
management of diabetic maculopathy – the Early Treatment Diabetic Retinopathy 
Study (ETDRS). 
3.1.2 The Early Treatment Diabetic Retinopathy Study (ETDRS) 
Between 1980 and 1985 this multicentre, randomised trial was designed with three 
aims in mind, one of which was to establish the efficacy of photocoagulation in the 
treatment of DMO.42 A total of 3928 patients were recruited. Patients with macular 
oedema were assigned to either immediate or deferred retinal laser; those assigned 
to immediate photocoagulation were further randomised to either immediate 
macular laser or peripheral retinal laser. A broad range of features was used to 
determine the presence of maculopathy - from a few small hard exudates within a 
disc diameter of the centre of the fovea to the presence of extensive cystoid 
changes, regardless of visual acuity.42  
All patients underwent visual acuity (VA) testing using a specifically designed chart, 
the ETDRS chart. Visual function was also assessed using the Farnsworth-Munsell 
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100-hue test, which analyses an individual’s ability to differentiate between subtle 
changes in colour, and Goldmann perimetry, for the assessment of peripheral visual 
field. 
Visits were scheduled for six weeks after treatment and then at four monthly 
intervals. Structural assessments were carried out through fundus photographs and 
fluorescein angiograms at specified intervals, and if clinically needed. The primary 
outcome was the percentage of patients who lost ≥15 letters on the ETDRS chart. A 
two-sample t-test was used to assess effects of photocoagulation between the two 
groups. A Z value of ±1.96 is equal to a p value of 0.05; a Z value of ±2.58 or greater 
corresponds to a p value of ≤0.01. 
In Report 1, eyes treated with immediate macular laser (n=754) were compared to 
eyes in which laser was deferred (n=1490).42 Those that underwent immediate 
macular laser were half as likely to lose ≥15 letters of vision at three years (12% vs 
24%, Z >2.58). Subgroup analysis identified that eyes with a vision less than 70 
letters (6/12) showed a gain of six letters or more in nearly 40% of eyes undergoing 
immediate laser as compared to 20% of those in whom laser was deferred (Z >1.96). 
Though eyes with a visual acuity worse than 60 letters (6/18) showed a reduction in 
loss of ≥15 letters, this was not statistically significant at three years (Z <1.96). Also, 
eyes with a visual acuity between 90 and 100 letters (20/15 or better) showed no 
significant difference in worsening by ≥15 letters between the two groups. In 
summary, the authors concluded that laser photocoagulation conferred benefit in a 
select group of patients. However, they also noted that, despite treatment, vision 
remained reduced in a significant proportion of patients.  
Along with demonstrating the benefits of laser photocoagulation, the ETDRS 
provided the clinician with a method for determining severity of diabetic macular 
oedema and thus guidelines for laser application. As described in Chapter 2, 
diabetic maculopathy comprises of the presence of macular oedema, with or 
without exudates, and microvascular changes. The ETDRS attempted to determine 
which patients with diabetic maculopathy would gain the most from macular laser.   
The authors reported that a subset of subjects with certain features appeared to 
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gain the most benefit from macular laser and introduced the term ‘clinically 
significant macular oedema (CSMO)’. 
Features of Clinically Significant Macular Oedema (CSMO)66 
 Thickening of the retina at or within 500 microns of the centre of the macula 
 Hard exudates at or within 500 microns of the centre of the macula, if 
associated with thickening of adjacent retina (not residual hard exudates 
remaining after disappearance of retinal thickening) 
 A zone or zones of retinal thickening 1 disc area or larger, any part of which 
is within 1 disc diameter of the centre of the macula 
 
At baseline, CSMO was present in 1287 eyes and absent in 822 eyes. Eyes with 
these features had a statistically significant reduction in risk of developing visual 
loss of ≥15 letters following immediate focal laser as compared to deferred laser 
(~5% vs ~11% at 1 year, and ~10% vs ~30% at 3 years, Z≥3.29).42 In comparison 
there was no statistically significant difference in development of visual loss of ≥15 
letters between immediate laser and deferred laser in patients without CSMO at 
baseline (Z<1.96). Even with the exclusion of data from one centre the findings were 
similar.66 
Patients were graded for presence or absence of retinal thickening at the centre of 
the macula at three years. Of those diagnosed with CSMO at baseline, 24% of 
patients (n=123) who underwent immediate laser demonstrated the presence of 
thickening as compared to 54% of patients (n=221) in whom laser was deferred.66 
This was statistically significant (Z≥2.58). Of those without CSMO at baseline, retinal 
thickening at the centre of the macula was detected in 16% of those undergoing 
immediate laser (n=81) and 25% those in the deferred laser group (n=173). This was 
not deemed to be statistically significant (Z<2.58).  
The authors suggested that laser should be performed once CSMO is detected. 
However the authors noted that some patients continued to develop severe visual 
loss and some were at risk of developing CSMO despite adequate laser. However no 
explanation was provided for continuing visual loss or development of CSMO 
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despite treatment. Likely causes included progression of disease, adverse effect of 
laser, and longstanding retinal damage resulting in atrophy of retinal structures. 
One limitation of the ETDRS is the lack of demographic data published in the initial 
reports. Though a subsequent report67 provided baseline data comparing patients 
who received mild laser treatment and those who received full treatment, only VA 
was available for other inter-group comparisons. No multivariate analysis was 
performed to identify possible risk factors for worse prognosis. Nevertheless, this 
pivotal study provided sound evidence that improved understanding and treatment 
of diabetic maculopathy and continues to be referred to for the clinical 
management of diabetic maculopathy. 
3.1.3 The Wisconsin Epidemiological Study of Diabetic Retinopathy 
The Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) recruited 
9283 patients with DM between 1980 and 1982 into a multicentre, prospective, 
observational study. Their aim was to determine the incidence of diabetic eye 
changes over specified time periods. Out of a sample population of 2990 patients 
with diabetes, there were 1426 subjects with no DMO at baseline and considered to 
be at risk of developing DMO. Macular oedema was defined as the presence of 
retinal thickening ≤ 1 disc diameter of the centre of the macula or the presence of 
photocoagulation scars in the macula as seen on stereoscopic fundus photographs. 
However no explanation was provided as to why these individuals were considered 
to be at risk. 
The authors reported on the four year results in 1989.68 8.2% of patients with type 1 
DM developed macular oedema, half of whom were diagnosed with CSMO. 5.2% of 
patients with type 2 DM developed macular oedema, with just over half identified 
as CSMO. The authors reported an increased incidence of DMO with increasing age 
in patients diagnosed with type 1 DM (p<0.005); no trend was found in patients 
with type 2 DM. An increased duration of DM was also associated with an increased 
incidence of DMO in type 1 but not type 2 DM (p<0.001 and p=0.17, respectively). 
Increasing severity of retinopathy was associated with a significantly increased risk 
of developing macular oedema in both groups of patients (p<0.0001). Other risk 
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factors identified for the development of DMO in patients with type 1 DM were 
elevated serum glycated haemoglobin (HbA1c, p<0.0001), higher diastolic blood 
pressure (p<0.01), current or previous smoking history (p<0.05), a history of 
cardiovascular disease (p<0.05), and a higher frequency of oral aspirin use 
(p<0.005). In patients with type 2 DM, a younger age at diagnosis of DM and a 
higher level of HbA1c were significantly associated with an increased incidence of 
DMO (p=0.0005 and p<0.0001 respectively). In neither group was systolic blood 
pressure or proteinuria shown to be significant. Sub-group analysis of those not on 
anti-hypertensive agents demonstrated only higher diastolic blood pressure to be 
significantly associated with an increased incidence of DMO in both groups (p=0.01 
and 0.02, respectively).  
In the 10 year report, the authors described an incidence of macular oedema and 
CSMO in 20.1% (130/688) and 13.6% (86/688) of patients with type 1 DM, 
respectively; in the patients with type 2 DM, the incidence was 18.6% (97/773) and 
12.6% (63/773) respectively.69  In patients with type 2 DM, those who were on 
insulin were more likely to develop macular oedema and CSMO (25.4% and 17.6% 
respectively) as compared to those treated without insulin (13.9% and 9.2% 
respectively). Duration of diabetes, severity of retinopathy, elevated diastolic blood 
pressure, and elevated HbA1c remained significant risk factors for both types of 
DM. In addition proteinuria and younger age at diagnosis were risk factors in 
patients with type 1 and type 2 DM respectively.  
A multivariate analysis was performed using discrete linear logistic regression.69 In 
patients with type 1 DM, an increase in HbA1c by 1%  was associated with a 56% 
increased risk of developing macular oedema (OR 1.56; 95% CI 1.38-1.76); an 
increase in HbA1c by 1% point between baseline and year 4 was associated with a 
37% increased risk (OR 1.37; 95% CI 1.23-1.52); an increase in severity retinopathy 
by one step was associated with 12% increased risk (OR 1.12; 95% CI 1.05-1.19); and 
a duration of diabetes at baseline up to 17.1 years was associated with a 6% 
increased risk (OR 1.06; 95% CI 1.01-1.12). However, duration of DM of 25 years at 
baseline was associated with a reduced incidence of macular oedema (OR 0.92; 95% 
CI 0.87-0.98).  
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In patients with type 2 DM,69 an increase in HbA1c by 1% was associated with a 65% 
increased risk of developing DMO (OR 1.65; 95% CI 1.42-1.92); an increase in HbA1c 
by 1% from baseline to year 4 was associated with 18% increased incidence of DMO 
(OR 1.18; 95% CI 1.03-1.34); being female was associated with a 74% increased 
incidence of DMO (OR 1.74; 95% CI 1.05-2.87); increased severity of retinopathy by 
one step was associated an increased incidence (OR 1.18; 95% CI 1.10-1.26); and an 
increase in diastolic BP by 10mmHg was associated with a 35% increased incidence 
(OR 1.35; 95% CI 1.10-1.66). 
However, WESDR may have underestimated the incidence of DMO as it only 
reported findings at a specific time points and not development of macular oedema 
at any point during the four years. No analysis was performed to assess risk factors 
for developing CSMO or to correct for confounders nor was there any evaluation of 
VA during the study. To minimise the effect of confounding in my study I aimed to 
match recruits for age and correct for blood pressure, duration of DM, HbA1c and 
lipid profile.  
The management of DM has altered considerably since these studies were 
undertaken. In addition, due to the population mix, these results may not be 
applicable to other populations. Nevertheless, like the ETDRS, WESDR has been a 
pivotal study in our understanding of diabetic maculopathy. It helped identify the 
risk factors for development of DMO, factors that the clinician still assesses to this 
day in the management of diabetic maculopathy. 
3.2 Longitudinal studies of diabetic maculopathy 
As described above, the WESDR established rates of development of DMO and 
CSMO and associated risk factors. The modification of systemic risk factors, such as 
HbA1c, lipid profile and BP, remain an essential component in the management of 
diabetic maculopathy. I explore these risk factors further in this chapter. 
The Los Angeles Latino Eye Study was a longitudinal, observational study of a Latino 
population with DM.70 The authors aimed to demonstrate the incidence of DR and 
diabetic maculopathy after four years. Out of 775 participants who completed four 
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years of follow up, the overall incidence of macular oedema (either retinal 
thickening within 1 disc diameter of the fovea or presence of macular laser) was 
5.4% and of CSMO was 7.2%. The study only found increasing duration of DM to be 
a significant factor in development of maculopathy. The authors reported that 
11.1% of those with a duration of DM greater than 15 years developed macular 
oedema as compared to only 5.1% of those with a duration less than 5 years 
(p=0.003).  The equivalent values for development of CSMO is 9.1% in those with 
duration greater than 15 years compared to 5.1% with duration less than 5 years 
(p=0.002). The authors did not look at incidence of development of exudates as a 
marker of macular oedema which I have included in my description of maculopathy. 
Also their data is limited to a certain ethnic group that is different to our local 
population and so may not be applicable to other populations.  
Early retinal changes have been studied that might predict the subsequent onset of 
diabetic retinopathy though the results have been inconsistent. One small 
retrospective study of patients who developed visual loss secondary to diabetic 
maculopathy had their screening images reviewed.71 Patients were selected if 
colour images demonstrating stable background diabetic retinopathy (BDR) for at 
least one year were found. For each study patient three controls were selected 
matched for retinopathy grade, age at onset of diabetes and duration of diabetes. 
There were 11 study patients and 33 controls. Retinal findings were graded by a 
computer according to total number of haemorrhages and exudates within the 
macula and their location with respect to the centre of the fovea. The study 
identified that those developing vision loss secondary to maculopathy had a 
significantly greater number and coverage of haemorrhages and exudates involving 
and temporal to the fovea. Limitations of this study include small number of 
subjects included in the study, being retrospective, lack of data on systemic risk 
factors and the onerous method of quantifying haemorrhages and exudates which 
is not practical in routine clinical practice.  
In my study I will record those risk factors associated with the development of 
diabetic maculopathy, namely age, duration of DM, severity of retinopathy, HbA1c, 
lipid profile, BP, smoking status, and systemic treatment (use of insulin, oral 
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hypertensive and oral lipid-lowering agents). Where appropriate I will correct for 
these factors during data analysis.   
3.3 Current clinical assessment of diabetic maculopathy 
Clinical examination remains the accepted standard in the assessment of diabetic 
maculopathy. In the following sections I will describe the benefits and drawbacks of 
each technique used in the assessment of diabetic maculopathy. 
3.3.1 Visual acuity 
Visual acuity (VA) is a subjective test of ocular function. It is assessed by the subject 
reading a chart at a specified distance. The chart is comprised of letters of specified 
sizes, and results recorded as without use of refractive correction (unaided VA), 
with use of subjects own glasses or a pinhole (VA with glasses/PH) or after 
refraction (best corrected visual acuity, BCVA).  
As the most commonly used measure of the health of the eye, a reduction in VA 
represents a red flag sign for the health professional. As seen in the preceding 
paragraphs, visual loss was used as the main outcome in ETDRS for determining 
response to treatment. However VA appears to be insensitive to early changes of 
DR. 
In a retrospective study of 103 eyes with diabetic maculopathy the authors 
concluded that VA was a poor predictor for the presence or absence of clinically 
significant diabetic maculopathy.72 The diagnosis of diabetic maculopathy was made 
on findings from clinical examination and divided into sub-types using FA for 
guidance. Overall 68% of eyes demonstrated a visual acuity of 6/12 or better 
despite the presence of retinal thickening ± exudates within 1 disc diameter of the 
fovea. Despite macular laser treatment 34.1% of treated eyes suffered worsening of 
vision. This was a retrospective study and, apart from HbA1c, it did not assess any of 
the systemic markers. The authors aimed to correlate vision to type of 
maculopathy, rather than determine severity of maculopathy such as CSMO. The 
follow up period was short (6 months) and so the findings cannot be used to 
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estimate progression of maculopathy. I will look at VA in relation to the different 
severities of maculopathy and progression to worsening or laser. 
A retrospective cross-sectional study of 1549 subjects with DM reported that 
diabetic maculopathy accounted for only 15% of cases of VA worse than 6/18.73 The 
authors concluded that VA is not a reliable criterion in predicting STDR with the 
majority of visual loss attributable to causes other than DR. However, these subjects 
had their VA tested with only glasses or contact lens correction rather than a full 
refraction. Therefore, it is possible that the reduction in VA may have been 
attributed to causes which could be corrected through refraction rather than 
diabetic maculopathy.  
In a prospective study of 59 eyes of patients, BCVA was assessed in the presence of 
varying severities of DR.74 Twenty subjects were deemed to have macular oedema, 
defined as the presence of any retinal thickening within the macula based on stereo 
fundus photographs. The authors reported that BCVA was not significantly worse in 
subjects with macular oedema compared to those without oedema (p=0.90). 
However VA was significantly worse in subjects who had oedema at the centre of 
the fovea (p=0.006). The authors concluded that VA would not be a good prognostic 
indicator to determine those who are likely to develop diabetic maculopathy, but 
would probably aid in determining severity of disease. 
In my study I will record BCVA using the ETDRS letter score as used in landmark 
studies such as the ETDRS and Diabetic Retinopathy Clinical Research Network 
(DRCR.Net). I will compare VA between different severities of maculopathy and to 
the functional investigations used in this study. I will exclude subjects who have 
reduced VA attributable to causes other than DR. 
3.3.2 Contrast sensitivity 
Contrast sensitivity (CS) is a specific measure of visual function that assesses the 
ability to distinguish an object from its background. Standard visual acuity charts 
present black letters on a white background. However, daily life comprises of 
objects of different shades against various background. Thus CS charts are 
comprised of target objects that reduce in contrast gradually, such as the Pelli-
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Robson chart. This chart comprises of a series of capital letters of equal size that are 
arranged in triplets and gradually fade. The chart is read at 1 metre until there are 2 
or 3 mistakes within a triplet. 
Reduction in CS was first described in subjects with DR in 1982.75 Since then several 
studies have described reduced CS in the presence of DR compared to those 
without DR in subjects with type 1 and type 2 DM76-79 and in subjects without DR as 
compared to healthy controls.80  
However there have been few studies that have reported changes in CS in the 
presence of diabetic maculopathy. In a prospective study81 of 20 subjects with DM 
and 20 healthy controls, static CS was assessed in relation to features of ischaemic 
maculopathy on FA, namely perifoveal intercapillary area (PIA) and greatest linear 
diameter of foveal avascular zone (FAZ). All subjects had normal VA and none 
demonstrated the presence of either macular oedema on clinical examination or 
leakage on FA. Increasing PIA and increasing FAZ were correlated to significantly 
decreased CS (p=0.016, r=-0.54 and p=0.005, r=-0.6, respectively). Interestingly 
decrease in contrast sensitivity in subjects with DM was only observed at spatial 
frequencies of 6 and 12 cycles/degree, but not at 3 or 18 cycles/degree. The authors 
were unable to explain why there is such specificity though Sokol et al (1985)82 
reported largest loss in contrast sensitivity in subjects with DM occurred at 
11.4c/deg.  Another study reported decreased contrast sensitivity at 12 and 18 
c/deg.83 
Talwar et al (2001) prospectively assessed CS after focal macular laser treatment in 
subjects with CSMO.84 The authors reported an improvement in CS after laser 
treatment, with a corresponding improvement in maculopathy, in 9/14 cases and 
concluded that CS offered an alternative method for assessing retinal function after 
treatment. Improvement after treatment suggests that CS is reduced in the 
presence of CSMO. However there was no control group to determine whether 
difference in CS is due to maculopathy or due to inter-subject variability. 
However there are no studies that have looked at CS with respect to different 
severities of diabetic maculopathy. I will analyse CS and compare it to BCVA to 
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determine if this assessment of visual function is better suited to determining 
severity of disease. 
3.3.3 Colour photographs 
Colour photographs (CF) were used in the DRS and ETDRS to capture images of the 
retina for grading of retinopathy.67,85 The authors utilised a seven-field stereo image 
schematic (Figure 3.1). 
There are several advantages of taking photographs for grading of retinopathy. It 
allows for objective monitoring of disease progression, rather than relying upon the 
subjective assessment of clinical examination, provides time for health 
professionals to evaluate the fundus, acts as a permanent record, and can be used 
for teaching and quality assurance. 
Figure 3.1: Schematic representation of the seven field fundus photographs 
showing the areas captured  
 
 
 
 
 
 
 
Each field covers a diameter of 30o and represent: 
 Field 1M – Centred on the optic disc   
 Field 2 – Macula centred  
 Field 3M – Temporal to macula 
 Field 4 – Superior temporal  
 Field 6 – Superior Nasal 
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 Field 5 – Inferior temporal 
 Field 7 – Inferior nasal  
However patients found the seven-field photographs to be uncomfortable due to 
the intensity of the flash and the time taken to capture the images, especially with 
stereo pairs. Moss et al (1989) compared 2, 3 and 4-field images to determine 
adequacy of grading retinopathy.86  Two-field photographs consisted of images F1 
and F2; 3-field consisted of images F1, F2 and F4; and 4-field photographs consisted 
of images F1, F2, F4 and either F3 or F5. Of the original cohort of subjects included 
in WESDR, images of 2410 eyes were included in the analysis. The overall 
agreement to the 7-field photographs was 80-85% for 2-field images; 87-93% for 3-
field images; and 91-95% for 4-field images. The authors also noted that for severe 
retinopathy there was a risk that patients may be assigned a lower grading with 
fewer image fields than the grade assigned with 7-field images. The authors 
concluded that the use of fewer fields may be adequate for some studies, but a cut-
off grade would need to be determined beyond which more fields would need to be 
included in grading. 
In the Liverpool Diabetic Eye Study, 295 subjects underwent three overlapping 45o 
images of the fundus (Figure 3.2) and direct ophthalmoscopy to detect the presence 
of STDR.87 Slit lamp biomicroscopy by a medical retina specialist was used as the 
reference standard. 
Figure 3.2: Schematic of the three 45o fields used in the Liverpool Diabetic Eye 
Study68      
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The authors reported high sensitivity (89%) for the detection of STDR. However, 
compared to the reference standard, photography missed five subjects with STDR, 
all with maculopathy. The positive predictive value for photography was 86%, but 
this fell to 51% if images that were not gradeable or obtainable were included in the 
analysis, with media opacity being implicated in the majority of these cases. The 
authors concluded that a community based photographic screening programme 
would be effective in detecting sight-threatening diabetic eye disease. 
The European Community funded Concerted Action Programme into the 
epidemiology and prevention of diabetes (EURODIAB) IDDM Complications Study 
used a 45o camera to take two images of the retina: i) the centre of the optic disc 
lies at the nasal edge of the image to view the macula and the temporal retina 
(Figure 3.3a); ii) the optic disc is located one disc diameter from the temporal edge 
of the image to view the nasal retina (Figure 3.3b).88 
Figure 3.3: Images of the 45o field taken in the EURODIAB IDDM Complications 
Study; a) macular field b) disc/nasal field88 
   
The authors compared detection of retinopathy between 2-field image sets and 7-
field image sets and reported 100% agreement on detection of retinopathy 
between the two methods. For grading severity of retinopathy, at least one grader 
matched verified results in 93% of eyes, and three or more graders matched in 76% 
of eyes. There was good intra- and inter-observer agreement for the 2-field images 
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(κ=0.85 and 0.83, respectively). The authors concluded that 2-field photography 
offered a comparatively simple method for assessment of diabetic retinopathy but 
also stated that the lack of stereoscopic images meant that maculopathy could not 
be fully assessed.  
Scanlon et al (2003) compared ophthalmologist examination using slit lamp 
biomicroscopy, 7-field 30o photographic imaging, and 2-field 45o photographic 
imaging in the screening of diabetic retinopathy.89 Compared to clinical 
examination, 2-field photography gave a sensitivity of 82.8% and specificity of 
92.9% while 7-field photography gave a sensitivity of 96.4% and specificity of 82.9%. 
However 15.3% of 7-field images and 1.5% of 2-field images were ungradeable 
compared to none of the eyes examined clinically. The authors concluded that 
clinical examination by an experienced retinal specialist compared favourably to 7-
field photography but suffers from difficulty of inter-observer comparisons. Seven-
field photography had a high technical failure rate. 
In the early 21st Century, following on from the establishment of several local 
population-based screening programmes for DR, the National Screening Programme 
(NSP) for diabetic eye disease was developed.90 The aim of the programme was to 
detect sight-threatening disease early enough so treatment could be initiated 
promptly to prevent visual loss. Within the programme, a minimum of two 45o or 
50o fields of the retina were to be taken. The grading system used is summarised in 
Table 3.1. 
Once the images are reviewed by a trained person, a grade is scored for each 
category. Therefore, each eye is scored as R 0/1/2/3, M 0/1, P 0/1. If images are of 
too poor a quality to grade or were not able to be obtained, then a grade of ‘U’ is 
given. Patients who score R≥2, M1 or U, or are found to have other lesions, are 
referred to the hospital eye service.  
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Table 3.1: Grading protocol used by the NSP. Haem = haemorrhage; IRMA = 
intraretinal microvascular abnormality; CWS = cotton wool spots; TRD = tractional 
retinal detachment; DD = disc diameter90 
Grading Level Diagnosis Features 
Retinopathy (R) 0  None 
 1 Background Microaneurysms (MA) 
Retinal haem ± exudates 
 2 Preproliferative Venous beading 
Venous loop or reduplication 
IRMA 
Multiple deep, round or blot haem 
(CWS - search for above features) 
 3 Proliferative New vessels on disc (NVD)  
New vessels elsewhere (NVE)  
Preretinal or vitreous haemorrhage  
Preretinal fibrosis ± TRD 
Maculopathy (M) 0  None 
 1  Exudate within 1 DD of centre of fovea 
Circinate/ group of exudates within macula  
Retinal thickening within 1 DD of centre of  
fovea (if stereo available)  
Any MA or haem within 1 DD of centre of 
fovea only if associated with a best VA of < 
(if no stereo) 6/12 
Photocoagulation 
(P) 
0  None 
 1  Focal/grid to macula 
Ungradeable/ 
Unobtainable (U) 
  Peripheral scatter 
Poor view 
Unscreenable 
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In my study I will perform slit lamp biomicroscopy to grade DR and to assess for 
maculopathy. I will also perform non-stereoscopic 7-field retinal photography so 
that a digital record of retinopathy status is available for any disagreements with 
retinopathy grading. I will grade retinopathy as per the NSP grading protocol in 
Table 3.1. Patients with a retinopathy grading of R3 will not be included due to their 
need for urgent photocoagulation.  
3.3.4 Fluorescein angiography 
As described earlier, DM is associated with vascular changes. Clinical examination 
allows for visualisation of some of the pathological changes. However early changes 
may only be subtle and so not seen on slit lamp biomicroscopy. Fluorescein 
angiography (FA) allows for indirect visualisation of retinal capillaries and is an 
invasive investigative tool consisting of the injection of a dye (fluorescein sodium 
20%) into the venous circulation followed by the capture of retinal images. It is 
routinely used in clinical practice to: 
 visualise the perifoveal capillary network and assess the FAZ 
 identify the source of any leakage  
 identify possible foci for performing laser treatment 
 determine the presence of transudate at the fovea 
 assess the perfusion of the peripheral retina 
The ETDRS utilised FA for two main reasons: i) to guide treatment of macular 
oedema, and ii) to assess characteristics not well assessed by colour photography.67 
Accredited photographers captured stereoscopic fluorescein angiograms of seven 
30o fields based on the colour photography protocol described above. One of the 
fields (2F) was centred ½ disc diameter (DD) temporal to the foveal centre, where 
1DD was equivalent to 1500µm. A standard protocol was described by the authors 
and consisted of: 
i) Transit/early phase 
 Rapid series of field 2F from 13 to 28 seconds after dye injection 
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 Selected depending on clinical judgement of investigator or randomly by birth 
month if both eyes were studied 
 Allowed for assessment of perifoveal capillary net 
 At least one stereoscopic pair of images were captured to show full capillary 
filling 
ii) Mid-phase 
 Lasted from 35 to 120 seconds after dye injection 
 Non-rapid series – stereoscopic pair of field 2F as soon as possible after rapid 
series 
 Stereoscopic pairs of field 1F to view this region 
iii) Late phase 
 Taken at 7 to 9 minutes 
 Stereoscopic pairs of field 2F of each eye 
 To document degree of late leakage of fluorescein 
To assess for location of lesions with relation to the foveal centre, images of field 2F 
had a grid superimposed onto the left hand image of the stereoscopic pair. This grid 
consisted of three solid circles of the following radii from the centre of the macula: 
 Innermost circle of 500µm – represents location of pathology to aid diagnosis 
of CSMO 
 Middle (2nd) circle of 1500µm – represents lesions within 1DD of the centre of 
the fovea 
 Outer (3rd) circle of 3000µm – represents the outer extent of the macula 
Images were then graded for disease severity. A grade was assigned depending 
upon extent of structural damage or comparison to standard photographs. Features 
that were assessed in the early and mid-phase included the size and outline of FAZ, 
loss of capillaries within the PIA, and narrowing, staining or loss of contour of 
arterioles within the macula. In the late phase the authors assessed for leakage, 
paying particular attention to source, severity and appearance of leakage.67 The 
 44 
 
standard photographs were selected from stereoscopic pairs of nine angiograms. 
They show specific subfields of the angiogram and define the boundaries between 
steps in the grading scale.67  
In the ETDRS a grid was used to analyse the macula on both CF and FA (Figure 3.4).67 
It was centred on the fovea and comprised of three rings: the central subfield ring 
has a diameter of 1000 µm; the inner ring 3000 µm; and the outer ring 6000 µm. 
The inner and outer rings were further divided into 8 subfields with superior, nasal, 
inferior and temporal zones within each ring. A 10th subfield was occasionally used 
when assessing lesions temporal to the grid.  
Grading of images was performed by one ophthalmologist and two graders who 
were trained by the ophthalmologist.67 Following an initial grading exercise 
consisting of inter- and intragrader comparisons, the graders analysed a random 
sample of angiograms of 100 eyes. Intergrader comparison was performed looking 
at percentages of agreement and degrees of disagreement and calculating kappa 
statistics. Weights for kappa varied depending on the number of steps in the 
grading protocol, the “weighted Kappa statistic”. 
Figure 3.4: Example of the grid used in the ETDRS for assessment of the macula. 1= 
central subfield; 2-5 = inner ring; 6-9 = outer ring. 
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Results of intergrader comparison demonstrated severity of leakage was the most 
reproducible characteristic with 99% agreement within one step (κ=0.742, p=0.044). 
There was ‘substantial agreement’ in comparing cystoid spaces (κ=0.674, p=0.127). 
Other features, such as FAZ size, showed only fair to moderate agreement (κ ranged 
from 0.342 to 0.583, p>0.05). However only 100 eyes were graded this way and 
severe grades of certain features were infrequently seen. This subjective variation 
in the analysis of FA often results in variations in clinical practice. 
In ETDRS report 19, the authors analysed FA features of diabetic maculopathy 
associated with poor visual outcome.91 All patients in this report had diabetic 
macular oedema that questionably or definitely involved the centre of the macula. 
They compared immediate macular laser and deferred laser groups using a two-
sample test and between the different severities of the baseline characteristics on 
FA using a Generalised Estimating Equation model. Z-values and their equivalent p 
values have been described in Section 3.1.2.91  
The authors reported that outcomes of MVL, regardless of FA feature, were less 
favourable in subjects in whom laser was deferred compared to subjects assigned to 
immediate focal laser. However the results are complicated by patients receiving 
focal laser during the study; at 5 years this occurred in 60.8% of those in whom laser 
was deferred at baseline and 75% of those who received immediate focal laser. 
Individuals also received peripheral scatter laser if required. These laser procedures 
are likely to affect visual acuity outcomes, either due to improvement in 
retinopathy, through laser applications involving the macula or worsening of DMO 
due to PRP.  
The results presented only describe findings for one variable on FA. The authors did 
not present findings when correcting for confounders or combining different FA 
features. It is likely that individuals with two or more severe features are likely to 
have a poorer outcome, though we do not have data to confirm this. Other 
limitations include the difficulty in acquiring 7-field images, the photographer 
training required and the small field of view. Nevertheless, the ETDRS was pivotal in 
demonstrating the role of FA in assessing diabetic maculopathy. The use of 
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stereographic FA with a systematic grading protocol and accredited graders 
provided robust evidence and protocols that are used in research and clinical 
practice to this day. 
A prospective analysis of perifoveal microcirculation on FA was performed 
comparing subjects with diabetic maculopathy and matched healthy controls.92 The 
subjects with maculopathy were further subdivided into those with impaired VA of 
6/15 or worse and those with normal VA; none had CSMO. Subjects with DM had 
significantly larger FAZ and PIA as compared to healthy controls (p<0.001). Subjects 
with reduced VA had a significantly increased FAZ (p<0.01) as compared to those 
with preserved VA. In addition VA was significantly correlated to FAZ (r2=0.51). 
However systemic risk factors (blood pressure, cholesterol) were not analysed.  
In my study all subjects will undergo FA to assess the greatest linear diameter (GLD) 
of the FAZ and assess for features of ischaemic maculopathy such as perifoveal 
capillary loss. 
3.4 Optical coherence tomography 
Optical coherence tomography (OCT) provides cross-sectional images of the retina 
with high reproducibility and high resolution.93 The OCT platform I have utilised in 
the studies described in this thesis is a spectral-domain (SD) OCT which relies on 
alterations in light frequency to demonstrate the retinal structures. A light source 
emits an infrared beam which passes through a partially reflective mirror and is split 
into two beams. One travels straight through to the retina and the other to a fixed 
reference mirror. The reflected light from the retina and the reference mirror is 
then distributed by a dispersive element onto a detector strip according to their 
optical frequencies. The signal generated is processed to produce a greyscale image 
of the retina reflecting the different depths and density of structures within each 
layer. 
Analysis of the OCT image consists of an ETDRS grid which I have described in Figure 
3.4. Two main measurements are recorded from the central subfield: central point 
thickness (CPT) refers to the thickness of the retina at the centre of the fovea; mean 
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central subfield thickness (CSFT) refers to the mean thickness across the whole of 
the central ring. A DRCR.net study demonstrated a very high correlation (correlation 
coefficient = 0.99) between CPT and CSFT in patients with DMO.94 However CPT 
measurements have been shown to vary greatly as compared to CSFT.95 In addition 
patients with CSMO may demonstrate a relatively normal CPT if fluid is present at 
the edge of the central ring. Therefore CSFT has been more commonly utilised in 
assessing DMO in research and clinical practice.93 
The reproducibility of OCT measurements has been demonstrated by several 
studies. In one small prospective study, 10 healthy volunteers and 10 patients with 
DMO underwent a series of radial OCT scans by two different examiners at one visit 
and then a further radial scan one week later.96 In healthy subjects the repeatability 
coefficient was 14 µm at the macula and ≤7 µm in all other areas, with inter-visit 
reproducibility of ±5 %. In patients with diabetes, the repeatability co-efficient was 
21 µm at the macula, with a reproducibility of ±6 %. The intraclass correlation 
coefficient was greater than 0.98 in all measurements for people with DM.  
In a retrospective study of 56 eyes97 of patients with DM with a follow up of 17 
months and a baseline mean CSFT of 219µm, the CSFT varied by a median of 18µm. 
None of the eyes had macular oedema at baseline or at last follow up. Thus the 
authors determined that a change of 10% or more in macular thickness over time 
would be clinically significant.  
The range of different OCT systems, such as time-domain (TD) and spectral-domain 
(SD), poses problems in comparing retinal thickness between them. SD-OCT systems 
generate significantly higher values for retinal thickness compared to TD-OCT.93 This 
is primarily due to the structures used as reference points. TD-OCT measures retinal 
thickness from the inner limiting membrane (ILM) to the IS/OS junction of the 
photoreceptors; SD-OCT measures from the ILM to the retinal pigment epithelial 
(RPE). To avoid this discrepancy all OCT imaging will be performed on a single SD-
OCT system. 
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3.4.1 OCT in detecting diabetic maculopathy 
In diabetic eye disease OCT has been used to demonstrate the presence and 
morphology of microaneurysms,98 diffuse DMO,41 retinal thickening,38 and retinal 
exudates as well as to monitor response to treatment.35 It allows for rapid detection 
and quantification of DMO.16 The main errors associated with OCT are based 
around the automated segmentation of the different retinal layers, substantial 
differences between platforms and misidentification of the foveal centre.99,100  
Studies have been performed to compare current methods of assessing diabetic 
maculopathy (clinical examination, FA) to OCT in the detection of DMO. A 
prospective, double-masked study comparing clinical examination to OCT in the 
detection of macular thickening identified moderate agreement between the two 
methods (κ=0.63 for the fovea, and 0.36-0.42 for the parafoveal zones).101 
Disagreement between the two techniques was more likely to be due to detection 
of thickening on OCT not seen clinically (68% of disagreements). The authors 
concluded that OCT could complement or maybe even supersede clinical 
examination in the detection of DMO. However the clinical significance of these 
extra cases of increased thickness was not discussed. One cause of the 
disagreement could be the use of the 78D lens for clinical examination rather than a 
60D lens or a contact lens, as used in the ETDRS, which could potentially 
underestimate the presence of macular thickening.   
A retrospective study of 195 eyes of patients with varying stages of diabetes was 
performed to compare OCT features with clinical and FA findings.38 CSMO was 
present in 57.4% of eyes and cystoid macular oedema (CMO) in 9.2%. There was no 
macular oedema in the remaining 33.3% of eyes. Retinal swelling was noted in 148 
eyes (75.9%) on OCT, 36 of which were not seen clinically. OCT demonstrated 
serous retinal detachment in 19 eyes that were not detected clinically or by FA. 
Macular oedema was detected by OCT but not clinical examination in 22% of eyes 
and by clinical examination and not OCT in 1% of eyes. The study also identified 
different types of macular oedema with varying levels of central foveal thickness 
(CSFT): ‘sponge like retinal swelling’ in 129 eyes with a mean CSFT of 347±110µm; 
CMO, 23 eyes, 441±96µm; sponge like swelling plus serous retinal detachment, 12 
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eyes, 460±135µm; combination of all, 7 eyes, 566±189µm. There was a statistically 
significant difference between the groups (ANOVA p<0.001, Bonferroni correction, 
p<0.05 for all patterns). There was also a significant negative correlation between 
CSFT and VA (correlation co-efficient: -0.528, p<0.01). There was no significant 
difference in CSFT between patients with macular ischaemia and those without. 
There was a statistically significant increase in macular thickness with increasing 
severity of leakage on FA (Bonferroni correction, p<0.05). As this was a 
retrospective study it is possible that the presence of macular oedema on clinical 
examination was underestimated.  
A prospective, cross-sectional study compared retinal thickness on OCT and 
fluorescein angiography findings in patients with macular oedema (n=136) and 
controls (n=30).102 OCT was performed using a Zeiss-Humphrey OCT 2000 scanner 
and comprised of three horizontal and one vertical scan through the fovea. Retinal 
thickness was manually measured at the centre of the fovea and 0.5mm and 1.0mm 
from the centre of the fovea. Foveal thickness was found to be greater in patients 
with macular oedema as compared to controls (307±136µm vs 153±15µm, 
p<0.001). In patients without CSMO there was no statistically significant difference 
in retinal thickness (159±15µm) though there were only 20 eyes. There was an 
intermediate relationship between average retinal thickness and leakage on OCT 
(r=0.44, p<0.00001) though this was not compared to central foveal thickness. 
There was no correlation between retinal thickness and retinal non-perfusion 
(r=0.004, p=0.96). Sensitivity was 89% and specificity 96% in detecting CSMO by 
measuring foveal thickness. These results suggest the value of OCT in detecting 
CSMO and assessing diabetic macular oedema but not macular ischaemia. Also the 
strength of the relationship between thickness and leakage suggests OCT cannot be 
used for determining treatment of CSMO. This study used only a central foveal 
point to determine foveal thickness, whilst our OCT records central foveal thickness 
as a mean thickness covering the central subfield, the mean CSFT. Measurements 
were performed by a single individual, resulting in possible bias in data recorded. 
Disruption of the photoreceptor layer in DMO has been associated with a reduced 
visual acuity. In a retrospective study of 62 eyes from 38 patients with DMO, the 
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inner segment/outer segment (IS/OS) junction over the central 1mm was assessed 
and correlated to visual acuity.103 38.7% of eyes did not demonstrate any 
disruption, whereas the remaining eyes had a mean percentage disruption of 
26.9%. There was a statistically significant correlation between percent disruption 
and visual acuity (p=0.0312) and a regression coefficient of -0.3, i.e. for each 1% 
increase in disruption, vision decreased by 0.3 letters. However 69.8% of eyes had 
previously received treatment, including laser photocoagulation, which is known to 
disrupt the RPE and thus the photoreceptor layer. The authors reported a trend 
association (p=0.07) between macular volume and visual acuity; this suggested that 
retinal thickening may be associated with changes in visual acuity. No multivariate 
analyses were performed to determine the relation between IS/OS junction 
disruption and visual acuity adjusting for macular thickness. 
In a retrospective case series, 15% of eyes with severe NPDR or PDR had retinal 
thickening on OCT not seen clinically.104 This has been termed ‘subclinical DMO’ 
though its importance has not yet been determined.  
3.4.2 Longitudinal studies of OCT in DMO 
In a retrospective study of male patients with type 2 DM and subclinical DMO, 
defined as OCT measured thickness of 200-300µm on OCT in the absence of clinical 
signs suggestive of macular oedema, the authors aimed to determine progression to 
CSMO.105 A control group was matched for age, sex, race and duration of DM and 
had an OCT thickness of <200µm. Of the 52 eyes with subclinical DMO, 16 (30.8%) 
progressed to CSMO as compared to 6 out of 72 eyes (8.3%) in the control group, 
though disappointingly statistical significance was not performed. Those who 
progressed to CSMO had a mean retinal thickness greater than those who did not, 
though statistical significance again was not provided. Multivariate analysis 
identified three risk factors for progression: prior history of CSMO (OR 3.69, CI 1.10 
to 12.31, p=0.03); 10µm increase in retinal thickness (OR1.15, CI 1.03 to 1.28, 
p=0.01); and lower age (each 1 year increase was associated with OR 0.91, CI 0.84 
to 0.98, p=0.01). The authors concluded that patients with subclinical DMO are at 
risk of developing CSMO but larger prospective studies were required. This study 
was retrospective and limited to male patients and so may not be fully applicable to 
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our clinical setting. Statistical significance was not calculated to compare subjects 
and controls and so the greater proportion of subjects developing CSMO may not 
be a statistically significant finding. More importantly there is no set definition of 
subclinical DMO and so it is difficult to compare different studies. In my thesis the 
diagnosis of severity of maculopathy is based on clinical examination and FA 
findings, as per current clinical standards, rather than OCT findings. 
3.4.3 OCT and systemic risk factors 
A prospective, cross-sectional study of patients with type 2 DM and mild or no DR 
looked at changes in macular thickness with respect to systemic risk factors.64 Mild 
DR was defined as less than 5 haemorrhages or micraoaneurysms (HMA) on 
examination. BP, serum HbA1c, lipid profile, VA, duration of DM and insulin use 
were recorded. Six line scans of 6 mm with the midpoint centred on the fovea were 
taken. A total of 37 points on the OCT were measured: i) central foveal thickness 
(CFT) was an average of the measurements at the midpoint of the six line scans; ii) 
total foveal thickness (TFT) was a mean of the 12 points at 500µm from the centre 
of the fovea; iii) total macular thickness (TMT) was a mean of all values within the 
6000µm ring excluding the CFT. Increased duration of diabetes was associated with 
a significantly decreased retinal thickness in patients with diabetes: CFT showed a 
regression coefficient of -0.28, p=0.003; TFT, r=-0.25, p=0.006; TMT, r=-0.25, 
p=0.003). There was no significant relationship between systemic HbA1c and the 
three macular thickness measurements (for all r= -0.07, p>0.46). There was no 
difference in thickness between patients with no DR and those with mild DR when 
adjusted for insulin use. Also there was no significant difference in retinal thickness 
between patients with DM and controls. The authors suggested that reduction in 
macular thickness with increasing duration of DM represented likely early retinal 
neurodegenerative changes. However, only a small subset of patients were included 
in the study (age between 60 and 75 years, type 2 DM, males >96%). So the results 
are not truly applicable to the general population. 
3.4.4 OCT in absence of diabetic retinopathy 
Similar to the study by Asefzadeh et al (2008),64 a prospective study of patients with 
type 1 DM was performed.106 The authors described no significant difference in 
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CSFT between patients with DM and controls. There was significant pericentral (i.e. 
the inner ring of the ETDRS grid) thinning in patients with mild DR (267±20µm) but 
not in those with no DR (276±14µm) as compared to controls (281±13µm, p=0.005, 
95% CI -23.10 to -4.46). The authors attributed these changes to neurodegenerative 
changes associated with DM. However the authors did not adjust for duration of 
DM which was significantly different between the two groups.  
A cross-sectional study of 39 subjects31 with DM but no DR reported a significant 
reduction in CPT (168.64µm vs 177.74µm, p=0.012) and mean photoreceptor layer 
thickness (PLT) (61.62µm vs 68.79µm, p<0.0001) compared to a group of healthy 
controls. Sub-analysis found decrease in CPT was only significant in those of age < 
50. Mean PLT was significantly reduced irrespective of age in patients with DM. 
Increased duration of DM was associated with decreased PLT but not CPT. Elevated 
HbA1c did not appear to influence CPT or PLT. This study only included patients 
above the age of 40. CPT was manually measured by a single grader; no inter- or 
intra-observer analysis was performed. Other systemic factors such as blood 
pressure and lipid profile were not recorded. No adjustment for age or duration of 
DM was made in the analysis of macular thickness.  
A similar study comparing OCT macular thickness between diabetic patients without 
DR and controls was performed with a different methodology.107 A single horizontal 
and a single vertical scan of 3 mm were performed through the foveal centre. Mean 
thickness was calculated along these lines to give mean retinal thickness. The 
authors reported a non-significant increased mean retinal thickness in patients with 
diabetes compared to controls (237.7µm vs 230.0µm, p>0.05). Sub-analysis 
revealed the superior retina to be significantly thickened in patients with diabetes. 
These results are in contrast to the study above.31 As the mean age was similar 
between the two studies it is likely that the difference may be due to differences in 
methods of calculating thickness, i.e. calculating the mean thickness across the 
central 3000 µm of the macula. In addition to relatively small numbers in both 
groups (n=34 and 32 in diabetics and controls, respectively), the study is limited to 
patients with type 2 DM.  
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3.4.5 OCT and VA 
Several studies have attempted to relate foveal thickness to VA.108-111 In a 
retrospective study of 27 subjects with CSMO108 there was moderate correlation 
between BCVA on Snellen chart and macular thickness (r=0.55, p=0.0027); however 
this study was limited to patients below the age of 40 with advanced maculopathy.  
In a prospective study comparing logarithm of minimal angle of resolution (logMAR) 
BCVA to CPT in patients with maculopathy111, the authors reported a significant 
decrease in BCVA with increasing CPT in patients with CSMO (r=0.640, p=0.0013); 
however the authors did not report their findings in patients with maculopathy 
without CSMO or healthy controls.  
In a prospective study of 251 eyes with definite increased retinal thickness on 
clinical examination, there was a moderate correlation between ETDRS protocol 
BCVA and CPT on OCT (r=0.52).109 The authors reported a 4.4 letter decrease in 
BCVA for every 100 µm increase in CPT (CI 3.5-5.3, p<0.001) following macular laser 
treatment. A multivariate analysis estimated a decrease of 3.6 letters (p<0.001). 
Following macular laser treatment a subset of eyes (17%) demonstrated a 
paradoxical improvement in BCVA with increasing CPT and 26% of eyes 
demonstrated worsening BCVA despite improvement in CPT. Once again this study 
focussed on individuals with CSMO with no data presented on non-CSMO 
maculopathy.  
In a prospective study of 62 eyes, CSFT was compared to ETDRS protocol BCVA in 
subjects with CSMO.110 The authors reported a moderate correlation between CSFT 
and BCVA only where thickening involved the central 1000 µm zone of the macula.   
Therefore OCT measured thickness appears to only be correlated to VA when 
severe disease is present and involves the central macula. Therefore, in early stages 
of diabetic maculopathy, OCT appears not be beneficial in determining severity of 
disease.  
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3.4.6 OCT to classify DMO 
OCT has been used to propose a classification for DMO.112 Their classification 
subdivided retinal thickening in DMO according to presence or absence of cystoid 
spaces and presence of subretinal fluid. However OCT findings had not been 
correlated to the current methods of assessing severity of diabetic maculopathy, 
namely FA, BCVA or slit lamp biomicroscopy. Thus this classification has not been 
universally accepted. 
3.4.7 OCT in my study 
OCT has become an important adjunct in the assessment and management of 
diabetic maculopathy. In my study I will perform OCT and use the CSFT to assess 
central macular function. I will correlate CSFT to both severity of disease and to the 
assessments of retinal function that I use in my study (mfERG, MP, OP and CS). In 
Chapter 5 I describe the technique I have developed to compare between OCT, 
mfERG and MP.  
3.5 Diabetic Retinopathy Clinical Research Network 
The DRCR.net is a collaboration of US institutes that lead multicentre research into 
diagnostic and therapeutic strategies for diabetic eye disease, including diabetic 
maculopathy.113 It is funded by the National Eye Institute and the National Institute 
of Diabetes and Digestive and Kidney disease, a part of the National Institutes of 
Health (a branch of the US government that funds medical research). It is comprised 
of community-based and university-based practices. As of January 2014, a total of 
179 sites and 786 investigators have joined the DRCR.net.  
As part of the DRCR.net, several studies have been completed or currently being 
undertaken. Each study is referred to as Protocol A, B, C etc. Details of each 
protocol are available on its website (www.drcr.net). I will refer to specific protocols 
in the following paragraphs.  
One study (Protocol B) prospectively compared treatment of CSMO with either focal 
or grid laser (n=330) to two doses of intravitreal triamcinolone (IVTA): 1mg (n=256) 
and 4mg (n=254).114 Subjects were followed at 4 monthly intervals and BCVA and 
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OCT were recorded. Subjects were retreated if there were signs of inadequate 
response or worsening. Short term results showed the 4mg IVTA to be superior. At 
24 months VA was better in the laser group as compared to the 1mg IVTA (p=0.02) 
and 4mg IVTA (p=0.002) groups. However VA only improved by 1 letter in the laser 
group. In addition use of IVTA was associated with an increased risk of developing 
elevated intraocular pressures and cataract surgery.  
A pivotal DRCR.net study in the management of DMO was Protocol I which 
compared single and combination therapies of intravitreal anti-VEGF injections 
(ranibizumab), intravitreal triamcinolone injections and macular laser. In this 
prospective study of 691 patients (854 eyes), the authors compared four groups: i) 
sham injection + prompt laser (n=293), ii) ranibizumab + prompt laser (n=187), iii) 
ranibizumab + deferred laser for ≥24 weeks, and iv) triamcinolone + prompt laser.115 
Subjects were followed for a minimum of 12 months. Subjects who received 
ranibizumab, regardless of whether laser was prompt or deferred, had a 
significantly greater improvement in VA and reduction in OCT CSFT as compared to 
subjects with laser alone (p<0.05) at both 12 months and 24 months. The authors 
concluded that intravitreal ranibizumab should be considered for the treatment of 
DMO.  
In Protocol A, the authors compared two methods of laser photocoagulation for 
diabetic maculopathy.116 An OCT based system was developed to identify 
characteristics of DMO that would explain variations in VA and predict outcome 
after laser treatment.  A total of 323 eyes were included. A database of 97 eyes of 
patients with diabetes but no maculopathy were used to determine normal mean 
values for each of the nine OCT subfields described above. A subfield was 
determined thickened if the thickness value was ≥3 standard deviations above the 
normal mean value. Associations between number of thickened subfields and a 
variety of outcome variables, including BCVA, CSFT and total macular volume were 
explored for both cross-sectional and longitudinal analysis. Better baseline VA was 
associated with fewer thickened subfields (r=0.38). However change in visual acuity 
showed no association with baseline number of thickened subfields at either 3.5 
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months (r=0.08) or at 12 months (r<0.01) after laser photocoagulation. Thus retinal 
thickness on OCT and VA were only moderately correlated.  
These pivotal studies in the DRCR.net collaboration have advanced the 
management of diabetic maculopathy and the role of OCT in its analysis. Due to the 
impact of laser and intraocular treatment on changes in both VA and OCT thickness, 
I will exclude any subjects who have undergone treatment for diabetic maculopathy 
to ensure accurate comparisons between my groups. I will also compare retinal 
thickness to central macular function to determine correlation between OCT and 
mfERG, MP, OP and CS. 
3.6 Systemic control 
3.6.1 Steno-2 study 
In this landmark prospective, randomised, parallel trial, Gæde et al (2003)  
compared two treatment regimes in the development of macro- and microvascular 
complications in subjects with type 2 DM.117 Eighty subjects were treated with 
conventional therapy (as per the recommendations of the Danish Medical 
Association) and 80 subjects received intensive therapy (as per study protocol). 
Intensive therapy comprised a specific dietary regimen, a protocol for prescribing 
antihypertensive agents and oral hypoglycaemic agents.  There was a mean follow 
up of 7.8 years with follow up every three months. Subjects in the intensive therapy 
group were significantly less likely to develop retinopathy (p=0.02) and blindness 
(level of VA was not reported) (p=0.03) as compared to the conventional group. The 
relative risk of development or progression of retinopathy was 0.42 (CI 0.21-0.86) in 
the intensive therapy group. The authors concluded that long term, targeted, 
intensive therapy reduced the risk of both cardiovascular and microvascular 
complications by about 50% in subjects with type 2 DM and microalbuminuria. 
However it should be noted the low numbers in each group with a 20% drop out 
rate by the end of follow up.118 
3.6.2 Cholesterol 
One feature of diabetic maculopathy is the presence of exudates, often 
accompanied by the presence of retinal thickening.119 Exudates are formed as a 
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result of lipoproteins “leaking” from damaged retinal vessels into the extracellular 
space. 
In the ETDRS 2709 patients with diabetes had baseline serum cholesterol levels 
available.100 Fundus photographs were graded by the reading centre staff and the 
extent of hard exudates determined as per the criteria in Table 3.2. 
Table 3.2: Grading of presence of hard exudate from colour photographs in the 
ETDRS (Std = standard)119  
Severity Level Description 
None No hard exudate present 
Questionable Questionable hard exudate present 
Definite Definite hard exudate but < Std photograph 3 
Obvious Hard exudate ≥ Std photograph 3 but < Std 
photograph 5 
Moderate Hard exudate ≥ Std photograph 5 but < Std 
photograph 4 
Severe Hard exudate ≥ Std photograph 4 
Cannot grade Unable to grade image 
 
Of the 2709 patients, ⅔ were aged over 40 and 57% had a duration of DM ≥15 
years. A multivariate logistic regression analysis was performed, adjusting for 
known confounders such as age, HbA1c, baseline retinopathy severity and extent of 
retinal thickening. Other confounders such as duration of diabetes or type of 
diabetes were not found to be statistically significantly associated with presence of 
hard exudate, with statistical significance set at p≤ 0.01. Analysis was performed on 
photographs graded as obvious or higher.  
The presence of hard exudates was also associated with worsening visual acuity 
(p=0.002) even when adjusting for retinal thickness.119 Increasing severity of hard 
exudates was associated with an increased risk of developing moderate visual loss 
(MVL, a decrease of ≥3 lines on the visual acuity chart); at 5 years ~45% of patients 
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with a grading of hard exudate of ‘severe’ at baseline developed MVL as compared 
to 15% of individuals with no hard exudates at baseline (odds ratio [OR], 2.27; 
confidence interval [CI] not specified; p<0.001). Even individuals with a grading of 
‘obvious’ were 46% more likely to develop MVL (OR 1.46; CI not specified). 
Patients with a cholesterol level of ≥6.21 mmol/l  were twice as likely to have hard 
exudates as compared to those with a level less than 5.17 mmol/l (odds ratio [OR], 
2.00; 99% confidence interval [CI], 1.35-2.95). In addition, Cox proportional hazards 
analysis of those in whom laser was deferred revealed that elevated levels of 
cholesterol were associated with the development of hard exudates 50% faster 
than those with levels below 5.17 mmol/l (OR, 1.54; 99% CI 1.17-2.02). Individuals 
with elevated serum cholesterol (>6.21 mmol/l) were 50% more likely to develop 
MVL as compared to those with level <6.21 mmol/l (OR 1.5; 99% CI 1.1-2.1). 
However we do not know the number of patients in each group and whether they 
were on any lipid lowering agents, though only 15 of the 3711 patients enrolled into 
ETDRS were known to be on a lipid lowering agent. Also we do not know if there 
were any changes in serum cholesterol level over time as only baseline cholesterol 
levels were used for analysis. The authors have not explained why levels of 5.17 and 
6.21 mmol/l were chosen for analysis, suggesting an arbitrary selection in post hoc 
analysis. Though the authors mention that eyes treated with laser at baseline were 
less likely to develop obvious hard exudates, there is no data provided to confirm 
statistical significance.  
These results indicate that serum cholesterol, and retinal exudates, are a risk factor 
for developing visual loss and hence should part of the investigative process. 
Reduction of serum cholesterol forms an important part of the management of 
patients with DM; although it is often overlooked.  
In a retrospective study of subjects with exudates in the presence of CSMO, mean 
serum cholesterol was assessed over a six month period.120  Cholesterol levels were 
significantly elevated (p<0.02) in subjects with progressing exudates compared to 
subjects in whom the  exudates had regressed. The former group also 
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demonstrated a significant decrease in BCVA (p<0.01). The authors concluded that 
strict lipid lowering therapy may result in better anatomical and visual outcomes.  
An uncontrolled case series of patients with diabetic maculopathy and elevated lipid 
profile were treated with oral atorvastatin.121 Subjects underwent clinical 
examination and FA at baseline and 3, 6 and 12 months. 18 eyes were included. At 
12 months, subjects had a significant decrease in total cholesterol (p<0.05). In 
addition exudates and fluorescein leakage had regressed. However the authors 
have not reported any changes in other systemic risk factors such as blood pressure. 
In the ACCORD Eye study the effect of intensive control of systemic risk factors was 
investigated in the development or progression of DR. Subjects were enrolled to 
intensive glycaemic control, intensive BP control or receiving simvastatin with either 
fenofibrate or placebo.122 Intensive glycaemic control was associated with a 33% 
reduction in relative risk of progression of DR but there was no significant reduction 
in MVL. Intensive BP control offered no significant benefit in reduction of DR 
progression or MVL. Subjects in the fenofibrate group showed a significantly lower 
triglyceride level (p<0.001) but not HDL or LDL cholesterol level. These subjects also 
demonstrated a significantly decreased rate of progression (CI, 0.42-0.87; p=0.006) 
but no significant difference in MVL (p=0.57). 
The FIELD study was a 4 year, multinational study that compared fenofibrate 
(n=4895) to placebo (n=4900) with outcomes being progression of retinopathy and 
requirement of laser for diabetic retinopathy in subjects with type 2 DM.123 Subjects 
receiving fenofibrate had a significantly decreased requirement for first laser (HR 
0.69, p=0.002). There was no significant difference in 2-step progression of DR 
between the two groups (p=0.19). There was no significant benefit of fenofibrate in 
reducing progression to DR in subjects with no DR at baseline (p=0.87); however, in 
subjects with pre-existing DR there was a significant reduction in progression with 
fenofibrate use (p=0.004). The authors also reported fewer instances of DMO in the 
fenofibrate group, though this was not significant (p=0.09). However, the subjects 
who underwent laser had no significant difference in serum cholesterol compared 
to those who did not receive laser; they did however have significantly higher 
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HbA1c, systolic BP, duration of DM, and rates of microvascular complications and 
were more likely to be on insulin compared to those who did not receive laser. The 
authors concluded that fenofibrate use, in addition to correction of other systemic 
risk factors, reduced need for laser treatment through reduction of inflammatory 
processes at the retinal capillary level rather than changes in serum lipid levels. One 
limitation of the study is that longitudinal values of systemic risk factors have not 
been reported. Therefore the need for laser or progression of retinopathy may be 
related to worsening systemic risk factors, rather than the effect of fenofibrate 
reducing risk. No correction for differences in systemic risk factors at baseline was 
made. 
Serum cholesterol appears to play a significant role in the development of diabetic 
eye disease. In my study I will perform serum cholesterol levels at baseline and in 
subsequent follow-up visits. I will record lipid-lowering agent use at baseline. Where 
appropriate, corrections for differences in serum cholesterol between groups will 
applied to data analysis. 
3.6.3 Glycated serum haemoglobin level (HbA1c) 
Serum HbA1c is the gold standard for the assessment of control of DM and has 
more recently gained acceptance for the diagnosis of DM.124 Association between 
serum HbA1c and the development of microvascular complications secondary to 
DM has been extensively studied. 
The United Kingdom Prospective Diabetes Study (UKPDS) was a landmark, 
multicentre, randomised trial that assessed therapies for DM in subjects with type 2 
DM. It received funding from the UK Medical Research Council, US National 
Institutes of Health, British Diabetic Association, along with several other local and 
commercial groups. In Report 35, the investigators longitudinally evaluated levels of 
glycaemia in the development of macro- and microvascular complications of DM.125 
Subjects were allocated to two groups: conventional control (n=1138) aimed for a 
fasting plasma glucose concentration <15.0 mmol/l and intensive control (n=2729) 
aimed for a concentration <6.0 mmol/l. The authors reported that increase in mean 
updated HbA1c was associated with an increased risk of development of 
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complications even after adjustment for various baseline variables. Though there 
was no specific analysis for development of DR or maculopathy, the authors 
reported that for every 1% reduction in HbA1c, there was a 37% decreased risk of 
developing microvascular complications and a 19% decreased risk of requiring 
cataract extraction. The authors concluded that any improvement in glycaemic 
control is likely to reduce risk of development of complications. 
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study was a 
parallel-group, randomised, multicentre trial that investigated the control of 
systemic factors in the development of diabetic microvascular complications.126 In 
the core study subjects were randomised to intensive glycaemic control (HbA1c 
<6.0, n=5128) or standard glycaemic control (HbA1c 7.0-7.9, n=5123). In addition 
subjects were randomised to receive either intensive BP control or a lipid 
intervention depending on baseline levels of both. Intensive therapy offered no 
significant reduction in risk of developing microvascular or ocular complications. 
However there was an increase in total mortality in the intensive group and so the 
study was stopped before reaching completion. The authors therefore concluded 
that tight glycaemic control may neither be achievable nor desirable. 
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation (ADVANCE) study investigated the effect of intensive 
glycaemic control on rates of macrovascular and macrovascular complication 
development.127 A total of 11,140 subjects aged 55 years or over with type 2 DM 
were randomised to either standard or intensive glucose control. Though there was 
reduced frequency in the major macrovascular events (p=0.01), there was no 
significant effect on DR development (p=0.50) or visual deterioration. 
The Veteran Affairs Diabetes Trial (VADT) assessed the effect of intensive glycaemic 
control on retinopathy.128 There was no significant change in either worsening of 
retinopathy or development of CSMO, though there was a trend in favour of 
intensive control (p=0.07). However the study was limited through having a 
predominantly male cohort, restricted availability of newer drugs and being 
underpowered. 
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In a cross-sectional study, Zander et al (2000) studied association between diabetic 
maculopathy and various risk factors.129 A total of 1796 patients with type 1 DM and 
1563 with type 2 DM were recruited. Clinical examination and FA were used to 
grade DR and assessing maculopathy. Diabetic maculopathy was deemed present if 
any of the criteria for CSMO was met. Maculopathy was reported in 15% of subjects 
with type 1 DM and 28% of subjects with type 2 DM. HbA1c levels were not deemed 
to be significantly different between subjects with maculopathy and those without. 
However elevated serum creatinine (p<0.01) and serum cholesterol (p<0.01) were 
reported in subjects with type 1 DM and maculopathy. Other risk factors 
significantly associated with prevalence of maculopathy were increasing duration of 
DM in both type 1 and type 2 DM, elevated cholesterol levels in type 1 DM and 
elevated BP in type 2 DM. However the authors have not reported medication use; 
therefore prior systemic control of HbA1c cannot be determined. 
 A community based survey in Taiwan of patients with type 2 DM aimed to find a 
relationship between the number of MA and systemic risk factors.130 In 527 
patients, a single 45o colour photograph centred at the macula was taken to 
determine presence and location of MA. Grading revealed 83.5% of patients had no 
DR, 6.3% demonstrated only MA and 10.2% demonstrated MA with other diabetic 
retinal lesions. Elevated HbA1c was associated with more MA (r=0.38, p=0.03). 
Every 10% increase in HbA1c was associated with an increase of 0.7 MA. Multiple 
logistic regression demonstrated duration of DM and HbA1c to be significantly 
associated with increasing level of retinopathy. Systolic and diastolic BP and 
cholesterol were found to be non-significant. As this study was cross-sectional it is 
probable that the retinopathy reflected previous systemic control. This may explain 
why cholesterol and blood pressure were found not to be clinically significant. Only 
MA present within the macula were considered; so patients with MA in the 
peripheral retina were considered to be free of DR. Those subjects excluded were 
found to be significantly older than the group studied, introducing possible 
selection bias. Only patients with type 2 DM were included; so results may not be 
applicable in type 1 DM.  
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One important consideration is the improvement in systemic control over the years. 
In the ETDRS, 40% of patients had a HbA1c of ≥10%.67 In the DRCR.net only 17% of 
subjects with an HbA1c of ≥10%.131 Therefore more recent studies are likely to have 
a patient population comparable to mine. 
HbA1c, unlike cholesterol, has not been shown to be associated with diabetic 
maculopathy. Nevertheless, it remains an important marker of DM control and is 
routinely assessed in clinical practice and research in diabetic eye disease. I will 
record HbA1c and perform inter-group comparisons. Where appropriate I will 
correct for HbA1c for such comparisons.  
3.6.4 Blood pressure 
In the UKPDS Reports number 36, 38 and 60, the relation between systolic BP and 
risk of developing complications in type 2 DM was assessed.132   
In Report 36, the incidence of developing complications was assessed in 4801 
patients, and 3642 patients underwent evaluation for potential confounders.133 
Ophthalmic end points were retinopathy requiring laser treatment and vitreous 
haemorrhage. The authors reported a twofold increased risk of developing any 
complication over a systolic BP range from 114 mmHg to 168 mmHg. Incidence of 
microvascular complications increased from <10 per 1000 years in the group with 
systolic BP <120 mmHg to 25 per 1000 years in the group with systolic BP >160 
mmHg. There was no threshold limit for any complications. The authors also 
reported that for every 10 mmHg decrease in systolic BP, the risk of developing 
microvascular complications decreased by 13% (p<0.00001). 
In report 38, the authors compared subjects who received intensive BP control 
(<150/85 mmHg, n=758) and those who received less intensive control (<180/105 
mmHg, n=390).134 Baseline characteristics were similar between the two groups. 
Median follow up was 8.4 years. Mean BP at end of study was 144/82 mmHg and 
154/87 mmHg in the intensive and less intensive groups, respectively. The author 
reported 37% reduction in risk of microvascular disease (mainly retinal 
photocoagulation) and 47% reduction in decrease in VA by ≥3 lines on ETDRS chart 
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in the intensive control group. Sub-analysis revealed no significant difference in risk 
of vitreous haemorrhage, most likely due to patients receiving treatment for PDR.   
In report 69, 1148 patients were assessed for development of retinopathy and 
maculopathy over 7.5 years.132 Subjects in the intensive BP control group developed 
significantly fewer exudates at 7.5 years (RR 0.53; p<0.001) and were less likely to 
require photocoagulation for maculopathy (RR 0.58; p=0.02). However the authors 
did not comment on rates of development of CSMO or ischaemic maculopathy. 
There was a small reduction in risk of developing MVL (Snellen VA 6/60 or worse) of 
3.1% in the intensive control group compared to 4.1% in the less intensive control 
group (RR 0.76, p=0.46).  The authors concluded that high BP was related to an 
increased risk of developing diabetic eye disease and tight BP control reduced risk 
of diabetic eye disease. 
In the ACCORD Eye study, subjects were randomised to intensive vs standard blood 
pressure control.122 At 4 years there was no significant difference in progression of 
retinopathy (p>0.2) or rates of MVL (p>0.1) between the two groups. However no 
results were published with respect to formation of diabetic maculopathy.  
Elevated BP is associated with an increased risk of developing diabetic retinopathy. 
In my study I will record BP for inter-group comparisons and, where appropriate, 
adjust comparisons accordingly.  
3.7 Functional assessment of diabetic maculopathy 
As described above the diagnosis of diabetic maculopathy is currently based on 
clinically visible changes combined with OCT findings to determine management of 
the maculopathy. More recently studies have shown that neural changes within the 
retina precede vascular changes. These neural retinal changes may be detected by 
assessing retinal responses to stimulation by light. These responses can be detected 
both objectively by electrodiagnostic testing (multifocal electroretinography, 
oscillatory potentials) and subjectively by microperimetry. I intend to use both 
methods to assess retinal function in different stages of diabetic maculopathy.  
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3.7.1 Electroretinography 
In the middle of the nineteenth century, animal experiments identified that eyes 
carried an electrical potential.135 Further experiments identified the retina to be the 
source of the electrical potential and that it responded to light. In 1877 Dewar 
performed in vivo experiments leading to the first successful recording of the 
human electroretinogram (ERG).135 The following 50 years saw an improvement in 
the recording equipment and clearer delineation of the electrical potential obtained 
in the presence of flashing lights. Extensive investigation by Granit in the fourth and 
fifth decades of the 20th century resulted in the identification of the various 
components of the ERG that are still used today.135 
3.7.2 Components of an ERG 
The wave pattern of an ERG represents the various structures of the neural retina 
and is illustrated in Figure 3.6. The initial negative deflection, the a-wave, 
represents photoreceptor activity and is the first response seen after retinal 
stimulation by a flash of light. The following positive deflection is termed the b-
wave and represents fluxes of potassium ions in Müller cells, though is highly 
dependent upon photoreceptor and bipolar cell function.23   
3.7.3 Advent of the multifocal electroretinogram 
The standard ERG evaluates the function of the retina as a whole, full field ERG.135 
Though this has benefits for assessing many retinal disorders, it does not provide 
information on localised disease. This led to the development of the multifocal 
electroretinogram (mfERG). 
The mfERG was demonstrated by Erich Sutter in 1991 and allows for simultaneous 
measurements of multiple retinal responses at different locations.136,137 It produces 
a topographical map of retinal function covering the central 40-50o of the retina, 
providing information on macular function.  
There are several commercially available systems for recording mfERG: the VERIS 
system (Electro-Diagnostic Imaging, San Mateo, CA), the RETIscan system (Roland 
Consult, Wiesbaden, Germany), and the Metrovision system (Metrovision, 
Pérenchies, France). Our unit utilises the RETIscan system. Each system has its own 
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set of parameters which influence the data collected. The International Society for 
Clinical Electrophysiology of Vision (ISCEV) has produced guidelines to aid clinical 
scientists and researchers with standardisation of test parameters and 
interpretation.136 
The standard mfERG predominantly measures cone function.136 There are 2 
responses produced by the mfERG that are most commonly analysed: the first order 
kernel and the second order kernel.  
The first order kernel represents the largest response and is a biphasic wave. It is 
the one that is most commonly presented as clinical data. This kernel is obtained by 
adding all the results generated by a bright flash and then subtracting away all the 
results generated by a dark flash. Experiments suggest that the first order kernel 
response represents cells in the outer retina, i.e. the photoreceptors and the on and 
off bipolar cells.136 
The second order kernel is a much smaller response and suffers from a poorer 
signal-to-noise ratio. Though this component was meant to represent ganglion cell 
activity, it appears to be more non-specific and is instead used to assess how the 
mfERG response is affected by the preceding flash.136 
3.7.4 Analysis of mfERG responses 
The responses generated by the mfERG may be analysed by several methods. Each 
discrete response may be analysed individually. More commonly, the responses are 
grouped and averaged for each ring structure. In my study, I utilise a 19 hexagonal 
array centred on the fovea (Figure 3.5a). Each hexagon, when stimulated, produces 
an individual waveform which can be studied. A three-dimensional topographical 
map is produced so the clinician can visualise any defects in retinal function (Figure 
3.5b).  
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Figure 3.5: Output of a 19 hexagon mfERG array: a) waveform generated for each 
hexagon; b) 3D topographical representation of amplitudes relative to the standard 
normal 
  
The main parameters recorded from the waveform are amplitude and implicit times 
(Figure 3.6). In my study amplitude recorded is from the first order kernel and is the 
height of the wave from the N1 trough through to the P1 peak. Implicit time is 
measured from the onset of stimulus to the peak of the waveform. Amplitude 
represents the strength of the response while implicit time represents speed of the 
response from stimulus. 
Figure 3.6: Schematic representation of the ERG response. Dashed lines represent 
stimulus (a); time from stimulus to 1st peak (implicit time, b); height of the response 
(amplitude, c)    
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Patients are light adapted for 15 minutes prior to commencement of data 
acquisition with the lights left on for constant light adaptation. This is because 
alterations of extent of retinal bleaching will affect the results obtained.136 
Monocular recording is carried out as it facilitates better fixation monitoring.136 
 
3.7.5 Factors affecting mfERG results.  
Patients are maximally dilated prior to testing. This is to maximise retinal 
illumination as changes in pupil size results in significant alterations of the 
amplitude and latency recorded.136 Alterations in room lighting have been shown to 
affect retinal bleaching and hence results obtained. Thus it is essential that patients 
are light adapted prior to recording. 
Increasing age is associated with a decrease in amplitude and increase in implicit 
time.137 Studies have reported a 5 to 10.5% reduction per decade in P1 amplitude 
and a 1 to 1.2% increase in P1 implicit time per decade.138,139  This effect seems to 
be more pronounced in the central retina compared to the peripheral retina. The 
causes of these age-related changes are a combination of optical factors and 
decreased neural retina function, such as loss of photoreceptors and inefficient 
synaptic transmission.136,138 
The presence of mild or moderate cataract leads to a reduction in P1 amplitude as 
compared to patients with very mild cataracts.140 This effect appears to be due to 
light scattering. Patients who underwent cataract demonstrated an improvement in 
mfERG responses.136,141 There did not, however, appear to be significant change in 
implicit times.142 Interestingly, light scattering conversely increases peripheral 
mfERG responses.117 
Refractive errors and axial length also appear to influence mfERG responses. 
Amplitudes were reduced and implicit times delayed as refractive errors 
increased.143 Increased axial length also results in reduced amplitudes. One 
postulated cause is the loss of cone function associated with high myopia. Chen et 
al144 demonstrated prolonged implicit times in myopic patients. They also 
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demonstrated that refractive error appeared to have a greater effect than axial 
length.  
Optical defocus has been shown to reduce P1 amplitude of the mfERG response by 
12 percent with blurring of both +1.00D and +3.00D.145 It is postulated that the area 
stimulated was larger than the hexagon resulting in reduced contrast of the image. 
The effect appeared to be greater in the central macula as compared to the 
peripheral macula. However there did not appear to be any influence on implicit 
time. However this study was performed on the VERIS system with a 103 hexagonal 
pattern. 
A study of eight patients found no significant difference in amplitude or latency in 
the central 4o but significant difference in the peripheral 6 to 25o due to refractive 
blur using the Retiscan system.146 They recommend refraction should be corrected 
prior to testing. They also demonstrated that refractive errors of up to 6 dioptres 
did not influence amplitude or implicit time. 
Therefore mfERG appears to be a useful test. There are several parameters which 
could influence the results and make them difficult to interpret. Nevertheless, 
mfERG provides an objective method of assessing neuronal function in the macula 
and should be useful in assessing diabetic maculopathy.  
3.7.6 Application of mfERG in diabetic retinopathy 
MfERG has been used in several studies to assess retinal function in the presence of 
DM. Most of these studies have found implicit time to be more sensitive than 
changes in amplitude in detecting retinal dysfunction.136 
Harrison et al (2011) reported on a prospective study of 78 eyes of 48 patients with 
DM.147 The authors aimed to predict development of DR in patients with no 
retinopathy at baseline using mfERG implicit time (IT) and were followed for 
between 1 to 6 years (mean 3 years). All patients also underwent HbA1c 
measurement and dilated fundus examination with colour photos. The mfERGs 
were recorded using the VERIS 4.3 system with a 103 hexagon stimulus array and a 
frame rate of 75Hz subtending 45 degrees of the retina. The mfERG IT of 50 control 
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subjects was used for comparison. A Z-score was assigned to each implicit time of 
diabetics using the mean and standard deviation of controls. The authors reported a 
20% (OR 1.16, 1.02-1.33) increase in risk of developing retinopathy with a one unit 
Z-score increase (i.e. delay) in mfERG IT. Duration of DM was reported as a risk 
factor too, with risk of developing retinopathy increasing by 7% (OR 1.07, 1.00-1.15) 
with every increasing year of duration. Patients with type 1 DM appeared to be at 
greater risk of developing retinopathy with comparatively small delays in implicit 
time.  
A study of 37 eyes in 27 patients looked at the presence of exudate and its effect on 
mfERG recordings of amplitude and IT.148 The authors reported a statistically 
significant prolongation of IT in areas of exudates compared to those without 
exudate. Amplitude was only reduced in the parafoveal and extrafoveal regions. The 
authors concluded that IT was prolonged as retinal capillaries are affected in DR and 
are responsible for supplying the inner nuclear layer of the retina, the same region 
as the bipolar cells. Limitations of the study include small numbers of patients (15 
eyes with exudates and 16 eyes without exudates), lack of information on severity 
of DR or maculopathy, and no assessment of macular ischaemia. Also, no 
explanation was given for how overlapping hexagons and the OCT were correlated. 
In a prospective cross-sectional study of 26 eyes of patients with DM with 
background DR,149 mfERG was performed on the VERIS system and used to evaluate 
macular function and correlate with macular thickness and medical parameters. 
Values recorded for mfERG included amplitude and IT for the central subfield, 
middle ring and outer ring corresponding to the ETDRS grid. Sixteen of the 26 eyes 
had macular oedema. Increase in central macular thickness was associated with a 
reduction in amplitude (r= -0.541, p= 0.004) and a prolongation of IT (r= 0.548, p= 
0.004) in the central area of the mfERG. BCVA was positively correlated with 
amplitude in the central area of the mfERG (r= 0.630, p= 0.001), but there was no 
correlation with IT. There was no correlation between mfERG and size of FAZ, 
though mean area of FAZ was 600 ± 24µm. No details were provided on 
architecture of the FAZ or the perifoveal capillaries. Increasing age was significantly 
associated with a reduction in central amplitude (r= -0.514, p= 0.029) but not 
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prolongation of IT. Increasing duration of DM was paradoxically associated with 
higher amplitudes (r=0.496, p=0.043) and shorter IT (r= -0.573, p= 0.016). No 
correlation was found between HbA1c and systolic BP. Subgroup analysis revealed a 
macular thickness greater than 300µm was associated with a significantly lower 
mfERG amplitudes (15.7±10.0 vs 29.3±10.0 nV/deg2; p=0.002), longer IT (32.5±3.6 
vs 29.1±4.5 ms; p=0.01) and lower VA (70 vs 87 letters (p=0.001). However no 
multivariate analysis was performed to adjust for factors such as age. Though 
retinopathy was graded, the authors did not state the severity of macular oedema 
and no comparison was made to healthy controls.  
In my study I use a 19 hexagonal mfERG array. However several studies have used 
103 hexagons (Figure 3.7).147,150-153 In these studies, rather than analysing individual 
hexagons, retinal zones are created where the amplitudes and IT of one hexagon 
and its surrounding hexagons are analysed together as one zone. Therefore 35 
zones are created. The difficulty with using so many hexagons is the time required 
to record responses, the poor signal to noise ratio and the post-procedural analysis 
required to analyse the individual retinal zones. The long duration of recording can 
be uncomfortable for patients. In addition, smaller stimuli have been shown to be 
more susceptible to fluctuations in fixation.154 Subsequently, a 61 pattern hexagon 
was developed.155 Though the duration of recording was reduced, the poor signal to 
noise ratio and the need for post-procedural analysis still remained. Therefore the 
19 hexagonal array is used in our unit.137 
Figure 3.7: Schematic of the 103 hexagonal array with a corresponding 3D 
topographical representation of output 
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In my study I will assess central macular function using mfERG in varying severity of 
diabetic maculopathy. I will assess both amplitude and IT and correlate them to 
retinal thickness. I will also evaluate change in amplitude and IT over 6 and 12 
months to determine whether change in function correlates to severity of disease.  
3.7.7 Oscillatory potentials in diabetic retinopathy 
Along the ascending limb of the b-wave of the ERG are small waves of increased 
frequency. These are known as oscillatory potentials (OPs) and are thought to 
originate from the inner retinal layers, especially the amacrine cells.156,157 ERG 
studies have shown these cells to be preferentially affected in diabetic retinopathy. 
As the retinal circulation is located within the inner retina, and DM is associated 
with disruption of this circulation, it is not surprising that OPs may be affected. 
In a retrospective study with a 6-8 year follow up, subjects with NPDR and abnormal 
OP amplitudes were more likely to progress to PDR than subjects with normal OP 
amplitudes (53% vs 4%).158 However information regarding severity of NPDR was 
not provided and follow up varied between subjects. No information was provided 
on level of maculopathy. 
As mentioned above, current mfERG stimuli assess function of the bipolar cells with 
only minor contribution from the amacrine cell. Thus assessing retinal dysfunction 
using OPs is likely to yield greater information. There have been some studies that 
demonstrate a delay in OP IT in patients with DM without DR155 in addition to a 
reduction in amplitude in patients with pre-proliferative DR.159 However, these 
studies averaged large areas of the retina rather than assessing local responses.  
Reduction in OP amplitude has been associated with DR severity.156 In a longitudinal 
study of 80 insulin-dependent diabetics with no clinical signs of DR, 35% developed 
DR at final follow up.160 OP amplitude had decreased by 46% in this group, 
compared to a 25% drop in those who did not develop DR. This difference was 
statistically significant (p<0.001). In addition of those who developed DR, 61% of 
eyes demonstrated a decrease in OP amplitude prior to development of DR. The 
authors concluded that subnormal OP amplitude may identify those at risk of 
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developing DR. However the study did not report on development of DMO or 
CSMO. The study only included patients below the age of 40.  
In a prospective study of 24 eyes of 12 patients with type 1 DM and no DR, and 26 
eyes of 14 healthy patients, the authors performed multifocal OPs to assess changes 
in implicit times and amplitude.155 Recordings were performed on the VERIS system 
using a 61 hexagonal pattern. For analysis one eye of each patient was selected at 
random and the authors comment on two peaks generated by the recording. The 
authors concluded that there was a significant delay in IT at fovea in subjects with 
DM compared to healthy controls (22.22±0.95ms vs 22.95±0.92ms) for the first 
peak but not for the second peak. However there was no significant difference in 
amplitude. The authors concluded that multifocal OPs demonstrated a dysfunction 
of the inner retina with rods more likely to be affected.  
A study of 32 eyes of patients with DM (16 with no DR and 16 with pre-proliferative 
DR) looked at different components of the OP waveform.157 The authors identified 
that individuals without DM had a statistically significant greater signal to noise 
ratio (SNR) as compared to patients with DM, suggesting greater retinal function. 
No further analysis was carried out on comparing diabetics with controls. They also 
identified decreased SNR with increasing severity of DR, though statistical 
significance was not reported. This study identified a greater abnormality in the 2nd 
order kernel of the OP waveform as compared to the 1st order kernel in patients 
with exudates or macular oedema, though statistical significance was not reported. 
In addition there were only small numbers in the groups (20 with hard exudates and 
10 with oedema). The authors do not describe the severity of these lesions in 
relation to their size and location from the fovea and no analysis was performed in 
relation to maculopathy status. 
The role of OPs in detecting progression was studied by Bresnick et al (1984).161 
Eighty-five eyes of subjects with DM who took part in the ETDRS underwent ERG at 
baseline at various stimulus intensities. Level of retinopathy was recorded and the 
end point was progression to PDR with high risk characteristics (HRC). A cut-off 
point of 75 µV for OP sum amplitude was selected as 95% of the non-diabetic 
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population studies by this group achieved a value greater than this. There were 25 
eyes in the abnormal group and 60 eyes in the normal group with a median follow 
up of 23.5 months and 29.0 months respectively. Subjects in the abnormal group 
were more likely to progress to PDR-HRC (p<0.0001). Rates of progression were 
28% in the abnormal group compared to 0% in the normal group at 1 year, 34% and 
7% respectively at 2 years, and 62% and 13% respectively at 3 years. When adjusted 
for retinopathy level hazard ratio for progression was 10.0 (p<0.001) for those in 
the abnormal group compared to those in the normal group. Sub-analysis of 
subjects with PDR at baseline revealed that those within the abnormal group were 
more likely to progress than those with a normal amplitude (hazard ratio 21.7, 
p<0.001). This study did not report on maculopathy levels. In addition no 
information is provided on the demographic values of the subjects included within 
the study.  
OPs were compared between patients with different severity of retinopathy 
(n=174) and healthy controls (n=54).156 The authors looked at different stimulus 
intensities and found a statistically significant reduction in mean amplitudes across 
all patients with DM compared to controls (at stimulus intensity of 0.5, amplitude 
was 112.8µV vs 175.0µV, p<0.001). The data was further subdivided into types of 
retinopathy, but maculopathy status was not reported. The authors reported no 
significant difference between healthy controls and subjects with no DR and mild to 
moderate NPDR. Regression analysis identified that vascular leakage on FA was a 
significant predictor of OP amplitude compared to capillary non-perfusion. However 
non-perfusion was not defined in terms of location, severity, and area of retinal 
involvement. Also data was not provided on visual acuity. 
Electrodiagnostic tests, such as mfERG and OP, appear to show reduced macular 
function in the presence of DM, with increasing severity of disease. MfERG appears 
to be more studied than OP and, as such, mfERG is being used in a multicentre 
study (European Consortium for the Early Treatment of Diabetic Retinopathy, 
EUROCONDOR) as a primary outcome (Simon Harding, personal communication). 
However, most studies have focused on analysis of diabetic retinopathy with limited 
information on diabetic maculopathy. Both amplitude and IT in mfERG and OP 
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appear to be affected. However, variability in stimuli and recording systems makes 
comparisons between studies difficult. In my study I will be performing mfERG and 
OP on the same subjects with the same recording system. This should make 
comparison between mfERG and OP more reliable. 
3.7.8 Microperimetry 
Microperimetry (MP) is an investigative tool that measures foci of retinal sensitivity 
and is an established technique for assessing macular function, at least in research 
active centres. Similar to fundus perimetry as used in the assessment of glaucoma, 
this subjective tool allows for the localisation of any reduced macular function. In 
my study I have used the Nidek MP1 microperimeter (Nidek Technologies, Padova, 
Italy) as it incorporates an eye tracker, allows for automated examination of the 
same retinal loci at follow-up visits, and can be co-registered to a colour image and 
therefore assessed in conjunction with pathology.162  
Microperimetry has been used to study various macular disorders such as 
geographic atrophy163 and subfoveal choroidal neovascularisation164 as well as 
monitoring response to laser treatment for diabetic macular oedema.165 
In a study of 50 eyes with various macular diseases, Chen et al (2009) studied the 
test-retest variability of the MP1.162 Subjects underwent a 68 loci grid covering the 
central 20o, performing the test twice on the same day with a break in between 
testing. A 95% co-efficient of repeatability was used to demonstrate variation 
between the tests. Results demonstrated that analysis of individual points (point 
wise sensitivity) had a coefficient of repeatability of 4.94 dB (SD 0.96), with 50% of 
points varying by 1 to 6 dB. The mean macular sensitivity (i.e. combining all the 
points) had a coefficient of repeatability of 1.81. The authors concluded that the 
mean macular sensitivity would not give sufficient topographic information and 
point wise sensitivity demonstrates too much variability to be clinically useful. 
However, if the central 16 points covering the central 5o were analysed (central 
macular sensitivity) then the coefficient of repeatability improved to 2.04 dB. Thus 
the authors recommended combining clusters of loci to assess a region.  
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A cross-sectional study of 39 subjects with DM but no DR and 39 controls reported a 
significant reduction in mean retinal sensitivity covering the central 20o (15.74dB vs 
17.70dB, p=0.003).31 The MP grid comprised of 33 stimuli and a stimulus projection 
of 120 ms was used. Sensitivity was significantly reduced in patients below the age 
of 50, but not above this age. There was no signification association with duration 
of DM or HbA1c. This study concluded that functional deficits appeared prior to 
vascular changes. However it excluded subjects below the age of 40 and analysis of 
sensitivity was not adjusted for age. The authors looked at sensitivity of the whole 
macula rather than just the central macula. 
In another study of 152 eyes of 99 healthy subjects, Rohrschneider et al (2008)166 
reported a mean reduction of 0.275 dB per decade, with a starting sensitivity of 
16.6 dB at age 10. The study used the MP1 instrument with a pattern comprised of 
53 loci within a 20o field centred on the fovea, with a stimuli projection of 120 ms. 
However, this was a cross-sectional study and results extrapolated from the whole 
group.  
Vujosevic et al (2006)167 prospectively compared microperimetric findings and OCT 
based retinal thickness in 32 patients with DM. A standard OCT scan and a 
microperimetric 45 stimuli radial grid covering the central 12o of the macula were 
used. Stimuli projection of 200 ms was used for this study. BCVA was calculated 
using an ETDRS grid with the letter score converted to logMAR. Patients were 
divided into three groups: no macular oedema (n=16 eyes), macular oedema but 
not CSMO (n=30 eyes) and CSMO (n=15 eyes). Macular thickness increased 
significantly from the no oedema group to the CSMO group (p<0.0001). There was 
no statistical difference in macular sensitivity in the central field between the no 
oedema group and the not CSMO group, but there was a significant reduction in 
mean sensitivity in the CSMO group compared to the other groups (p<0.05). There 
was a significant correlation between retinal thickness and macular sensitivity in the 
CSMO group (r=-0.48; p<0.0001) but not within the other groups. Though there was 
a statistically significant correlation between VA and retinal sensitivity in the central 
five fields of the OCT grid in the not CSMO group, interestingly the same was not 
true for the CSMO group. The authors concluded that sensitivity decreased with 
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increasing severity of macular oedema. However the authors have not assessed for 
presence of macular ischaemia or reported on retinopathy severity. No comparison 
was made to healthy controls.  
In a study of 20 eyes of 15 patients with type 2 DM and DMO, Soliman et al (2010) 
studied microperimetric findings in the presence of specific retinal lesions.168 
Patients were tested with a 73 stimuli pattern covering the central 10o and a 
projection time of 200 ms, CF and FA to assess retinal structure and function. 
Sixteen eyes had CSMO and 4 eyes had a lesser degree of macular oedema. Macular 
sensitivity was negatively correlated to foveal exudates (r=-0.56, p=0.01), petalloid 
appearance of foveal leakage (r=-0.50, p=0.02), and honeycomb appearance of 
foveal leakage (r=-0.80, <0.0001). There were non-significant negative correlations 
between macular sensitivity and presence of retinal haemorrhage, diffuse leakage, 
focal leakage and ischaemic areas. The authors did not comment on differences in 
macular sensitivity between CSMO and non-CSMO macular oedema, or on macular 
sensitivity in presence of enlarged FAZ which will be part of my study. Foveal 
sensitivity was positively correlated to VA though this was of borderline significance 
(r=0.44, p=0.051).  
One advantage of MP is that it allows for automated determination of stability of 
fixation. The built in tracker records foveal fixation and records percentage of points 
seen within central 2o and central 4o of fixation. If >75% of points are located within 
central 2o then fixation is deemed stable, <75% within 2o but >75% within 4o fixation 
is relatively unstable, and <75% within 4o is unstable. In a study of 84 eyes with 
CSMO, 59.5% of eyes showed unstable fixation.159 However mean BCVA was 6/24. 
In another study of 178 eyes with DMO, 25.7% of eyes were deemed relatively 
unstable or unstable.170 Presence of exudates, rather than oedema, was deemed 
significant. Mean VA was better than the previous study at 6/15. However, 90% of 
subjects with VA worse than 6/60 had poor fixation stability.  
In the studies on MP described above, there are considerable variations in the study 
parameters.  The researcher, or clinician, can adjust the number of stimuli, the size 
of fixation target, the stimulus projection time and the size of the overall field 
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projected, amongst others. Although this allows for targeted assessment of specific 
conditions, it makes it difficult to compare results between studies. In my study, I 
have developed a 48 stimuli grid which covers the central 32o, with a stimulus 
projection time of 200 ms. This grid pattern was developed so that it corresponded 
to the mfERG 19 hexagon array. I have described this in more detail in Chapter 5.  
In my study I combine the central 5 points covering the central ring of the ETDRS 
grid and take a mean value to calculate mean foveal sensitivity. My aim is to look at 
foveal sensitivity and adjust the analysis for various variables such as age, duration 
of diabetes, etc. I will address these issues as well as analyse changes in retinal 
sensitivity longitudinally, which was a recommendation of this paper. I will analyse 
foveal sensitivity in relation to the greatest linear diameter of the foveal avascular 
zone.    
3.8 Discussion 
Current methods of diagnosing and analysing diabetic maculopathy are based upon 
studies performed over 30 years ago that highlighted specific pathological findings. 
However by this stage the patient is likely to have developed visual impairment 
which may be permanent. Recent studies have demonstrated that neural changes 
may be detectable in patients with DM prior to developing DR.  
Assessment of neural function of the macula has been performed in DM, using 
mfERG and MP. Most studies have focused on DR with few studies assessing 
macular function in diabetic maculopathy. Overall, retinal function appears to 
decrease in the presence of severe diabetic eye disease with conflicting evidence in 
early disease. OP has previously been studied in DM but appears to have gone out 
of favour, with early studies suggesting OP may be beneficial in assessing diabetic 
eye disease.  
With improvements in imaging and the availability of newer assessments of neural 
function, macular function can now be studied to improve our understanding of the 
retina in disease. However there appeared to be a lack of co-ordination between 
structural and functional assessments. With the advent of tracking systems that co-
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register functional assessments to retinal structures, it is possible to analyse 
structural and functional changes in the retina simultaneously. Therefore I have 
developed a technique of multimodal analysis which I describe in Chapter 5. 
Diabetic maculopathy, especially DMO, remains the leading cause of visual 
disturbance in subjects with DM. Therefore, the aim of my study is to assess central 
macular function in subjects with varying severities of diabetic maculopathy. 
Initially, I aim to determine level of function in these subjects with respect to their 
maculopathy and subsequently monitor how function alters over time. In Chapter 4 
I describe the methods used in my study and introduce the outcomes I will be 
analysing.       
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Chapter 4 Methods and materials 
In this chapter I describe the methods of patient screening and recruitment of 
subjects with diabetes mellitus (DM) and healthy controls, the patient 
characteristics for inclusion into the study, and the protocols for systemic 
examination, multifocal electroretinography (mfERG), oscillatory potential (OP), 
microperimetry (MP), colour photography (CF), optical coherence tomography 
(OCT) and fundus fluorescein angiography (FFA). I will also describe the study 
design, data collection and statistical methods used for which I follow STROBE 
guidelines.171,172 In addition I will describe the terminology used in my study. 
4.1 Definitions 
Macula: area located within the temporal vascular arcades, centred on the fovea 
and measuring roughly 5500µm in diameter173,174 
Fovea: central retinal depression measuring 1500µm in diameter174 
Foveola: maximum depression at the macular centre measuring 350µm in 
diameter174 
Foveal avascular zone: area within the centre of the fovea lacking capillaries and 
bordered by an interlinked vascular supply as seen on FFA; in health measures less 
than 1000µm maximally 
Clinically significant macular oedema (CSMO): as defined by the Early Treatment 
Diabetic Retinopathy Study (ETDRS),66 it refers to the presence of at least one of the 
following features: retinal thickening, any part of which is within 500µm of the 
centre; exudates within 500µm of the centre of the fovea, with associated retinal 
thickening; retinal thickening measuring more than 1 disc area in size, any part of 
which is within 1 disc diameter of the centre of the fovea (described in detail in 
Chapter 3) 
Early maculopathy: the presence of macular oedema and/or exudates within the 
macula but which does not meet the criteria for CSMO 
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Ischaemic maculopathy: increase in the greatest linear diameter (GLD) of the 
perfused perifoveal capillary arcade as seen on FA to ≥1000µm 
4.2 Recruitment of subjects with diabetes mellitus 
Pre-screening of subjects was commenced in September 2010. Patients were 
recruited predominantly from the diabetic retinopathy screening assessment clinic 
and a dedicated diabetic retinopathy clinic, both based in the Clinical Eye Research 
Centre (CERC) of St. Paul’s Eye Unit, Royal Liverpool University Hospital (RLUH), UK. 
Other sources of referral included the general and specialist clinics of the St Paul’s 
Eye Unit and the Liverpool Diabetic Eye Screening Programme, also based at the 
RLUH. The inclusion and exclusion criteria are shown in Table 4.1. 
Table 4.1: Summary of the inclusion and exclusion criteria for the study 
Inclusion Criteria Exclusion Criteria 
Patients diagnosed with type 1 or type 2 
DM by general practitioner 
Age < 18 years 
Best corrected visual acuity greater than 
35 ETDRS letters (equivalent to 6/60 on 
the Snellen chart) 
Patient unable to fully understand the 
informed consent process or comply 
with the study investigations 
 Any ocular disease that may affect the 
blood-retinal barrier (e.g. vascular 
occlusions) 
 Previous macular laser to study eye 
 Peripheral laser photocoagulation 
performed within the previous 6 months 
 Any intraocular procedure performed 
within the previous 3 months 
 Any media opacities, abnormalities in 
pupillary dilatation or patient posturing 
which would preclude good quality 
image acquisition 
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4.3 Recruitment of controls 
Controls were recruited from patients attending the St. Paul’s Eye Unit at Royal 
Liverpool University Hospital, members of staff based at the hospital and friends 
and relatives of members of staff. 
The inclusion/exclusion criteria for controls were similar to subjects with DM, 
except that the controls did not have DM. The absence of DM was confirmed 
through the oral glucose tolerance test (OGTT), which was carried out as per local 
protocol and comprised the following steps: 
1) Collection of fasting blood glucose sample, with the subject fasted overnight 
2) Consumption by the subject of either 75g of oral glucose or 410ml of 
Lucozade 
3) Collection of a further blood glucose sample 2 hours after consumption of 
the glucose 
The World Health Organisation has published guidelines on reference ranges for 
blood glucose measurements of venous plasma in the diagnosis of DM.175 Subjects 
are diagnosed as normal if fasting plasma glucose is <6.1mmol/l, or if fasting plasma 
glucose is <7.0mmol/l and 2 hour plasma glucose is <7.8mmol/l.  
4.4 Methods  
The study was planned as a case-control observational study. Ethical approval for 
the study was obtained from the North West 2 Research Ethics Committee – 
Liverpool Centre (reference number 09/H1005/68), and was registered with the 
RLUH Research Development and Innovation department (R&D No 3853).  
Once subjects agreed to take part, and met the inclusion/exclusion criteria, a 
consent form was completed. One eye per subject was included in the study. This 
was to minimise selection bias as subjects with severe disease were more likely to 
have only eye that met criteria, whilst those without disease were more likely to 
have both eyes suitable for inclusion. If both eyes were eligible then one was 
selected if it had not previously received any treatment, had the clearer media or 
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had the better corrected visual acuity. Clinical care was not compromised, with 
subjects receiving appropriate treatment as required, including regular review by 
senior staff.  
All subjects recruited underwent the following procedures during the study: 
 best corrected visual acuity and contrast sensitivity 
 blood pressure, serum lipid profile, serum glycated haemoglobin 
 clinical examination 
 multifocal electroretinography 
 oscillatory potentials 
 microperimetry 
 colour photography 
 optical coherence tomography 
 fundus fluorescein angiography 
4.4.1 Best corrected visual acuity (BCVA) and contrast sensitivity (CS) protocol 
BCVA and CS were assessed by an accredited optometrist using our standard clinical 
protocol.  
For BCVA, subjects initially underwent subjective refraction. An ETDRS chart was 
placed at 4 metres and each eye was tested individually in a well-lit room. Standard 
illumination was used for the chart. The number of letters on the chart that were 
read was recorded. BCVA was calculated as the number of letters read at 4 metres 
plus 30 and recorded as the equivalent to the numbers of letters read at 1 metre. . 
A score of 85 is equivalent to 6/6 on a Snellen chart. 
A Pelli-Robson chart located at 1m was used for assessment of CS. In a well-lit room, 
each eye was tested individually with the fellow eye covered. The chart comprised 
48 letters (eight rows of six letters) of equal size but with decreasing contrast of 
0.15 log units for every group of three letters. The number of letters read by the 
subject was recorded. 
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4.4.2 Blood pressure, serum cholesterol level, serum glycated haemoglobin 
protocol 
Blood pressure (BP) was recorded (in mmHg) as an average of four recordings taken 
from the same arm, two minutes apart. Systolic and diastolic BP were recorded 
separately for analysis. 
Blood serum analysis comprised total cholesterol level in all subjects and glycated 
haemoglobin (HbA1c) in subjects with DM. As described above, healthy controls 
underwent OGTT to confirm absence of DM.  
Total cholesterol was recorded in mmol/l and HbA1c as proportion of haemoglobin 
molecules that were glycosylated (%). All blood analyses were performed in the 
biochemistry laboratory of RLUH. These blood tests were repeated at subsequent 
visits. 
4.4.3 Clinical examination 
A clinical history was taken at baseline consisting of age of subject in years, age at 
diagnosis of DM, duration of DM, gender, smoking status, previous diabetic 
retinopathy treatment, previous medical history and medication history. I recorded 
the number of antihypertensive and lipid lowering agents prescribed, the use of 
insulin and the number of oral hypoglycaemic agents. 
Both eyes of each subject were then maximally dilated with 1% tropicamide and 
2.5% phenylephrine for examination of the eye and for the remaining 
investigations. Clinical examination was performed by me on a slit-lamp 
biomicroscope using a 60D non-contact lens to assess the fundus and record the 
diabetic retinopathy status and other retinal pathology, such as previous retinal 
laser. 
4.4.4 Multifocal electroretinography (mfERG) 
A standard departmental protocol was utilised for performing mfERG on a Retiscan® 
(Roland Consult, Brandenburg, Germany). Three Liverpool thread electrodes were 
used for recording and placed around the eye being tested as follows: 
i) Ground electrode – forehead 
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ii) Reference electrode – lateral canthus 
iii) Active electrode – lower conjunctival fornix 
MfERG was performed as per the local protocol by accredited clinical 
electrophysiologists.137 A 19 hexagon stimulus array covering 43° was presented on 
a 60 Hz CRT, and the stimulus was buffered with 4 blank filler frames so that the 
time between each step of the m-sequence was 83ms. Subjects focused on a central 
cross. Luminance of the mfERG was 110candela/m2. Filter settings for the mfERG 
was 2-200Hz, with digital signal processing (DSP) between 1-50Hz.  
The subject fixates on the stimulating monitor. The stimulus consists of an array of 
19 hexagons covering an area of 40o centred on the fovea. These hexagons 
alternate between light and dark flashes. The sizes of the hexagons are scaled 
according to the density of retinal response, and so get larger as they extend 
peripherally.  
The 19 responses were then averaged into three concentric rings containing one, six 
and twelve hexagons respectively (radii being 2.65°, 2.65-10.75°, 10.75-21.75°) 
(Figure 4.1). The group waveforms were analysed and described by the central ring 
amplitude density (nV/deg2) and latency (ms). The central hexagon covered the 
fovea and was used for analysis.  
Figure 4.1: a) Representation of the hexagonal arrays and the areas of the retina 
stimulated; b) the hexagons comprising the three rings: central (pink), middle 
(green) and purple (outer). The central ring is used for analysis of central macular 
function 
a b 
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4.4.5 Oscillatory potentials (OPs) 
Photopic OPs were gathered as per our local protocol and performed to ISCEV 
standards.176 A full-field ERG (Ganzfeld) stimulation (3cd.s/m2 on 30 cd/m2) was 
used. Bandpass was set at 75-300Hz and artefact reject at 200µV. Sum amplitude 
(µV) of the four peaks generated was analysed. Preliminary analysis revealed that 
there was no significant difference between groups with respect to the implicit time 
of the 1st, 2nd, 3rd and 4th peaks and so only the findings of the 1st peak have been 
reported for implicit time (ms).   
Electrophysiology testing was conducted with silver thread electrodes located at 
forehead and just beside outer canthi for ground and reference electrode 
respectively.   
4.4.6 Microperimetry (MP) 
MP was performed on all subjects using an automatic fundus-related perimeter 
(MP1 Microperimeter, Nidek Technologies, Padova, Italy). For the purpose of my 
study a protocol was specifically designed based upon the 19 hexagon mfERG array 
and the OCT grid pattern. The following parameters were set: a fixation target 
consisted of a red cross, 2o in diameter; a white monochromatic background was 
set at 4 asb; a stimulus size of Goldmann III, with a projection time of 200ms; a 
customized radial grid of 48 points covering an area of 32o in diameter centred on 
the fovea. A 4-2-1 double-staircase strategy was used with a starting stimulation of 
10dB. The stimulus was projected onto a predefined retinal focus and the 
automated eye tracker ensured the same positions were stimulated at different 
light intensities. The results of the stimuli were then projected onto a digital colour 
photograph.  
The central five points were averaged to give a mean sensitivity (dB) of foveal 
function (Figure 4.2). Central fixation of the subject was also recorded through 
automated eye tracking prior to assessing retinal sensitivity and provides a measure 
of fixation stability. For the purpose of my research if <75% of stimuli were seen in 
the central 4o of fixation then the test was recorded as being unstable and not 
suitable for analysis.  
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Figure 4.2: Example of the output generated from the MP1 showing the foci of 
stimulus and the sensitivities recorded; the central five points were used for 
analysis of foveal function 
 
 
4.4.7 Colour photography (CF) 
All colour photographs were captured by an accredited image technician using a 
TopconTRC-50 X camera (Topcon Great Britain Ltd, UK). The protocol for the seven 
field photographs is described in Chapter3, Section 3.3. 
CF was used to assess retinopathy status and to monitor disease progression. 
Images were stored on the ImageNet programme accessible on the local network. I 
analysed all CF images to confirm retinopathy status. 
4.4.8 Optical coherence tomography (OCT) 
OCT images were captured using a Spectralis HRA+OCT camera (Heidelberg 
Engineering, Heidelberg, Germany). The following settings were used: 
i) Scan area = 20mm by 15mm; centred on the fovea 
ii) 37 B-scans per scan area, spaced approximately 50µm apart 
iii) 537 A-scans per B-scan 
iv) Automatic-real time (ART) = 16 
Two sets of images were produced. Firstly cross-sectional images of the retina 
corresponding to the B-scans were viewed individually. Secondly, the cross-
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sectional images were then collated and the gaps filled to create a volume scan. An 
ETDRS grid, composed of 3 rings measuring 1000µm, 3000µm and 6000µm in 
diameter, was superimposed onto the volume scan and used to determine 
thickness of the retina within each ring structure. Though the Heidelberg software 
generates the ETDRS grid and automatically determines the foveal centre, I 
assessed the location of the grid and manually readjusted it if necessary. 
For the purpose of my research I am using central subfield thickness (CSFT) as a 
measure of macular thickness as it corresponds to mean thickness within the 
central 1000µm of the macula. In Chapter 5, I describe how I have used this 
measurement to compare OCT to MP and mfERG.  
4.4.9 Fundus fluorescein angiography (FA) 
This investigation was also performed by accredited image technicians on the 
HRA+OCT camera. A local protocol was used for capturing FA images. Thirty degree 
images were taken based on the same seven fields described for CF in Chapter 3, 
Section 3.3. Following an intravenous injection of 3ml of 25% sodium fluorescein 
over 3 seconds, images were taken of both the study eye and the fellow eye (Table 
4.2) 
Images captured during transit phase allow for assessment of FAZ and the 
perifoveal capillary network. Stereo images of the macula were used to assess 
leakage from microaneurysms whilst peripheral images were assessed for signs of 
diabetic retinopathy (DR). Late phase images were assessed for the presence of 
cystoid leakage and dye accumulation at the fovea. 
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Table 4.2: Summary of the images captured during FA. F1 = images centred on the 
optic disc; F2 = images centred on the fovea; F3-F7 = images focused on the 
peripheral retina 
Phase Time Image Capture Eye 
Transit 
0-30s(approx) 
30-40s(approx) 
40-60s 
F2 every 1-2 seconds 
F2 single images 
F2 single images 
Study 
Fellow 
Study 
Mid 1-5min 
F1+F2 stereo 
F1+F2 stereo 
F3-7 
F3-7 
Study 
Fellow 
Study 
Fellow 
Late 
5 min 
10 min 
F1+F2 stereo 
F1+F2 stereo 
Both 
Both 
 
I manually assessed the transit phase images to determine the clearest image for 
assessing the FAZ. Once the FAZ was outlined I measured its greatest diameter 
(GLD) in microns and used this value to determine the presence of ischaemic 
macular changes. A GLD greater than 1000 µm with disruption of the perifoveal 
capillary network was used for diagnosis of ischaemic maculopathy. 
4.5 Subject recruitment and follow up 
Subjects were recruited into four different groups: 
I. Healthy controls 
II. Diabetic controls (subjects with DM but no DR) 
III. Early diabetic maculopathy 
IV. Sight-threatening maculopathy (CSMO +/- ischaemic maculopathy) 
Groups 2-4 were then followed up at six months and 12 months and all above the 
investigations were repeated at each visit. Subjects exited the study if they 
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completed the 12 month visit or if intraocular treatment was required for 
maculopathy.  
The sample size for each group had been estimated, by medical retina specialist and 
statistician, based on the following outcomes: 
 mean value of retinal sensitivity (dB) at 12° on MP 
(mean difference of 4.5 (±3.5) dB judged clinically relevant) 
 mfERG central ring implicit time  
(mean difference of 3 (±1) ms judged clinically relevant) 
 summed OP amplitude 
    (mean difference of 4 (±6) μV judged clinically relevant)  
 mfERG central ring amplitude 
 OP 1st peak implicit time 
To detect these differences statistically with 90% power using ANOVA test and a 
paired t-test with p<0.05, a minimum sample size of 26 patients was calculated. 
Taking into account potential dropouts, it was decided to recruit 30 subjects to each 
group.  
4.6 Study outcomes 
4.6.1 Primary outcomes 
The primary outcomes of my study are based around changes in function at the 
cross sectional analysis with regards to severity of maculopathy. These outcomes 
are: 
 Is MP sensitivity reduced with increasing severity of maculopathy? 
 Is mfERG central ring amplitude reduced with increasing of severity of 
maculopathy?  
 Is mfERG IT prolonged in the presence of maculopathy? 
 Is OP sum amplitude reduced with increased severity of maculopathy? 
 Is OP IT prolonged in the presence of maculopathy? 
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4.6.2 Secondary outcomes 
 Are BCVA/CS reduced with increased severity of maculopathy? 
 Is there increased CSFT in maculopathy? 
 Is severity of maculopathy associated with change in central macular 
function over time? 
 Is there an association between functional tests and subjects who required 
treatment for maculopathy or were diagnosed with CSMO or ischaemic 
maculopathy? 
4.7 Statistical analysis 
Data were recorded on an Excel Spreadsheet. All data quality control checks and all 
statistical analyses were performed on SPSS for Windows version 22 (SPSS Inc, 
Chicago, USA), under the guidance of the departmental biostatistician (Dr G. 
Czanner, CStat), with the aim to answer the research questions as stated in Chapter 
3. Subjects were given their own unique study code and details were kept 
confidential in accordance with the Data Protection Act 1998 and the Research 
Governance Framework for Health and Social Care 2010. 
4.7.1 Baseline data analysis 
I initially performed the Kolmogrov-Smirnov test to determine whether the data 
were normally distributed. If data was normally distributed, in order to evaluate 
potential confounders across 5 groups, I used the ANOVA with 1 factor test to 
determine statistical significance; if not normally distributed I used the Kruksal-
Wallis test. I used Levene’s test for analysis of homogeneity of variance. 
4.7.1.1 Demographic data analysis 
For continuous variables I calculated the mean and standard deviation of the 
demographic data of each group. The continuous variables include age, duration of 
DM, serum cholesterol level, serum HbA1c level, and systolic and diastolic BP. 
For discontinuous data I assessed median and interquartile range. Discontinuous 
variables included number of antihypertensive agents used and number of oral 
hypoglycaemic agents. 
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For categorical data, such as gender, retinopathy grading, smoking status and 
insulin use, I calculated percentage of subjects within each category. For 
retinopathy grading I used Fisher’s exact test of association and Pearson chi-square 
test of association for comparison of subjects with maculopathy. 
For the demographic data, p<0.05 was deemed significant for inter-group 
comparisons. 
4.7.1.2 Structural and functional data analysis 
I calculated the mean and standard deviation for the following variables: 
 BCVA 
 CS 
 CSFT on OCT 
 mfERG central ring amplitude 
 mfERG central ring implicit time 
 OP sum amplitude 
 OP 1st peak implicit time 
 MP central ring sensitivity 
The differences in retinal function across groups were analysed by ANOVA with 
adjustment for possible confounders via ANCOVA. To accomplish a family-wise 
error rate of 0.05 for our five primary outcomes Bonferroni correction was used by 
comparing the five p-values with significance level of 0.01. After ANCOVA, post-hoc 
comparisons between the groups were performed using the two-sample t-tests and 
multiple comparison method of Sidak. Such p-values were then compared with 
significance level of 0.01. For other outcomes, such as BCVA, CS and OCT CFT, 
p<0.05 was deemed to be significant but should be interpreted with caution as they 
are not primary outcomes. Results are presented in a tabular format.  
4.7.2 Longitudinal analysis 
Only subjects who completed the month 6 and month 12 visits were included in the 
analyses. Firstly I performed ANOVA to assess for confounders to change in 
functional assessment. Variables analysed were age at baseline, serum cholesterol, 
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serum HbA1c, systolic blood pressure, diastolic blood pressure, BCVA and CS. 
P<0.05 was deemed significant. 
I used ANOVA, with adjustment for possible confounders via ANCOVA, to compare 
subjects who completed the study to those who exited the study. I calculated the 
mean and standard deviation. P<0.05 was deemed significant. 
To determine change in retinal function over 6 months and 12 months, I analysed 
mean baseline values and mean change in function for the data as a whole at both 
time points. For this I used ANCOVA with adjustment for baseline function. Along 
with mean I calculated standard deviation and range. For change in function I 
analysed number of subjects in whom function had improved, worsened or stayed 
the same to highlight trend. P<0.05 was deemed to be significant. 
In the intra-group comparison of subjects with DM I performed Wilcoxon test to 
assess mean change in function from baseline. Once again I analysed number of 
subjects in whom function had improved, worsened or stayed the same. I also 
performed the paired t-test to compare subjects with maculopathy. For both tests 
P<0.05 was deemed to be significant. 
4.7.3 Analysis of association 
To further evaluate the diagnostic potential of these tests I performed the following 
analyses. For each test of visual function I found the critical quartile value that 
represented reduced function. For BCVA, CS, MP, mfERG amplitude and OP sum 
amplitude I used the lower quartile; for OP IT and mfERG central ring IT I used the 
upper quartile. The quartiles were calculated from all subjects with DM.  
In the cross-sectional analyses I divided the subjects with DM into those with sight-
threatening maculopathy and those who did not have sight-threatening 
maculopathy. In the longitudinal analyses I divided the subjects into those who 
received treatment and those who did not receive treatment within 6 and 12 
months of entering the study. I then tested the association between the two 
categories for each analysis with the Fisher exact test. I calculated the confidence 
intervals for probability of either having CSMO or ischaemic maculopathy in the 
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cross-sectional analysis, or requiring treatment in the longitudinal analysis, using 
the Binomial confidence interval (Clopper-Pearson formulae).177 
Using the same statistical method I performed a further analysis to determine 
whether combining two investigations demonstrated a stronger association for the 
two groups mentioned above. The investigations analysed were those related to 
visual function, i.e. BCVA, CS, MP, mfERG and OP.  
4.8 Summary 
In this chapter I have demonstrated the investigative techniques that will be 
undertaken to answer the research questions. In the subsequent chapters I will 
present the results of my analysis following the methods described above. 
However, before I present the results, I demonstrate in Chapter 5 how I have 
correlated the structural assessments (ETDRS grid) with the functional assessments 
(mfERG hexagonal array and MP stimulus foci) as a multimodal imaging 
methodology. 
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Chapter 5 Multimodal analysis of 
retinal structure and function 
Central to the work that I will present in my thesis is the use of a multimodal 
approach to the assessment of retinal function using mfERG and MP and structure 
using OCT, diverse platforms that have been developed independently. Each uses a 
map or grid to allow a topographical segmentation of the macula. In this chapter I 
describe an analysis of the published anatomical measurements of retinal structures 
to allow the development of co-registration of the platform maps and subsequent 
multimodal analysis of the pathology of diabetic retinopathy.  
5.1 Measurement of structures within the retina in micrometres 
Anatomical studies have estimated values of the sizes of various structures within 
the retina, some of which form the macula. These structures include: 
 Fovea 
 Foveola 
 Macula  
 Optic disc 
 Distance between centre of fovea and temporal edge of optic disc 
 Distance between centre of fovea and centre of optic disc 
 5.1.1 Fovea, foveola and macula 
It has been shown that the diameter of the foveola ranges from 300 to 400 µm, 
with the commonest stated value as 350 µm.174 The diameter of the fovea ranges 
from 1200 to 1800 µm, with the commonest value estimated as 1500 µm.174 The 
macula ranges from 5000 to 6000 µm, with a diameter of ~5500 µm accepted 
universally.173,174,178  
5.1.2 Optic disc 
Other distances that have been analysed include the relationship of the fovea to the 
optic disc. The horizontal diameter of the optic disc may range from 900 µm to 2600 
µm, though the commonest values are estimated at 1500 to 1800 µm.173,179,180 
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In addition the distance from the centre of the fovea to the temporal edge of the 
disc ranges from 3000 to 3800 µm, i.e. the outer edge of the macula does not 
intersect the temporal edge of the disc.180,181 Another value is from the centre of 
the disc to the centre of the fovea, which ranges from 3750 to 4500 µm.180 
5.2 The ETDRS grid 
As described in Chapter 3, the Early Treatment Diabetic Retinopathy Study (ETDRS) 
outlined criteria for CSMO. To assess the location of lesions relative to the centre of 
the fovea the investigators utilised a grid that could be placed on the colour 
photograph and FA, initially applied manually to colour 35mm film and then later to 
digital images. This circular grid comprised three rings of diameters of 1mm, 3mm 
and 6mm (Figure 5.1). These diameters were chosen because the inner ring (1mm) 
would identify any lesions within 500µm of the centre of the fovea; the middle ring 
(3mm) would identify any lesions within one disc diameter of the fovea; and the 
outer ring (6mm) would identify any lesions within the macula. 
Figure 5.1: Schematic to show the three rings of the EDTRS grid centred on the 
foveal centre 
 
The ETDRS grid has become an essential component of clinical practice, as it is used 
routinely in the analysis of images of the macula generated by OCT. Thus any study 
of diabetic maculopathy is likely to use this tool in the analysis of its data. Therefore 
I will be using the ETDRS grid in the analysis of OCT images in my data. 
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5.3 Applying multifocal electroretinography and microperimetry to 
retinal analysis 
As described above, the ETDRS grid is based upon a measurement in millimetres. 
However the mfERG hexagonal and MP patterns are measured in degrees from the 
foveal centre. Therefore, to compare these investigative techniques, a conversion 
rate is required to convert millimetres to degrees. Unfortunately neither the mfERG 
nor the MP software provides a ratio of degrees to millimetres to allow cross 
calibration. 
5.3.1 Measurement of structures in the retina in degrees 
Wolff’s Anatomy states that the fovea has a diameter of 1850 µm and represents 5o 
of the visual field.173 It also states that the macula is 5500µm in diameter and covers 
15o of visual field. This suggests that 1o is equivalent to ~370 µm. It also states that 
the foveola is 350 µm in diameter and covers 1o of visual field. However, Drasdo and 
Fowler (1974)179 state that “one degree of visual angle is equal to 288 µm on the 
retina without correction for shrinkage”. They also state that centre of the fovea is 
3400 µm or 11.8o from the temporal edge of the disc. This means 1o equates to just 
over 288 µm. Therefore 1o of visual angle may range from 288 µm to 366.67 µm. 
Due to the variations in the distances in the retina and equivalent degrees of visual 
angle, there may be discrepancies when comparing the ETDRS ring to the MP and 
mfERG hexagonal grids.  
5.3.2 Combining MP grid with ETDRS ring 
To determine a suitable conversion factor from microns to degrees I compared in 
one subject the MP grid as generated by Nidek’s MP1 software to the ETDRS grid 
generated by the Heidelberg Spectralis system when capturing infra-red reflectance 
images of the macula during OCT acquisition. 
Figure 5.2 shows the infra-red reflectance image of a subject with early diabetic 
maculopathy. The ETDRS grid has three rings of the standard diameters and has 
been generated automatically by the supporting software. I will use this image to 
compare with the MP grid for the same subject.  
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Figure 5.2: Infra-red reflectance image of subject demonstrating the position of the 
ETDRS grid centred on the fovea 
 
Figure 5.3 is the MP for the same subject. I have selected a 12o grid with 45 points 
for comparison as it is a grid pattern that is most commonly reported in literature 
and the points are located closely together allowing for more accurate assessment 
of distance measurements.165,167,182 
Figure 5.3: MP grid centred at the fovea for the same subject as Figure 5.2 
demonstrating the foci of retinal sensitivities that were assessed. 
 
The rings on this 12o MP grid comprise of the following diameters: 
 inner ring = 2o in diameter  
 2nd ring = 4o in diameter 
 3rd ring = 8o in diameter 
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 outer ring = 12o in diameter 
 
As demonstrated previously 1o of visual angle may vary between 288 µm and 
366.67 µm. For ease of calculations I will compare the position of the ETDRS ring 
within a 12o MP grid if 1o was equivalent to 250 µm and 350 µm. Table 5.1 
calculates the MP ring diameters if 1o was equivalent to 250 µm and 350 µm.  
Table 5.1: Diameter of the MP rings converted from degrees to microns if 1o was 
equivalent to 250 µm and 350 µm 
Ring If 1o = 250 µm If 1o = 350 µm 
Inner 500 µm 700 µm 
2nd 1000 µm 1400 µm 
3rd 2000 µm 2800 µm 
Outer 3000 µm 4200 µm 
  
Using these ring calculations I calculated the location of the ETDRS grid to the 12o 
MP grid shown in Figure 5.3. I then compared the results to the grid shown in Figure 
5.2. In particular I looked at the outer ring of the ETDRS grid and its relation to the 
optic disc and the superotemporal retinal vascular arcade.  
Figure 5.4a demonstrates the position of the ETDRS grid based upon the MP grid if 
1o is equivalent to 250 µm. The inner ring of the ETDRS grid would overlay the 
points on the 2o MP ring. The outer ring would transect the optic disc and the 
superotemporal retinal vascular arcade. Compared to Figure 5.2, the grid would 
cover a larger area than expected. This suggests that 1o is more than 250 µm 
Figure 5.4b demonstrates the position of the ETDRS grid based upon the MP grid if 
1o is equivalent to 350 µm. Though the outer ring is now within the arcade, it no 
longer crosses the edge of the optic disc as in Figure 5.2. Therefore the ETDRS now 
appears to cover a smaller area than expected and so 1o must be less than 350 µm. 
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Figure 5.4: Comparison of the position of the ETDRS grid to a 12o MP grid if (a) 1o is 
equivalent to 250µm and if (b) 1o is equivalent to 350µm 
 
Therefore it appears that 1o lies between 250 and 350 µm. I compared Figures 5.2-
5.4 and noted that the outer ring in Figure 5.2 lay in between the outer rings of 
Figures 5.3 and 5.4. 
I then calculated the distance between the centre of the fovea and the centre of the 
optic disc using the in-built measurement tool on OCT which measured 3550 µm. 
The customised 32o MP grid used in my study, as seen in Chapter 4, had a focus 
corresponding to the centre of the disc. This focus was at 12o from the centre of the 
fovea. Thus 1o equates to ~296 µm which is not dissimilar from the 288 µm quoted 
by Drasdo and Fowler.179  
For ease of calculation I used a value of 1o = 300 µm and returned back to the 12o 
MP grid. I repositioned the ETDRS grid over the 12o MP grid for the subject in Figure 
5.3. The result can be seen in Figure 5.5 and shows the ETDRS grid is positioned 
closely to that in Figure 5.2. Having determined that 1o = 300 µm, I compared the 
placement of the EDTRS grid to the customised 32o MP grid and repeated the 
process for the first five subjects in my study to check the credibility of this 
calculation.  This confirmed that 1o equates closely to 300 µm.  
 
a) 
b a 
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Figure 5.5: Comparison of the position of the ETDRS grid to a 12o MP grid if 1o is 
equivalent to 300µm 
 
 
 
 
 
 
 
Therefore I have used a conversion of 1o to 300µm when comparing the central ring 
of the customised 32o MP grid to the ETDRS grid used for OCT measurements.  
5.3.3 Comparing mfERG to ETDRS grid and MP grid 
The rapid 19 hexagonal pattern developed in Liverpool and utilised in performing 
mfERG, as described in Chapter 4, is essentially composed of 3 rings made up of 
four different hexagonal structures (Figure 5.6).  
Figure 5.6: Hexagonal pattern of multifocal electroretinogram showing the 19 
hexagons  
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Figure 5.6 shows that the hexagonal pattern can be considered to be composed of 
three rings: an inner ring, middle ring and outer ring. The central ring comprises a 
single hexagon (Figure 5.7a). The middle ring is composed of six hexagons of equal 
dimensions (Figure 5.7b). The outer ring is composed of 12 hexagons alternating 
between two hexagonal structures (Figure 5.7c & d). 
These sizes of these hexagons are shown in Figure 5.7 and are measured in degrees. 
Using the previously calculated conversion of 1o to 300µm the sizes of the 
hexagons, in microns, are described in Table 5.2. 
Figure 5.7: Hexagons of the mfERG grid to show their location and the 
measurements acquired: a) inner ring, b) middle ring, c) &d) outer ring  
 
 
 
 
 
6
a 
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Table 5.2: Measurements of the lengths marked in figure 5.7 in both degrees and 
microns using a conversion of 1o to 300µm 
Hexagon Line Degrees Microns 
Inner  
(Figure 5.7a) 
Line A 3.2 960 
Line B 5.4 1620 
Line C 6.4 1920 
Middle  
(Figure 5.7b) 
Line D 4.2 1260 
Line E 7.6 2280 
Line F 8.2 2460 
Outer 1  
(Figure 5.7c) 
Line G 5.4 1620 
Line H 9.6 2880 
Line I 11.8 3540 
Outer 2  
(Figure 5.7d) 
Line J 7.4 2220 
Line K 8.3 2490 
Line L 11.4 3420 
 
Using the calculations in Table 5.2, it is possible to project the 32o MP grid onto the 
hexagonal grid for the mfERG (Figure 5.8a) for comparison. In Figure 5.8b, I present 
a schematic that combines the ETDRS grid, MP grid and mfERG hexagonal pattern. 
5.4 Combining analysis of the MP, mfERG and OCT  
As can be seen in Figure 5.8, the central five loci of the MP grid sit within the central 
ring of the ETDRS grid and the central hexagon of the mfERG. Also, the central 
ETDRS ring sits within the central mfERG hexagon. Therefore, to compare these 
investigative modalities, I will use the mean of the five central loci of the MP grid, 
the central ring of the ETDRS grid for CSFT and the central hexagon of the mfERG. 
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Figure 5.8: Schematics combining the different investigative modalities a) mfERG 
hexagonal pattern and MP grid; b) mfERG hexagonal pattern, MP grid and ETDRS 
ring 
 
A larger version of Figures 5.8a and 5.8 b are presented in Appendices 1 and 2 at the 
end of this thesis. 
 5.5 Summary 
In this chapter I have demonstrated how to convert degrees of visual field into 
distances in microns. I have subsequently demonstrated how this conversion allows 
for the comparison between structural and functional assessments of macular 
function. In the next chapter I present the cross-sectional analysis of the baseline 
data.  
  
a b 
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Chapter 6 Results – cross-sectional 
In this chapter I will present the results of the baseline data. I will describe the 
recruitment of subjects to my study and the cross-sectional results of the functional 
assessments of the central macula in subjects with diabetes mellitus (DM). 
6.1 Recruitment 
In Chapter 4 I described the eligibility and exclusion criteria of my study. In brief, 
subjects with DM were recruited into three groups: diabetic controls (no diabetic 
retinopathy); early maculopathy (presence of diabetic maculopathy not meeting 
criteria for clinically significant macular oedema (CSMO)); sight-threatening 
maculopathy (presence of CSMO with or without ischaemic macular changes).  A 
healthy control group comprised subjects without DM. 
Subjects were recruited prospectively from a single centre (St Paul’s Eye Unit) and 
were recruited in two phases. During the first phase, pre-screening commenced on 
30th September 2010, and screening the following week. Pre-screening comprised 
of determining whether subjects met the inclusion/exclusion criteria and so would 
be eligible to take part in the study. Subjects were provided with a patient 
information leaflet. Screening comprised of determining whether inclusion criteria 
were met and whether the subject was willing to take part in the study. 
Recruitment commenced on 27th October 2010, with the last subject recruited in 
phase 1 on 5th December 2012. A second phase of recruitment commenced 
screening on 7th August 2013 and completed recruitment on 3rd June 2015. 
Figure 6.1 is a consort diagram that summarises the recruitment of subjects to my 
study and the groups to which they were recruited: 
i) Healthy controls n=29 
ii) Diabetic controls n=24 
iii) Early diabetic maculopathy n=24 
iv) Sight-threatening maculopathy n=41 
a) Presence of ischaemic maculopathy n=9 
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Figure 6.1: Consort diagram summarising the pre-screening, screening and 
recruitment of subjects to my study and the groups to which they were allocated. 
 
6.2 Demographic data  
A total of 118 subjects were recruited into the study. Sixty eight (55.9%) were male. 
Only eight (6.8%) were pseudophakic. The majority were non-smokers (83.1%) with 
14 (11.9%) active smokers and 6 (5.1%) ex-smokers.  
Table 6.1 shows the mean age in years of the groups. Healthy controls were 
younger than the other groups, but this difference was only statistically significant 
compared to diabetic controls (p=0.03). There was no statistically significant 
difference between the groups with DM (p>0.2 for all comparisons). 
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Table 6.1: Comparison of age (in years) between the groups. The second column 
shows mean age, standard deviation (SD) and range for each group. The third 
column shows mean difference in age, 95% confidence limits (CL) and p value for 
intergroup comparison. *P<0.05 is deemed significant  
 
6.2.1 Systemic disease 
Nearly half of subjects with DM (49.2%) had a diagnosis of hypertension and over 
half (57.6%) had a diagnosis of hyperlipidaemia. Eight subjects with DM (9.0%) had 
 Mean age 
(yrs) 
(SD) 
Range 
Mean difference in age (years) 
(95% CL) 
P value 
  Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy control 
n=29 
50.6 
(12.6) 
28-68 
9.9 
(0.8, 18.9) 
0.03* 
5.2 
(-3.9, 14.2) 
0.56 
3.4 
(-4.6, 11.3) 
0.84 
Diabetic control 
n=24 
60.5 
(11.2) 
35-78 
 -4.7 
(-14.2, 4.8) 
0.71 
-6.5 
(-15.0, 1.9) 
0.22 
Early maculopathy 
n=24 
55.8 
(12.9) 
27-78 
  -1.8 
(-10.2, 6.6) 
0.99 
Sight-threatening 
maculopathy 
n=41 
54.0 
(12.2) 
28-74 
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a diagnosis of peripheral neuropathy and 13 (14.6%) of cardio- or cerebrovascular 
disease. 
Of those subjects with DM, just over half (52.8%) were on insulin as part of their 
medical management. 
Diabetic controls had a statistically significant shorter mean duration of DM (7.3 
years) as compared to those with early maculopathy (16.3 years, p<0.01) and those 
with sight threatening maculopathy (15.9 years, p<0.01) (Table 6.2). There was no 
significant difference in duration between both groups with maculopathy (p>0.50).   
6.2.2 Serum glycated haemoglobin (HbA1c) 
Of those subjects with DM, those without retinopathy had a significantly lower 
mean HbA1c (7.0%) compared to subjects with early maculopathy (8.7%, p<0.01) 
and subjects with sight threatening maculopathy (8.6%, p<0.01) (Table 6.3). There 
was no significant difference in serum HbA1c between the two maculopathy groups 
(p>0.50). 
6.2.3 Serum cholesterol 
There was no significant difference in serum cholesterol levels between any of the 
four groups (p>0.50) (Table 6.4). Healthy controls were less likely to be on lipid 
lowering agents (17%) as compared to subjects with DM (76%, p<0.01). However 
there was no significant difference between subjects with DM (p>0.50).  
6.2.4 Blood pressure (BP) 
Mean systolic BP (SBP) was significantly higher in the sight-threatening maculopathy 
group (134.0 mmHg) compared to healthy controls (123.7 mmHg, p<0.05) (Table 
6.5). SBP in diabetic controls (133.1mmHg, p>0.10) and subjects with early 
maculopathy (133.7mmHg, p>0.10) was greater than healthy controls though this 
did not reach statistical significance.  
There was no significant difference in diastolic BP (DBP) between any of the groups 
(p>0.50).  
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Similar to statin use, subjects with DM were more likely to be taking anti-
hypertensive agents (63%) compared to healthy controls (10%, p<0.01). There was 
no significant difference between subjects with DM (p>0.50). 
Table 6.2: Comparison of duration of DM (years) between the groups. Column 2 
shows mean duration with standard deviation (SD) and range. Column 3 is an 
intergroup comparison of mean difference in duration with confidence limits (CL). 
*P<0.05 is deemed significant. 
 Mean 
duration of 
DM (years) 
(SD) 
Range 
Mean difference in duration of 
DM (years) 
(95% CL) 
P value 
  Early 
maculopathy 
Sight-
threatening 
maculopathy 
Diabetic control 
n=23 
7.3 
(6.6) 
0.5-25 
9.0 
(3.4, 14.5) 
<0.01* 
8.6 
(3.6, 13.5) 
<0.01* 
Early 
maculopathy 
n=24 
16.3 
(9.5) 
4-43 
 -0.4 
(-5.3, 4.5) 
1.00 
Sight-
threatening 
maculopathy 
n=40 
15.9 
(7.3) 
0.3-30 
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Table 6.3: Comparison of mean serum HbA1c (%) between the groups. Column 2 
shows mean duration with standard deviation (SD) and range. Column 3 is an 
intergroup comparison of mean difference in duration with confidence limits (CL). 
*P<0.05 is deemed significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mean serum 
HbA1c (%) 
(SD) 
Range 
Mean difference in HbA1c (%) 
(95% CL) 
P value 
  Early 
maculopathy 
Sight-
threatening 
maculopathy 
Diabetic control 
n=23 
7.0 
(1.2) 
5.1 – 9.7 
1.7 
(0.5, 3.0) 
<0.01* 
1.6 
(0.6, 2.7) 
<0.01* 
Early 
maculopathy 
n=24 
8.7 
(1.6) 
5.6 – 11.1 
 -0.1 
(-1.2, 1.0) 
1.00 
Sight-threatening 
maculopathy 
n=41 
8.6 
(1.8) 
5.6 – 13.7 
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Table 6.4: Comparison of mean serum cholesterol (mmol/l) between groups. 
Column 2 is mean level with standard deviation (SD), range. Column 3 is comparison 
of mean difference (confidence limits (CL)). *P<0.05 is deemed significant. 
 Mean serum 
cholesterol 
(mmol/l) 
(SD) 
Range 
Mean difference in serum cholesterol (mmol/l) 
(95% CL) 
P value 
  Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy control 
n=28 
4.9 
(0.9) 
3.3 – 7.2 
-0.4 
(-1.1, 0.4) 
0.76 
-0.4 
(-1.2, 0.3) 
0.61 
-0.2 
(-0.9, 0.4) 
0.92 
Diabetic control 
n=23 
4.5 
(0.9) 
3.0 – 6.0 
 -0.1 
(-0.9,0.8) 
1.00 
0.1 
(-0.6, 0.8) 
1.00 
Early 
maculopathy 
n=24 
4.5 
(1.1) 
3.0 – 7.0 
  0.2 
(-0.5,0.9) 
0.99 
Sight-
threatening 
maculopathy 
n=41 
4.6 
(1.1) 
2.2 – 6.8 
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Table 6.5: Intergroup comparison of mean systolic blood pressure (mmHg). Column 
2 shows mean duration with standard deviation (SD) and range. Column 3 is an 
intergroup comparison of mean difference in duration with confidence limits (CL). 
*P<0.05 is deemed significant. 
 Mean 
systolic BP 
(mmHg) 
(SD) 
Range 
Mean difference in systolic BP (mmHg) 
(95% CL) 
P value 
  Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy control 
n=29 
123.7 
(17.5) 
96-170 
9.4 
(-2.3, 21.1) 
0.19 
10.1 
(-1.6, 21.7) 
0.13 
10.3 
(0.1, 20.5) 
<0.05* 
Diabetic control 
n=23 
133.1 
(14.3) 
112-170 
 0.6 
(-11.7, 12.9) 
1.00 
0.9 
(-10.1, 11.9) 
1.00 
Early 
maculopathy 
n=24 
133.7 
(17.5) 
111-168 
  0.3 
(-10.5, 11.1) 
1.00 
Sight-
threatening 
maculopathy 
n=41 
134.0 
(13.9) 
109-168 
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6.2.5 Ophthalmic history 
Of those subjects with DM, 39 (43.8%) had prior peripheral retinal laser. Very few 
subjects had other ophthalmic conditions, with one subject suffering from primary 
open angle glaucoma, two with mild corneal pathology and two having had 
previous laser refractive surgery. 
6.2.6 Retinopathy grading 
With respect to retinopathy grading, 58.3% of subjects with early maculopathy had 
a grading of R1 and 41.7% a grading of R2.  In subjects with sight-threatening 
maculopathy, these figures were reversed with 41.5% having a grading of R1 and 
58.5% a grading of R2. This was not found to be statistically significant on both 
Pearson chi square test of association (2-sided, p=0.19) and Fisher’s exact test of 
association (2-sided, p=0.21). 
6.3 Assessments of central macular function and structure 
6.3.1 Best corrected visual acuity (Table 6.6, Figure 6.2) 
Refraction protocol best corrected visual acuity (BCVA) differed significantly across 
groups (p<0.05, ANOVA F-Test). Mean BCVA was significantly reduced in subjects 
with early maculopathy (84.8 letters, p<0.05) and subjects with sight-threatening 
maculopathy (80.6 letters, p<0.01) as compared to healthy controls (90.6 letters) 
(Table 6.6). There was no significant difference between healthy and diabetic 
controls (86.8, p>0.1).  
Mean BCVA was significantly reduced in subjects with sight-threatening 
maculopathy compared to diabetic controls (p<0.02). There was no significant 
difference between diabetic controls and subjects with early maculopathy (p>0.5), 
nor between subjects with maculopathy (p>0.10).  
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Table 6.6: Intergroup comparison of best corrected visual acuity without and with 
correction for age. P value represents age corrected comparison. *P <0.05 is 
deemed significant. CL = confidence limits. 
 Mean 
BCVA 
(letters) 
(SD) 
Range 
Mean 
BCVA 
(letters) 
Age corrected mean difference in BCVA 
(letters) 
(95% CL) 
P value 
  Corrected 
for age 
Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy 
control 
n=29 
90.7 
(4.3) 
77-97 
90.6 -3.8 
(-9.6, 2.0) 
0.40 
-5.8 
(-11.3, -0.2) 
0.04* 
-9.9 
(-14.8, -5.1) 
<0.01* 
Diabetic 
control 
n=23 
86.7 
(6.2) 
68-95 
86.8  -2.0 
(-7.8, 3.9) 
0.94 
-6.2 
(-11.5, - 0.9) 
<0.02* 
Early 
maculopathy 
n=24 
84.8 
(6.7) 
60-95 
84.8   -4.2 
(-9.3, 1.0) 
0.17 
Sight-
threatening 
maculopathy 
n=41 
80.6 
(9.8) 
55-95 
80.6    
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Figure 6.2: Boxplot of inter-group comparison of BCVA. Values represented are the 
median, upper and lower quartiles, and the 95% confidence interval. Outliers are 
represented by a circle (value more than 1.5 times the length of the box from the 
end of the box) or an asterisk (value more than 3 times the length of the box from 
the end of the box). Numbers next to outliers represent the study number of the 
subject 
 
 
 
6.3.2 Contrast sensitivity (Table 6.7, Figure 6.3) 
Mean contrast sensitivity (CS) differed significantly across groups (<0.05, ANOVA F-
Test). Similar to BCVA, mean CS was significantly reduced in subjects with early 
maculopathy (38.0 letters, p<0.05) and subjects with sight-threatening maculopathy 
(34.9 letters, p<0.01) compared to healthy controls (40.9 letters). There was no 
significant difference between healthy and diabetic controls (38.7 letters, p>0.1). 
Subjects with sight threatening maculopathy had a significantly worse mean CS 
compared to both the diabetic controls (p<0.01) and subjects with early 
maculopathy (p<0.01). There was no significant difference between diabetic 
controls and subjects with early maculopathy (p>0.50).  
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Table 6.7: Intergroup comparison of contrast sensitivity (letters). Mean values 
corrected for age. P value represents age corrected comparisons. *P<0.05 is 
deemed significant. CL = confidence limits. 
 
 
 
 Mean CS 
(letters) 
(SD) 
Range 
Mean CS 
(letters) 
Age corrected mean difference in CS (letters) 
(95% CI) 
P value 
  Corrected 
for age 
Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy 
control 
n=29 
41.1 
(1.4) 
37-42 
40.9 -2.2 
(-5.1, 0.6) 
0.20 
-2.9 
(-5.6, -0.1) 
0.04* 
-6.1 
(-8.5, -3.6) 
<0.01* 
Diabetic 
control 
n=23 
38.4 
(3.2) 
30-42 
38.7  -0.6 
(-3.5, 2.3) 
0.99 
-3.8 
(-6.4, -1.2) 
<0.01* 
Early 
maculopathy 
n=24 
38.0 
(3.7) 
30-42 
38.0   -3.2 
(-5.7, -0.7) 
<0.01* 
Sight-
threatening 
maculopathy 
n=40 
34.9 
(4.9) 
24-42 
34.9    
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Figure 6.3: Boxplot of inter-group comparison of CS. Values represented are the 
median, upper and lower quartiles, and the 95% confidence interval. Outliers are 
represented by a circle (value more than 1.5 times the length of the box from the 
end of the box) or an asterisk (value more than 3 times the length of the box from 
the end of the box). Numbers next to outliers represent the study number of the 
subject 
 
6.3.3 Microperimetry (Table 6.8, Figure 6.4) 
Mean microperimetry (MP) central ring sensitivities differed significantly between 
groups (p<0.01, ANOVA F-Test) and are shown in Table 6.8. Mean central ring 
sensitivity was significantly reduced in subjects with sight-threatening maculopathy 
(12.7 dB) compared to healthy controls (17.9 dB, p<0.01).  Subjects with early 
maculopathy showed a trend towards reduced mean sensitivity (15.2 dB, p>0.05). 
There was no significant difference between healthy controls and diabetic controls 
(16.5 dB, p>0.50).  
Subjects with sight threatening maculopathy had a significantly reduced mean 
sensitivity compared to diabetic controls (p<0.01) and there was a trend towards 
reduced mean sensitivity compared to subjects with early maculopathy (p<0.05). 
There was no significant difference between diabetic controls and subjects with 
early maculopathy (p>0.50). 
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Table 6.8: Intergroup comparison of MP central ring sensitivity without and with 
correction for age. P value represents age corrected comparison. *P ≤0.01 deemed 
significant. CL = confidence limits. 
 Mean MP 
sensitivity 
(dB) 
(SD) 
Range 
Mean MP 
sensitivity 
(dB) 
Age corrected mean difference in MP 
sensitivity (dB) 
(95% CL) 
P value 
  Corrected 
for age 
Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy 
control 
n=25 
17.9 
(1.9) 
14.2-20.0 
17.9 -1.4 
(-4.4, 1.7) 
0.79 
-2.7 
(-5.5,0.1) 
0.06 
-5.2 
(-7.7,-2.8) 
<0.01* 
Diabetic 
control 
n=18 
16.4 
(2.8) 
9.8-20.0 
16.5  -1.3 
(-4.3,1.7) 
0.82 
-3.8 
(-6.6,-1.1) 
<0.01* 
Early 
maculopathy 
n=24 
15.2 
(3.3) 
7.4-20.0 
15.2   -2.5 
(-5.0,-0.1) 
0.04 
Sight-
threatening 
maculopathy 
n=41 
12.7 
(4.6) 
1.4-19.2 
12.7    
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Figure 6.4: Boxplot of inter-group comparison of MP. Values represented are the 
median, upper and lower quartiles, and the 95% confidence interval. Outliers are 
represented by a circle (value more than 1.5 times the length of the box from the 
end of the box) or an asterisk (value more than 3 times the length of the box from 
the end of the box). Numbers next to outliers represent the study number of the 
subject 
 
6.3.4 Multifocal electroretinogram (Tables 6.9 and 6.10, Figure 6.5) 
The mean mfERG central ring amplitudes are shown in Table 6.9.  Mean mfERG 
central ring amplitude significantly differed across groups (p<0.01, ANOVA F-test). 
Mean amplitude was significantly reduced in subjects with sight-threatening 
maculopathy (41.7 nV/deg2) as compared to healthy controls (76.0 nV/deg2, 
p<0.01). There was a trend towards reduced mean amplitude in subjects with early 
maculopathy (58.6 nV/deg2, p<0.05). There was no significant difference compared 
to diabetic controls (75.6 nV/deg2, p>0.50). 
Subjects with sight threatening maculopathy showed reduced mean amplitude 
compared to diabetic controls (p<0.01) and a trend towards reduced amplitude 
compared to subjects with early maculopathy (p<0.05). There was also a trend 
towards reduced mean amplitude in subjects with early maculopathy compared to 
diabetic controls (p>0.05). 
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The mean central ring mfERG implicit times (IT) are shown in Table 6.10. Mean IT 
differed across groups (p<0.01, ANOVA F-test) and was significantly prolonged in 
subjects with sight-threatening maculopathy (40.3 ms) compared to healthy 
controls (37.8 ms, p<0.01). Though mean IT was prolonged in subjects with early 
maculopathy, this did not reach statistical significance (38.9 ms, p>0.50). There was 
no difference between healthy controls and diabetic controls (37.7 ms p>0.50). 
Mean IT was significantly prolonged in sight-threatening maculopathy compared to 
diabetic controls (p≤0.01). It was also prolonged in sight threatening maculopathy 
compared to early maculopathy though this did not reach statistical significance 
(p>0.10). There was no significant difference between diabetic controls and subjects 
with early maculopathy (p>0.50). 
Figure 6.5: Boxplot of inter-group comparison of mfERG central ring amplitude and 
implicit time. Values represented are the median, upper and lower quartiles, and 
the 95% confidence interval. Outliers are represented by a circle (value more than 
1.5 times the length of the box from the end of the box) or an asterisk (value more 
than 3 times the length of the box from the end of the box). Numbers next to 
outliers represent the study number of the subject 
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Table 6.9. Intergroup comparison of mean mfERG central ring amplitude without 
and with correction for age. P value represents age corrected comparisons.  P<0.01 
is deemed significant* CL = confidence limits. 
 
 
 Mean 
mfERG 
amplitude 
(nV/deg2) 
(SD) 
Range 
Mean 
mfERG 
amplitude 
(nV/deg2) 
Age corrected mean difference in mfERG 
amplitude (nV/deg2 ) 
(95% CL) 
P value 
  Corrected 
for age 
Diabetic 
control 
Early 
maculopath
y 
Sight-
threatening 
maculopath
y 
Healthy 
control 
n=29 
76.4 
(20.1) 
44.5-129.7 
76.0 -0.3 
(-18.5, 17.8) 
1.00 
-17.4 
(-34.7, -0.1) 
<0.05 
-34.4 
(-49.6, -19.1) 
<0.01* 
Diabetic 
control 
n=22 
75.0 
(32.0) 
32.9-144.4 
75.6  -17.1 
(-35.5, 1.4) 
0.09 
-34.0 
(-50.7, -17.3) 
<0.01* 
Early 
maculopathy 
n=24 
58.4 
(18.4) 
20.9-91.0 
58.6   -17.0 
(-33.0, -0.9) 
0.03 
Sight-
threatening 
maculopathy 
n=40 
41.7 
(21.9) 
0.5-91.2 
41.6    
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Table 6.10: Intergroup comparison of mfERG central ring implicit time without and 
with correction for age. P value represents age corrected comparison. *P<0.01 is 
deemed significant. CL = confidence limits. 
 Mean mfERG 
implicit time 
(ms) 
(SD) 
Range 
Mean 
mfERG 
implicit 
time (ms) 
Age corrected mean difference in mfERG 
implicit time (ms) 
(95% CL) 
P value 
  Corrected 
for age 
Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy 
control 
n=29 
37.6 
(2.3) 
35.3-44.1 
37.8 -0.1 
(-2.6, 2.3) 
1.00 
0.9 
(-1.4, 3.3) 
0.87 
2.5 
(0.4, 4.6) 
<0.01* 
Diabetic 
control 
n=22 
38.1 
(2.8) 
34.4-45.1 
37.7  1.1 
(-1.4 to 3.6) 
0.83 
2.6 
(0.4, 4.9) 
0.01 
Early 
maculopathy 
n=24 
38.9 
(2.4) 
36.3-44.1 
38.8   1.6 
(-0.6, 3.7) 
0.30 
Sight-
threatening 
maculopathy 
n=40 
40.3 
(4.3) 
31.4-50.0 
40.3    
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6.3.5 Oscillatory potentials (Tables 6.11 and 6.12, Figure 6.6) 
Mean OP sum amplitudes are shown in Table 6.11 and differed significantly across 
groups (p<0.01, ANOVA F-test). Mean OP sum amplitude was significantly reduced 
in subjects with sight threatening maculopathy (44.9 µV) as compared to healthy 
controls (69.5 µV, p<0.01), diabetic controls (68.7 µV, p≤0.01) and subjects with 
early maculopathy (74.5 µV, p<0.01). There were no significant differences between 
any of the other groups (p>0.50 for all comparisons). 
Mean OP 1st peak implicit times are shown in Table 5.12. OP implicit time differed 
significantly across groups (p<0.01, ANOVA F-test). Mean OP IT showed a trend 
towards prolongation in sight-threatening maculopathy (18.8ms) compared to 
healthy controls (17.7 ms, p≤0.02). Mean OP IT in diabetic controls (18.6 ms, 
p>0.10) and early maculopathy (18.0 ms, p>0.50) was non-significantly prolonged 
compared to healthy controls. Early maculopathy showed a shorter mean OP IT 
compared to the other groups with DM but this was statistically not significant 
(p>0.20 for all comparisons). 
Figure 6.6: Boxplot of inter-group comparison of OP sum amplitude and OP 1st peak 
implicit time. Values represented are the median, upper and lower quartiles, and 
the 95% confidence interval. Outliers are represented by a circle (value more than 
1.5 times the length of the box from the end of the box) or an asterisk (value more 
than 3 times the length of the box from the end of the box). Numbers next to 
outliers represent the study number of the subject 
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Table 6.11: Intergroup comparison of mean OP sum amplitude without and with 
correction for age. P value represents age corrected. *P<0.01 is deemed significant. 
CL = confidence limits. 
 Mean OP 
sum 
amplitude 
(µV) 
(SD) 
Range 
Mean OP 
sum 
amplitude 
(µV) 
 
Age corrected mean difference in OP sum 
amplitude (µV) 
(95% CL) 
P value 
  Corrected 
for age 
Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy 
control 
n=29 
73.3 
(32.5) 
22.6-177.0 
69.5 -0.8 
(-22.2, 20.7) 
1.00 
5.0 
(-15.5,25.4) 
0.99 
-24.5 
(-42.6, -6.5) 
<0.01* 
Diabetic 
control 
n=22 
63.4 
(34.5) 
23.2-132.0 
68.7  5.7 
(-16.1,27.5) 
0.98 
-23.8 
(-43.7, -3.9) 
0.01 
Early 
maculopathy 
n=24 
73.3 
(31.5) 
19.0-154.0 
74.5   -29.5 
(-48.6, -10.4) 
<0.01* 
Sight-
threatening 
maculopathy 
n=39 
45.8 
(22.9) 
12.7-118.0 
44.9    
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Table 6.12: Intergroup comparison of OP 1st peak implicit time without and with 
correction for age. p value represents comparison to diabetic controls, early 
maculopathy, sight-threatening maculopathy. *P<0.01 is deemed significant. CL = 
confidence limits 
 
 
 
 Mean OP 
implicit 
time (ms) 
(SD) 
Range 
Mean OP 
implicit 
time (ms) 
 
Age corrected mean difference in OP implicit 
time (ms) 
(95% CL) 
P value 
  Corrected 
for age 
Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy 
control 
n=29 
17.6 
(1.5) 
15.0-23.8 
17.7 1.0 
(-0.2,1.9) 
0.18 
0.3 
(-0.7,1.3) 
0.96 
1.0 
(0.1,1.9) 
0.02 
Diabetic 
control 
n=21 
18.7 
(2.1) 
17.0-25.5 
18.6  -0.5 
(-1.6,0.5) 
0.70 
0.2 
(-0.8,1.2) 
1.00 
Early 
maculopathy 
n=24 
18.1 
(0.9) 
17.0-20.0 
18.0   0.7 
(-0.2,1.6) 
0.25 
Sight-
threatening 
maculopathy 
n=38 
18.7 
(1.1) 
17.0-22.0 
18.8    
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6.3.6 Optical coherence tomography (Table 6.13) 
Mean OCT central subfield thicknesses (CSFT) are shown in Table 6.13.  Mean OCT 
CSFT differed significantly across groups (p<0.01, ANOVA F-test).There were no 
significant differences in mean CSFT between healthy controls, diabetic controls and 
early maculopathy (p>0.50 for all comparisons). Mean CSFT was significantly thicker 
in sight-threatening maculopathy compared to all other groups (>60 µm, p<0.01 for 
all comparisons). 
6.3.7 Ischaemic maculopathy (Table 6.14) 
Sub-analysis of the sight-threatening maculopathy group is presented in Table 6.14. 
Subjects with ischaemic macular changes showed a significantly reduced mean 
BCVA, contrast sensitivity, MP central ring sensitivity and mfERG central ring 
amplitude compared to those with no ischaemic changes (p<0.01 for all 
comparisons). There was a reduced mean OP sum amplitude in subjects with 
ischaemic macular changes but this was not statistically significant (p>0.50). Implicit 
time for both mfERG central ring and OP 1st peak were prolonged in those with 
ischaemic maculopathy but this again did not reach statistical significance (p>0.50). 
Subjects with ischaemic macular changes showed prolongation of mean mfERG 
central ring IT compared to both healthy (4.2 ms, p<0.01) and diabetic controls (4.3 
ms, p<0.01). Mean OP IT was also prolonged compared to healthy controls though 
this did not reach statistical significance (1.5 ms, p<0.10). 
After exclusion of subjects with ischaemic maculopathy, subjects with only CSMO 
still showed reduced retinal function compared to healthy controls in BCVA (-7.2 
letters, p<0.01), CS (-4.7 letters, p<0.01), MP central ring sensitivity (-3.6 dB, 
p<0.01), and mfERG central ring amplitude (-27.4 nV/deg2, p<0.01). There was a 
trend towards reduced OP sum amplitude (-20.7 µV, p<0.05). Mean mfERG central 
ring IT was no longer significantly prolonged (2.0ms, p>0.10). 
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Table 6.13: Intergroup comparison of OCT central subfield thickness (CSFT) without 
and with correction for age. P value represents age corrected comparison. *P<0.05 
is deemed significant. CL = confidence limits 
 
 
 
 Mean 
OCT CSFT 
(µm) 
(SD) 
Range 
Mean OCT 
CSFT (µm) 
(SD) 
Range 
Age corrected mean OCT CSFT (µm) 
(95% CL) 
P value 
  Corrected 
for age 
Diabetic 
control 
Early 
maculopathy 
Sight-
threatening 
maculopathy 
Healthy 
control 
n=28 
283.7 
(19.0) 
235-340 
281.6 -9.1 
(-52.3, 
34.1) 
1.00 
-2.8 
(-44.1, 38.5) 
1.00 
60.5 
(24.1, 96.9) 
<0.01* 
Diabetic 
control 
n=22 
269.6 
(22.8) 
211-306 
272.4  6.3 
(-37.3, 49.9) 
1.00 
69.6 
(30.0, 109.2) 
<0.01* 
Early 
maculopathy 
n=24 
278.2 
(31.1) 
190-349 
278.8   63.3 
(25.3, 101.3) 
<0.01* 
Sight-
threatening 
maculopathy 
n=40 
342.5 
(86.0) 
242-636 
342.1    
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Table 6.14: Sub-analysis of sight-threatening maculopathy group, comparing 
subjects with ischaemic maculopathy to subjects CSMO only. Mean values corrected 
for age. *P<0.01 is deemed significant 
 CSMO 
(n=32) 
Ischaemic 
maculopathy 
(n=9) 
P value 
Mean BCVA (letters) 
(SD) 
83.4 
(7.1) 
70.8 
(12.0) 
<0.01* 
Mean CS (letters) 
(SD) 
36.2 
(4.2) 
30.3 
(4.7) 
<0.01* 
Mean MP central ring sensitivity (dB) 
(SD) 
14.3 
(3.1) 
6.9 
(4.6) 
<0.01* 
Mean mfERG central ring amplitude 
(nV/deg2) (SD) 
48.5 
(19.1) 
17.7 
(11.8) 
<0.01* 
Mean mfERG central ring implicit time (ms) 
(SD) 
39.8 
(3.8) 
42.0 
(5.8) 
0.50 
Mean OP sum amplitude (µV) 
(SD) 
48.8 
(21.7) 
32.2 
(23.2) 
0.69 
Mean OP implicit time (ms) 
(SD) 
18.0 
(1.1) 
18.6 
(1.0) 
0.94 
 
6.4 Analysis of association and of diagnostic potential 
I analysed the outcomes of visual function to determine the probability that a 
subject with DM and compromised function has sight-threatening maculopathy. As 
described in Chapter 4, Section 7.3, compromised function of an investigation was 
determined by the quartile closest to reduced function and what I have termed the 
critical value. This was deemed to be the lower quartile for BCVA, CS, MP, mfERG 
amplitude and OP amplitude, and the upper quartile for mfERG and OP implicit 
times. The Fisher exact test of association was used to determine significance; 
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p<0.05 was deemed significant. Binomial confidence intervals were calculated using 
Clopper-Pearson formula.  
In addition to association, I also calculated the sensitivity, specificity, positive 
predictive value and negative predictive value for each test.  
 Sensitivity: proportion of subjects with sight-threatening maculopathy with 
function equal to or worse than the critical value 
 Specificity: proportion of subjects without sight-threatening maculopathy with 
function better than the critical value  
 Positive predictive value (PPV): proportion of subjects with function equal to or 
worse than critical value who have sight-threatening maculopathy  
 Negative predictive value (NPV): proportion of subjects with function better 
than critical value who do not have sight-threatening maculopathy    
6.4.1 Analysis of single functional outcomes (Table 6.15) 
In Table 6.15, I present the results of using one outcome in analysing likelihood of a 
subject having sight-threatening maculopathy. The association tests the likelihood 
that a subject with visual or retinal function worse than or equal to the critical value 
has sight-threatening maculopathy. 
There were significant associations between the presence of sight-threatening 
maculopathy and function worse than the critical value for BCVA (p<0.01), CS 
(p<0.001), MP (p<0.03), mfERG amplitude (p<0.01) and OP IT (p<0.02). For all 
investigations sensitivity was low (33.3 - 55.3%) but specificity was high (73.3 – 
89.4%). Each test showed moderate PPV (61.9 – 78.3%) and NPV (58.1 – 66.0 %). 
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 Table 6.15: Univariate associations of central macular function and sight-
threatening maculopathy with analysis of sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV). amp = amplitude; IT = implicit time. 
*P < 0.05 is deemed significant. CI = confidence interval  
 
 
 Critical 
value 
Association 
(p value) 
Sensitivity 
(%) 
(95% CI) 
Specificity 
(%) 
(95% CI) 
PPV(%) 
(95% CI) 
NPV(%) 
(95% CI) 
BCVA 
(letters) 
≤79.0 <0.01* 41.5 
(26.3-57.9) 
85.1 
(71.7-93.8) 
70.8 
(48.9-87.4) 
62.5 
49.5-74.3 
CS 
(letters) 
≤34.0 <0.001* 45.0 
(29.3-61.5) 
89.4 
(76.9-96.5) 
78.3 
(56.3-92.5) 
65.6 
(52.7-77.1) 
MP (dB) ≤12.6 <0.03* 36.6 
(22.1-53.1) 
85.7 
(71.5-94.6) 
71.4 
(47.8-88.7) 
58.1 
(44.9-70.5) 
mfERG 
amp 
(nV/deg2) 
≤33.9 <0.01* 40.0 
(24.9-56.7) 
89.1 
(76.4-96.4) 
76.2 
(52.8-91.8) 
63.1 
(50.2-74.7) 
mfERG IT 
(ms) 
≥41.2 >0.05 37.5 
(22.7-54.2) 
82.6 
(68.6-92.2) 
65.2 
(42.7-83.6) 
60.3 
(47.2-72.4) 
OP sum 
amp (µV) 
≤34.5 >0.10 33.3 
(19.1-50.2) 
82.6 
(68.6-92.2) 
61.9 
(38.4-81.9) 
59.4 
(46.4-71.5) 
OP IT 
(ms) 
≥19.0 <0.02* 55.3 
(38.3-71.4) 
73.3 
(58.1-85.4) 
63.6 
(45.1-79.6) 
 
66.0 
(51.2-78.8) 
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6.4.2 Analysis of combined functional outcomes (Table 6.16 and Table 6.17) 
In Table 6.16, I present the results of association of visual function to sight-
threatening maculopathy if two investigations are combined, i.e a subject has 
reduced visual function in two separate investigations. In Table 6.17 I present the 
results of association of central macular function to sight-threatening maculopathy. 
By combining two investigations, there is a significant association to sight-
threatening maculopathy in all investigations except for the following combinations: 
MP + mfERG IT; mfERG IT + OP amplitude; mfERG + OP IT; OP amplitude + OP IT. 
Sensitivity was low for all comparisons (15.4 – 30.0%) but specificity was high (87.0 
– 100.0%). For combinations with significant association to sight-threatening 
maculopathy, PPV was high (83.3 – 100.0%) and NPV was moderate (56.4 – 62.0%). 
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Table 5.16:  Bivariate associations of visual function and sight-threatening 
maculopathy. amp = amplitude; IT = implicit time. *P < 0.05 is deemed significant.   
Investigation Association 
(p value) 
Sensitivity(%) 
(95% CI) 
Specificity(%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
BCVA + CS <0.01* 30.0 
(16.6-46.5) 
93.6 
(82.5-98.7) 
80.0 
(51.9-95.7) 
61.1 
(48.9-72.4) 
BCVA + MP <0.01* 29.3 
(161.-45.5) 
100.0 
(91.2-100.0) 
100.0 
(73.5-100.0) 
58.0 
(45.5-69.8) 
BCVA + 
mfERG amp 
<0.01* 25.0 
(12.7-41.2) 
100.0 
(92.1-100.0) 
100.0 
(69.2-100.0) 
60.0 
(48.0-71.2) 
BCVA + 
mfERG IT 
<0.03* 17.1 
(7.2-32.1) 
97.8 
(88.2-99.9) 
87.5 
(47.4-99.7) 
56.4 
(44.7-67.6) 
BCVA + OP 
amp 
<0.05* 15.4 
(5.9-30.5) 
97.8 
(88.2-99.9) 
85.7 
(42.1-99.6) 
57.1 
(45.5-68.4) 
BCVA + OP 
IT 
<0.01* 23.7 
(11.4-40.2) 
97.7 
(88.0-99.9) 
90.0 
(55.5-99.8) 
59.7 
(47.5-71.1) 
CS+MP <0.01* 27.5 
(14.6-43.9) 
97.6 
(87.1-99.9) 
91.7 
(61.5-99.8) 
58.0 
(45.5-69.8) 
CS + mfERG 
amp 
<0.01* 25.6 
(13.0-42.1) 
97.8 
(88.2-99.9) 
90.9 
(58.7-99.8) 
60.3 
(48.1-71.6) 
CS + mfERG 
IT 
<0.01* 17.5 
(7.3-32.8) 
100.0 
(92.1-100.0) 
100.0 
(59.0-100.0) 
57.7 
(46.0-68.8) 
CS + OP amp <0.01* 20.5 
(9.3-36.5) 
100.0 
(92.1-100.0) 
100.0 
(63.1-100.0) 
59.2 
(47.3-70.4) 
CS + OP IT <0.01* 30.8 
(17.0-47.6) 
100.0 
(92.0-100.0) 
100.0 
(73.5-100.0) 
62.0 
(49.7-73.2) 
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Table 6.17:  Bivariate associations and diagnostic potential of central macular 
function in sight-threatening maculopathy when two outcomes are combined. amp 
= amplitude; IT=implicit time. *P<0.05 is deemed significant. CI=confidence interval  
Investigation Association 
(p value) 
Sensitivity 
(%) 
(95% CI) 
Specificity 
(%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
MP + mfERG 
amp 
<0.02* 25.0 
(12.7-41.2) 
95.2 
(83.8-99.4) 
83.3 
(51.6-97.9) 
57.1 
(44.8-68.9) 
MP + mfERG 
IT 
>0.10 17.5 
(7.3-32.8) 
92.9 
(80.5-98.5) 
70.0 
(34.8-93.3) 
54.2 
(42.0-66.0) 
MP + OP 
amp 
<0.01* 17.9 
(7.5-33.5) 
100.0 
(91.6-100.0) 
100.0 
(59.0-100.0) 
56.8 
(44.7-68.2) 
MP + OP IT <0.01* 25.6 
(13.0-42.1) 
97.6 
(87.4-99.9) 
90.9 
(58.7-99.8) 
58.6 
(46.4-70.2) 
mfERG amp 
+ mfERG IT 
<0.01* 17.5 
(7.3-32.8) 
100.0 
(92.3-100.0) 
100.0 
(59.0-100.0) 
58.2 
(46.6-69.2) 
mfERG amp 
+ OP amp 
<0.03* 18.4 
(7.7-34.3) 
97.8 
(88.5-99.9) 
87.5 
(47.4-99.8) 
59.2 
(47.3-70.3) 
mfERG amp 
+ OP IT 
<0.01* 26.3 
(13.4-43.1) 
97.8 
(88.2-99.9) 
90.9 
(58.7-99.8) 
61.1 
(48.9-72.4) 
mfERG IT + 
OP amp 
>0.10 17.9 
(7.5-33.5) 
93.5 
(82.1-98.6) 
70.0 
(34.8-93.3) 
57.3 
(45.4-68.7) 
mfERG IT + 
OP IT 
>0.10 28.2 
(15.0-44.9) 
87.0 
(73.7-95.1) 
64.7 
(38.3-85.8) 
58.8 
(46.2-70.6) 
OP amp + 
OP IT 
>0.05 28.9 
(15.4-45.9) 
88.9 
(75.9-96.3) 
68.8 
(41.3-89.0) 
59.7 
(47.0-71.5) 
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6.5 Discussion 
6.5.1 Key results 
In this chapter I have found the following absolute statistically significant worsening 
in mean visual function corrected for age for sight threatening maculopathy: 
 a two line (9.9 letters) reduction in BCVA compared to healthy controls and just 
over one line (6.2 letters) reduction compared to diabetic controls 
 15% (6.1 letters) reduction in contrast sensitivity compared to healthy controls, 
10% (3.8 letters) reduction compared to diabetic controls and 8% (3.2 letters) 
compared to early maculopathy  
 29% reduction in microperimetry sensitivity compared to healthy controls and 
23% reduction compared to diabetic controls  
 45% reduction in mfERG central ring amplitude compared to both healthy 
controls and diabetic controls 
 7% prolongation of mfERG central ring implicit compared to both healthy and 
diabetic controls 
 35% reduction in OP sum amplitude compared to both healthy and diabetic 
controls and 40% reduction compared to early maculopathy 
 trend towards prolongation of OP 1st peak implicit time 
In sight-threatening maculopathy this is followed by the following significant 
changes in structure: 
 an increase in 20-25% in mean CSFT on OCT 
For early maculopathy there were trend associations, all indicating reduced 
function: 
 reduction in BCVA of over one line (5.8 letters) compared to healthy controls 
 reduction in CS (2.9 letters) compared to healthy controls 
 15% reduction in MP central ring sensitivity compared to healthy controls 
 23% reduction in mfERG amplitude compared to healthy and diabetic controls 
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For diabetic controls compared to healthy controls there was reduced function 
across many measures but none of the differences reached statistical significance. 
6.5.2 Microperimetry 
In my study, subjects with sight-threatening maculopathy (12.7 dB) showed a 29% 
reduction in central ring sensitivity compared to healthy controls (17.9 dB, p<0.01) 
and a 23% reduction compared to diabetic controls (16.5 dB, p<0.01). There was a 
trend towards reduced function compared to subjects with early maculopathy (15.2 
dB, p=0.04). Subjects with early maculopathy demonstrated a 15% reduction in 
sensitivity compared to healthy controls though this difference did not reach 
significance (p=0.06). 
My findings are similar to a study by Okada et al (2006).183 The authors 
retrospectively assessed MP sensitivity in the central 2o of the macula in subjects 
with CSMO without ischaemic macular changes (n=32) and compared them to 
healthy controls (n=17). The authors reported significantly reduced sensitivity 
(p<0.0001) in subjects with CSMO and correlated sensitivity to BCVA (r2=0.62, 
p<0.0001) and CSFT (r2=0.58, p<0.0001).  The authors concluded that MP may be 
used as a measure to assess the effects of CSMO. However this was a retrospective 
analysis with no correction for risk factors or age. Median CSFT was 523 µm and 
median BCVA was ~6/30, while my subjects had better BCVA and less foveal 
thickening. It is, therefore, possible that subjects in this study had more advanced 
disease. 
Other studies have also reported reduced function in subjects with CSMO.184,185  
However, these studies assessed the macula as a whole rather than just the central 
macula. Al-Shafaee et al (2011)184 demonstrated reduced function in all subjects 
with DMO, though the authors did not report whether these subjects had CSMO or 
early maculopathy.  Gella et al (2016)185 prospectively analysed retinal sensitivity in 
357 subjects with type 2 DM. The authors only reported reduced sensitivity at 8o, 
10o and 12o in subjects with DMO, but not in the central 2o or 4o. However the 
authors did not report whether these subjects had CSMO. The authors concluded 
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that the presence of macular oedema was associated with significant reduction in 
function.  
In my study, subjects with CSMO showed reduced function compared to subjects 
with early maculopathy though this was not statistically significant (p=0.04). There 
have been no studies which have compared between different severities of diabetic 
maculopathy. There has been a study comparing different severities of DR. Nittala 
et al (2012)186 assessed retinal sensitivity between healthy controls, diabetic 
controls, subjects with mild, moderate and severe non-proliferative DR (NPDR) and 
subjects with proliferative DR (PDR). The authors reported a reduction in sensitivity 
in subjects with DR (p=0.001). Sub-analysis reported the following mean sensitivities 
in the central 2o of the macula: healthy controls, 16.68 dB; diabetic controls, 14.73 
dB; mild NPDR, 14.87 dB; moderate NPDR, 13.37 dB; severe NPDR, 8.46 dB; PDR, 8.6 
dB. However p values were not reported for comparison between the NPDR groups. 
Nevertheless, there appears to be a dramatic decrease in MP sensitivity in subjects 
who develop severe disease. This may indicate a critical point in DR after which 
function decreases more rapidly. 
The presence of ischaemic macular changes resulted in a 61% reduction in retinal 
sensitivity compared to healthy controls in my study. This finding is similar to results 
published by Cennamo et al (2015)187 who reported a 59% reduction in sensitivity in 
subjects with ischaemic maculopathy as compared to healthy controls. These 
subjects showed a significant reduction in retinal thickness compared to retinal 
thickness, whilst our subjects had clinically significant macular oedema (CSMO) in all 
but one case and so had an overall increased thickness compared to healthy 
controls.  
In my study, comparison between subjects with CSMO and ischaemic maculopathy 
revealed a significant reduction in sensitivity of 51% in the latter group. This 
suggests that the presence of macular ischaemia is a risk factor for reduced central 
macular function.   Therefore the clinician should be suspicious of the presence of 
ischaemic macular changes in subjects with CSMO and severely reduced central 
retinal sensitivity. 
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In my study, there was no significant difference between healthy controls and 
diabetic controls, though sensitivity was reduced on average by 8%. De Benedetto 
et al (2014) reported a less than 10% reduction in sensitivity between subjects with 
non-proliferative DR and healthy controls.188   
Other studies have also reported reduced sensitivity in subjects with no DR 
compared to healthy controls. However these studies have either used the whole 
macula for analysis,31,189 did not report p values,184  used only 1 point for 
assessment of central macular function,186 or included subjects with varying levels 
of retinopathy within the main analysis.190 In my study I analysed only the central 
macula using an average of five points to provide a more accurate reflection of 
foveal function. 
Nittala et al (2012) reported no significant difference between subjects with no DR 
and those with mild to moderate DR.186 Al Shafaee et al (2011)184 reported 24% of 
healthy controls and 20% of diabetic controls as having abnormal function. 
However the authors have not reported what constitutes abnormal function. Gella 
et al (2016) reported no significant difference between subjects with no DR and 
those with macular oedema in the central ring of the OCT.185 This suggests that 
decrease in function occurs in a step-wise fashion rather than a linear pattern, i.e. 
there is an initial dysfunction which is preserved until severe disease develops. 
These results are similar to my study in which function continues to decrease with 
increasing severity across maculopathy groups though statistical significance was 
only reached in the sight-threatening maculopathy group. It is possible that larger 
groups may have provided significant results in the inter-group comparisons in 
earlier disease groups. 
Other features in diabetic maculopathy have been associated with reduced 
sensitivity. In a study of subjects with DMO, point sensitivity was analysed in the 
presence of disruption of the photoreceptor layer.191 The authors reported a mean 
3.28 dB reduction in retinal sensitivity at points with disruption compared to points 
without disruption. However there was a significant increase in retinal thickness in 
subjects at points with disruption compared to those without disruption. Therefore 
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the difference in sensitivity may reflect difference in retinal thickness rather than 
photoreceptor layer disruption. In a study of 12 eyes with exudates, mean retinal 
sensitivity over regions with exudates was associated with reduced retinal 
sensitivity compared to regions without exudates.192 However, retinal thickness was 
significantly increased in the regions and not adjusted for in analysis. In a study of 
34 eyes with DMO, retinal sensitivity was compared to type of DMO.193 The authors 
reported a significant difference between subjects with diffuse retinal thickening, 
cystoid macular oedema (CMO), subretinal fluid (SRF) and neurosensory retinal 
detachment (NRD). The authors concluded that diabetic macular oedema 
progressed from diffuse thickening to CMO, with the latter associated with worse 
retinal function, and subsequently progressed to the more severe forms of SRF and 
NRD. I did not assess for these potential risk factors but these studies suggest the 
presence of such features should alert the clinician to probable reduced function.  
6.5.3 Multifocal electroretinogram 
Subjects with sight threatening maculopathy demonstrated significant reduction in 
amplitude (41.6 nV/deg2) and prolongation of IT (40.3 ms) compared to healthy 
controls (76.0 nV/deg2 and 37.8 ms, respectively; p<0.01 for both comparisons) and 
diabetic controls (75.6 nV/deg2 and 37.7 ms, respectively; p<0.01 and p=0.01, 
respectively). Subjects with sight-threatening maculopathy showed a trend towards 
reduced amplitude compared to early maculopathy (58.6 nV/deg2, p<0.03) and a 
non-significant prolongation of IT (38.8 ms, p>0.20). 
Similar findings have been reported in several studies. Yamamoto et al (2001) 
reported a >50% decrease in amplitude and prolongation in IT of ~15% in the 
presence of DMO compared to healthy controls.194 This study analysed the central 
10o of the macula, a larger area than I have analysed, and did not perform 
fluorescein angiography (FA) to assess for ischaemic maculopathy. Tehrani et al 
(2015) reported compared mfERG amplitude and IT in 29 subjects with CSMO to 
healthy controls.195 The authors reported reduced amplitude and prolonged IT in 
subjects with CSMO in the central macula (5o). 
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Greenstein et al (2000) reported similar findings with respect to amplitude and IT in 
DMO.152 Using a 103 hexagon array, the authors reported that IT appeared to be 
more severely affected than amplitude. However the authors reported findings of 
the whole macula rather than central macula only. The authors concluded that 
though function is reduced in CSMO, IT was not a good predictor of reduced 
function due to wide variation in function in disease. 
It is important to note that subjects with early and sight-threatening maculopathy 
contained subjects with normal amplitude and IT. This reflects the variable 
structural changes in the macula in subjects with DMO. Hood suggests that damage 
to different structures may result in varying mfERG results.153 He surmised that 
disruption of the ganglion cell layer may not alter amplitude or IT; disruption of the 
cone receptors, outer plexiform layer or on-bipolar cells may result in decreased 
amplitude and IT; disruption of the inner plexiform layer may only affect IT; and 
disruption of the off-bipolar cells may actually be associated with improved 
function. This suggests that combined assessment of structure and function would 
yield more information on severity of disease.  
In my study subjects with early maculopathy showed a trend towards reduction in 
central ring amplitude compared to healthy controls (p<0.05) and a non-significant 
reduction in amplitude compared to diabetic controls (p>0.05). Implicit time (IT) 
was non-significantly prolonged compared to both healthy and diabetic controls 
(p>0.50 for both comparisons).  
Holm et al (2010) reported that the presence of exudates was associated with 
prolonged IT.148 Amplitude was reduced but only in the parafoveal and extrafoveal 
regions. The difference between amplitude and IT results between my study and 
published literature is most likely related to how the mfERG stimulus is set up. I will 
discuss this further in the summary of mfERG findings below.   
In my study there was no significant difference in amplitude or IT between diabetic 
and healthy controls. This replicates findings of Wright et al (2012)151 who reported 
no significant difference in the central ring in subjects with type 1 DM, and 
Dhamdhere et al (2012)196 who reported no significant reduction in function in 
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subjects with type 1 DM. However several studies have reported significant changes 
in amplitude, IT or both in subjects with no DR. 
Reis et al (2014) reported a significant reduction in mfERG amplitude only in the 
central macula.197 However this study only included type 1 DM subjects with a 
mean duration of DM of >14 years which is much longer than my cohort. Tyrberg et 
al (2005) also reported decreased amplitude only, though their subjects had a mean 
duration of DM >23 years.198 Lung et al (2012) also reported reduced amplitude but 
no change in IT.199  
Several studies have reported mfERG IT to be more sensitive with prolongation in IT 
seen but no significant difference in amplitude.150,200-202 The reason IT may be more 
sensitive is that amplitude reflects the strength of summed responses from retinal 
cells.201 Therefore amplitude is likely to be affected only by loss of cells. IT on the 
other hand reflects efficiency of retinal cell function. Therefore, in disease, there 
may be disruption of cell function without loss of the cell and results seen reflect 
inefficiency rather than permanent structural change. 
A few studies have reported both decrease in amplitude and prolongation of IT.203 
Bronson-Castain et al (2012) and Dhamdhere et al (2012) reported significant 
changes in type 2 DM but not type 1 DM, though there were only 10 patients in 
type 1 cohort.196,204  
The difference between my findings and those of the studies listed above may be 
due to how the mfERG is performed. In my study we used a 19 hexagon grid; the 
studies described above use either a 61 or 103 hexagon grid. Therefore each 
hexagon in my study is larger than those used in the other grids. Although this 
allows for quicker data acquisition, the larger stimulus may contain proportionally 
healthier rather than diseased retina.205 This may explain why there was no 
significant difference between the early maculopathy group and diabetic controls 
for both amplitude and implicit time. In addition our mfERG system flashes stimuli 
at a rate of 60 Hz whilst the other studies have a flash rate of 75Hz. With the 
incorporation of 4 blank filler frames for every stimulus, this results in a stimulus 
being presented every 83.3 ms; other studies presented a stimulus every 16.6 ms.137 
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This stimulus was chosen as it allows the neurons time to repolarise prior to the 
next stimulus. (Richard Hagan, personal communication) By presenting a stimulus 
every 16.6 ms, neurons may not have enough time to repolarise. So a compound 
effect may result in which any minimal delay is magnified by subsequent stimuli to 
give a more significant delay at the end of the procedure. By allowing 
repolarisation, any delay in IT would reflect true dysfunction of the stimulated 
neurons. This may explain why there was no significant difference between healthy 
and diabetic controls as there may not be a significant number of neurons affected.  
Two studies have stated that the nasal macula appears to be more susceptible to 
damage in early disease.202,206 Therefore our analysis of just the central macula may 
have missed neuronal dysfunction in early disease.  
Central ring amplitude was significantly worse in subjects with ischaemic 
maculopathy (17.7 nV/deg2) compared to subjects with CSMO (48.5 nV/deg2, 
p<0.01). Though IT was prolonged in the ischaemic group (42.0ms vs 39.8 ms, 
p>0.50) this was not statistically significant.  
Tyrberg et al (2008)207 reported that an enlarged foveal avascular zone (mean 
diameter 0.92 mm) was associated with prolonged IT in the central ring. A decrease 
in amplitude was noted but no correlation to ischaemia was found. The difference 
in mfERG set up between my study and Tyrberg et al (2008) may once again explain 
the difference in outcomes between the two studies.  
In summary, mfERG reveals decreased function in subjects with DM. It has the 
potential to identify subjects with neuronal dysfunction in early disease. I feel 
mfERG offers a method of determining disease severity and, in conjunction with 
other methods, could aid in building a comprehensive picture of a subjects disease 
status. However the outcomes generated may differ depending on parameters used 
and so my results may not be applicable to different cohorts. Use of an approved 
protocol would help to standardise the results and improve our understanding of 
diabetic maculopathy. 
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6.5.4 Oscillatory potentials 
Mean OP sum amplitude (44.9 µV) was significantly reduced in the sight-
threatening maculopathy group compared to healthy controls (69.5 µV, p<0.01), 
diabetic controls (68.7 µV, p=0.01) and subjects with early maculopathy (74.5 µV, 
p<0.01). There was a trend towards prolonged OP IT in subjects with sight-
threatening maculopathy (18.8 ms) compared to healthy controls (17.7 ms, p<0.02). 
IT was non-significantly prolonged compared to diabetic controls (18.6 ms, p>0.50) 
and subjects with early maculopathy (18.0 ms, p>0.20). However there was no 
significant difference between healthy controls, diabetic controls and subjects with 
early maculopathy. This suggests that OP function is well preserved until later 
stages of disease. Similar results have been previously reported.152,208,209 
In some studies prolongation of OP IT has only been reported in diabetic subjects 
with no DR.201,208 In another study only sum OP amplitude was reduced; summed 
OP IT was prolonged but not the 1st peak IT.210 However no adjustments for age or 
systemic risk factors were made in these studies. 
6.5.5 Contrast sensitivity 
In my study contrast sensitivity (CS) was reduced in early maculopathy compared to 
healthy controls, and in sight-threatening maculopathy compared to the other 
three groups. There was no significant difference between healthy and diabetic 
controls. CS disruption has been reported prior to development of vasculopathy,209 
in early DR,211,212 and in ischaemic maculopathy.81 However Jackson et al (2012) 
reported no difference between healthy and diabetic controls.213 
One study reported a reduction in CS in subjects with no DR.80 However this study 
only included subjects aged 55-75 years, and mean duration of DM was 16 years. 
Also, this study utilised a computerised method of testing and only noted changes 
in mesopic conditions. 
6.5.6 Systemic risk factors 
In my study subjects with early and sight-threatening maculopathy had a 
significantly greater HbA1c and longer duration of DM as compared to diabetic 
controls, and subjects with DM were more likely to be on anti-hypertensive and 
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lipid lowering agents. As described in Chapter 3, the Wisconsin Epidemiological 
Study of Diabetic Retinopathy (WESDR) reported that duration of DM and elevated 
HbA1c were risk factors for the development of diabetic macular oedema.69 The 
Early Treatment of Diabetic Retinopathy Study (ETDRS) reported that elevated 
cholesterol levels was associated with an increased likelihood of developing hard 
exudates and visual loss119 and the use of lipid lowering agents in the Effect of 
Fenofibrate on the need for Laser treatment for Diabetic retinopathy (FIELD) study 
was associated with a reduced risk of developing macular oedema.123 In the UK 
Prospective Diabetes Study (UKPDS) group tighter BP control was associated with a 
reduced risk of developing retinal hard exudates and a reduced need for laser for 
treatment of diabetic maculopathy.214 Therefore the differences in systemic risk 
factors between the groups are not unexpected and my cohort appears to be 
representative of patients seen in clinical practice.  
6.5.7 Ischaemic maculopathy  
As seen in the sub-analysis of the sight-threatening maculopathy group (Section 
6.3.7 and Table 6.14), subjects with ischaemic macular changes had reduced retinal 
function, compared to subjects with only CSMO, across all functional assessments. 
Statistically significant worsening was reached in BCVA (16% reduction), CS (16% 
reduction), MP central ring sensitivity (52% reduction) and mfERG central ring 
amplitude (64% reduction). These findings are important as many recent studies do 
not include fluorescein angiography (FA) for determination of the foveal avascular 
zone as part of the assessment of macular function.147-149,155,157,167,168  
In current clinical practice, diagnosis of CSMO is based upon clinical findings with 
OCT highlighting the extent or severity of macular oedema. Therefore I believe the 
sight-threatening maculopathy group appears to be representative of those 
patients whom we encounter in clinical practice. I excluded subjects who required 
treatment for their maculopathy at baseline. So my cohort does not include 
subjects with the worst disease. It is likely that inclusion of those with worst disease 
may have produced reduced mean amplitude and prolonged IT in the sight-
threatening maculopathy group.   
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6.5.8 Diagnosing disease using tests of macular function 
In my analysis of association, I demonstrated that reduced function in BCVA, CS, 
MP, mfERG central ring amplitude and OP IT were significantly associated with a 
diagnosis of sight-threatening maculopathy (p<0.03 for all comparisons). There was 
a trend towards reduced function in mfERG IT (p>0.05) but there was no 
significance with OP sum amplitude (p>0.10). 
There has been only one study that has assessed the predictive power of tests of 
central macular function in subjects with diabetes mellitus. Al Shafaee et al (2011) 
assessed MP in an Omani population, comparing healthy controls, subjects with DM 
and subjects with abnormal blood sugar levels that does not meet criteria for DM 
(pre-diabetes).184 The authors reported that MP was sensitive in differentiating 
between subjects with DM and healthy controls (p=0.001); and between subjects 
with pre-diabetes and healthy controls (p<0.01). Further sub-analysis demonstrated 
that MP was sensitive in determining between subjects with DM and DR, and 
subjects with DM but no DR (p<0.001). There was no difference between subjects 
with DM and subjects with pre-diabetes (p>0.50). The authors did not conclude on 
these findings. However the authors did not report their critical value nor have they 
reported sensitivity and specificity.  
Using a single investigation to determine reduced function in sight-threatening 
maculopathy, sensitivity was weak (33.3-55.3%) but specificity was moderate (73.3-
89.4%). By combining two investigations, sensitivity falls further (17-5-28.9%) and 
specificity improves (87.0-100%).  There have been no studies that have analysed 
sensitivity and specificity of MP, mfERG or OP as predictive biomarkers for sight-
threatening maculopathy. My results suggest that tests of central macular function 
would be more beneficial in determining early or no disease rather than sight-
threatening maculopathy. By combining investigations specificity improves, 
suggesting the use of multiple investigations would be more beneficial. 
Using a single investigation, the positive predictive value (PPV, 61.9-78.3%) and 
negative predictive value (NPV, 58.1-66.0%) demonstrated moderate probability in 
determining if a subject has sight-threatening maculopathy. By combining two 
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investigations, there was only a small change in PPV (64.7-100%) and NPV (54.2-
61.1%). There have been no studies that have analysed the predictive value of these 
tests. My results suggest that these tests offer a moderate predictive value in 
predicting presence of sight-threatening maculopathy. 
These results in specificity, sensitivity, PPV and NPV should be treated with some 
caution. The study was not powered for such analysis. The critical value chosen may 
not be applicable to other studies or cohorts due to use of local protocols in data 
collection. However, with the interest in predictive and prognostic biomarkers for 
macular disease and DR, my study demonstrate that CS, MP, mfERG and OP offer an 
opportunity to quantify disease severity. I discuss the potential benefits of these 
investigations in Chapter 8   
6.5.9 Limitations of the study 
In my study I excluded any potential subjects with CSMO who required treatment 
for their maculopathy within three months of entering the study.  Thus it is likely 
that the reduction in retinal function in the sight-threatening maculopathy group 
would have been greater had I included those subjects in the study. DM is a 
multisystem disease with varying levels of morbidity depending on severity of 
disease. Subjects with worse disease may have been inadvertently excluded from 
the study as they may have been unable to undertake the investigations or were 
unwilling due to poor health. 
Sample size calculations recommended individual group sizes of 30 subjects. This 
was not achieved in the diabetic controls, early maculopathy and ischaemic 
maculopathy group despite the recruitment period being extended. Therefore my 
analyses may be underpowered. The difficulty in recruitment of subjects with 
ischaemic maculopathy was predominantly due to previous macular treatment. 
Nevertheless, the reduction in retinal function across all assessments suggests that 
a larger cohort may not have added any more strength to the results gathered. 
Recruitment took place over two periods due to changes in personnel and need for 
more healthy and diabetic controls. Nevertheless, I was involved in all data 
 146 
 
collection and analysis to ensure continuity in interpretation of the raw data and all 
were subjected to the same conditions during the study.   
Subjects with DM were already on systemic treatment prior to entering the study, 
hence similarities in serum cholesterol and blood pressure. However I do not have 
any information on prior systemic control with which to compare retinal function. 
6.6 Summary 
In this chapter I have demonstrated that sight-threatening maculopathy is 
associated with reduced central macular function over a variety of measures of 
function (BCVA, CS, MP central ring sensitivity, mfERG central ring amplitude, 
mfERG central ring IT and OP sum amplitude). In addition there appears to be 
reduced macular function in early maculopathy in investigations of CS, MP and 
mfERG central ring amplitude. I was unable to demonstrate any significant 
difference in central macular function between healthy controls and diabetic 
controls. This suggests that these investigations may help determine severity of 
disease in conjunction with current clinical techniques of assessing diabetic 
maculopathy. In addition, the reasonably high specificity levels of these 
investigations may aid in excluding subjects with severe diabetic maculopathy. In 
the next chapter I will present the results of the longitudinal investigations to 
determine change in central macular function in subjects with diabetic maculopathy 
and in Chapter 8 I will explore the potential role of visual function assessment in the 
management of diabetic maculopathy. 
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Chapter 7 Results – longitudinal 
In this chapter I present the results of the longitudinal data. I describe the follow up 
of those subjects described in Chapter 6, and explore the reasons for those who 
exited the study. I present the longitudinal results of the structural and functional 
assessments described in Chapter 4. 
7.1 Follow up 
As described in Chapter 6, a total of 118 subjects were recruited to my study. Of 
these there were 89 subjects with diabetes mellitus (DM) who were all considered 
for the longitudinal study. In Figure 7.1 I present the consort style diagram that 
summarises the allocation of the subjects with DM.  Of these 89 subjects, 2 subjects 
did not complete the baseline visit, 11 were recruited during the second phase of 
recruitment, and 15 subjects received treatment for their maculopathy. Therefore, 
61 subjects (70%) were invited to follow up. Of these 39 (64%) completed the 
month 6 visit and 31 (51%) completed the month 12 visit.  
Figure 7.1: Consort style diagram summarising the allocation of subjects with DM at 
6 months and 12 months 
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Subjects with DM were divided into the three groups as follows: diabetic controls, 
n=4 and n=4 at 6 and 12 months respectively; early maculopathy, n=17 and n=13; 
sight-threatening maculopathy, n=18 and n=14 (Table 7.1). 
Table 7.1: Distribution across groups for 89 baseline subjects with DM for follow-up. 
Outcome at month 6 and month 12 represents reasons subjects who did not attend 
for that particular visit. The missed visit represents the two subjects who did not 
attend the month 6 visit but did attend for month 12.  
Time point Outcome Number of subjects 
  Diabetic 
Controls 
Early 
Maculopathy 
Sight-threatening 
maculopathy 
Baseline Recruited 24 24 41 
Month 6 Completed 4 17 18 
Single visit 10 0 1 
Treated 0 0 15 
Withdrew 6 4 6 
No reason given 3 2 1 
Missed visit 1 1 0 
Month 12 Completed 4 13 14 
Treated 0 1 2 
Withdrew 1 4 2 
 
Between the baseline and month 6 visit, 20 subjects withdrew from the study and a 
further two subjects missed their appointment. Therefore 39 of the invited subjects 
(64%) completed a month 6 visit. Subjects either declined to take further part in the 
study or failed to attend their appointment. If subjects failed to attend then a 
further appointment was made and the subject contacted. If the subject again failed 
to attend, then they were withdrawn from the study. 
Of those who completed the month 6 visit, 10 subjects did not attend for the month 
12 visit. Therefore, 31 of the invited subjects (31/61, 51%) completed the month 12 
visit. Three of these subjects received treatment for their maculopathy while seven 
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subjects declined to take further part in the study and so were withdrawn. Two 
subjects who did not attend for the 6 month visit agreed to complete the month 12 
visit. 
7.2 Demographic analysis 
I performed a comparison of the demographic data between subjects who 
completed the month 6 and month 12 visits with those who exited the study prior 
to these time points. 
7.2.1 Comparison at month 6 
In Table 7.2 I present a comparison of the demographic variables (age, serum 
HbA1c, serum cholesterol, systolic and diastolic blood pressure), best corrected 
visual acuity (BCVA) and contrast sensitivity (CS) between subjects who completed 
the month 6 visit and those who exited the study prior to the month 6 visit. For the 
subjects who exited the study I have separated the analysis between those who 
required treatment for their maculopathy (Treated) and those who no longer 
wanted to continue with the study (Withdrew).  
Between all three groups there were no significant differences in age, serum 
cholesterol, and systolic and diastolic BP at baseline (p>0.10 for all comparisons). 
There were significant differences between the groups for serum HbA1c (p<0.05), 
BCVA (p<0.01) and CS (p<0.01). Analysis was performed using ANOVA, with p<0.05 
deemed to be significant. Post-hoc comparison, using Sidak, was then performed to 
compare between the three groups. 
Subjects who received treatment prior to the month 6 visit had a significantly 
greater mean HbA1c at baseline than subjects who withdrew from the study but did 
not receive treatment (p<0.05); mean HbA1c was also increased compared to those 
who completed the study, though this was not significant (p>0.20) (Table 7.3). 
Subjects who were treated also had a significantly reduced BCVA (mean reduction 
of 9%, p<0.05) and CS (mean reduction of 13%, p<0.01) as compared to the other 
two groups. There was no significant difference between subjects who completed 
the study and those who withdrew but were not treated. 
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Table 7.2: Intergroup comparison of demographic variables at baseline between 
subjects who completed the study, those who were treated and those who were 
withdrawn without treatment prior to the month 6 visit. BP = blood pressure; BCVA 
= best corrected visual acuity; CS = contrast sensitivity; SD = standard deviation. 
*P<0.05 was deemed significant. 
 Variable Completed 
(n=39) 
Treated 
(n=15) 
Withdrew 
(n=35) 
P Value 
Mean age at baseline (years) 
(SD) 
57.5 
(10.6) 
51.7 
(11.7) 
56.8 
(14.1) 
0.29 
Mean serum HbA1c (%) (SD) 8.3 
(1.6) 
9.1 
(2.6) 
7.6 
(1.5) 
0.03* 
Mean serum cholesterol 
(mmol/L) (SD) 
4.5 
(1.1) 
4.6 
(1.1) 
4.6 
(1.1) 
0.82 
Mean systolic BP (mmHg) 
(SD) 
135.7 
(15.1) 
131.5 
(15.1) 
132.3 
(14.7) 
0.52 
Mean diastolic BP (mmHg) 
(SD) 
76.2 
(8.3) 
74.3 
(9.8) 
79.3 
(8.8) 
0.13 
Mean BCVA (letters) (SD) 84.7 
(6.7) 
77.2 
(8.6) 
84.4 
(9.4) 
<0.01* 
Mean CS (letters) (SD) 37.6 
(3.7) 
32.5 
(4.4) 
37.5 
(4.3) 
<0.01* 
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Table 7.3: Post-hoc sub-analysis of baseline demographic variables, using SIdak, of 
subjects who were treated prior to the month 6 visit compared to those who either 
completed the study or withdrew but did not receive treatment. CL = confidence 
limits. *P values <0.05 are deemed significant.  
 Treated Completed Withdrew 
 Mean value 
(SD) 
Range 
Mean 
difference 
(95% CL) 
P value Mean 
difference 
(95% CL) 
P value 
Serum 
HbA1c (%) 
9.1 
(1.6) 
6.4-13.7 
-0.7 
(-0.5, 2.0) 
>0.20 -1.4 
(-2.7, -0.1) 
<0.05* 
BCVA 
(letters) 
77.2 
(8.5) 
57-89 
7.5 
(1.5, 13.6) 
<0.01* 7.2 
(1.1, 13.4) 
<0.05* 
CS (letters) 32.5 
(4.4) 
24-39 
5.2 
(2.2, 8.2) 
<0.01* 5.0 
(1.9, 8.1) 
<0.01* 
 
Subjects who completed the study were not significantly different from those who 
withdrew with respect to their demographic variables. The significant difference 
was the poorer control of DM and reduced visual function in subjects who required 
treatment. This would suggest that any bias introduced by subjects being 
withdrawn could be small.  
7.2.2 Comparison at month 12 
In Table 7.4 I present a comparison of demographic variables between subjects who 
completed the study at month 12 and those who did not. Once again I have 
separated the group who did not complete the study into those requiring treatment 
and those who no longer wanted to continue. 
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Similar to the comparison at month 6, there were no significant differences in age, 
serum cholesterol and systolic and diastolic BP between the three groups, but there 
were differences between serum HbA1c, BCVA and CS. 
Table 7.4: Intergroup comparison of demographic variables at baseline between 
subjects who completed the study and those who were treated or withdrawn 
without treatment prior to the month 12 visit. BP = blood pressure; BCVA = best 
corrected visual acuity; CS = contrast sensitivity; SD = standard deviation. *P<0.05 
was deemed significant. 
Variable Completed 
(n=31) 
Treated 
(n=18) 
Withdrew 
(n=40) 
P Value 
Mean age (years) (SD) 59.3 
(11.8) 
52.0 
(10.6) 
55.8 
(13.0) 
0.13 
Mean serum HbA1c (%) 
(SD) 
8.4 
(1.6) 
9.0 
(2.2) 
7.7 
(1.5) 
0.02* 
Mean serum cholesterol 
(mmol/L) (SD) 
4.6 
(1.2) 
4.7 
(1.0) 
4.5 
(1.0) 
0.77 
Mean systolic BP 
(mmHg) (SD) 
136.0 
(15.9) 
130.7 
(14.8) 
133.2 
(14.3) 
0.47 
Mean diastolic BP 
(mmHg) (SD) 
74.7 
(8.7) 
75.7 
(9.9) 
79.6 
(8.0) 
0.06 
Mean BCVA (letters) 
(SD) 
85.5 
(6.6) 
79.1 
(9.0) 
83.6 
(9.2) 
0.04* 
Mean CS (letters) (SD) 38.0 
(3.9) 
33.6 
(4.9) 
37.1 
(4.1) 
<0.01* 
 
Post-hoc analysis, using Sidak, demonstrated no significant difference between 
subjects who completed the study and those who withdrew but did not receive 
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treatment (Table 7.5). As at month 6, subjects who were treated had a higher 
HbA1c than the other two groups, and this was significant compared to those who 
withdrew (14% higher in those treated, p<0.05). 
BCVA was significantly reduced in subjects treated compared to those who 
completed the study (reduction of 8%, p<0.05). CS was significantly reduced 
compared to those who completed the study (reduction of 13%, p<0.01) and those 
who withdrew but were not treated (reduction of 10%, p<0.02). 
Table 7.5: Post-hoc sub-analysis of baseline demographic variables, using SIdak, of 
subjects who were treated prior to the 12 month visit to those who either 
completed the study or withdrew but did not receive treatment. CL = confidence 
limits. *P values <0.05 are deemed significant and compare each group to those 
treated.  
 
 Treated Completed Withdrew 
 Mean value 
(SD) 
Range 
Mean 
difference 
(95% CL) 
P value Mean 
difference 
(95% CL) 
P value 
Serum 
HbA1c (%) 
9.0 
(2.2) 
5.6 – 13.7 
-0.5 
(-1.7, 0.7) 
0.68 -1.3 
(-2.4, -0.1) 
0.03* 
BCVA 
(letters) 
79.1 
(9.0) 
57 - 93 
6.4 
(0.4, 12.4) 
<0.04* 4.6 
(-1.2, 10.4) 
0.16 
CS (letters) 33.6 
(4.9) 
24 - 41 
4.4 
(1.4, 7.4) 
<0.01* 3.4 
(0.5, 6.4) 
<0.02* 
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In summary, there was no significant difference in systemic risk factors between 
subjects who completed the study and those who withdrew before the month 6 
and month 12 visits. This would suggest that any bias introduced by subjects falling 
out of the study by month 12 could be small. The only significant difference was 
between subjects who exited the study for treatment of their maculopathy and the 
subjects who withdrew or completed the study. The worse serum HbA1c, BCVA and 
CS are a reflection of poor control of DM that has resulted in development of 
maculopathy and our current clinical pathway in which decrease in visual function 
triggers the clinical decision to commence treatment.  
7.3 Longitudinal assessment of central macular function and structure 
In the following tables I present the longitudinal results of my study. Data are 
presented as means throughout. I have used the Wilcoxon nonparametric test due 
to the low number of subjects in each group. I have also used the paired Student t-
test to compare between subjects with early maculopathy and subjects with sight-
threatening maculopathy. This was done as there were similar numbers in each 
group and to consolidate the findings with the Wilcoxon test. 
In the tables I firstly present the results for the group as a whole, i.e. all subjects 
who completed the month 6 and month 12 visits. I have reported the mean baseline 
value and then the mean change from baseline. P < 0.01 was deemed significant for 
analyses of the five primary outcomes of microperimetry (MP) central ring 
sensitivity, multifocal electroretinogram (mfERG) central ring amplitude, mfERG 
implicit time (IT), oscillatory potential (OP) sum amplitude and OP IT following 
Bonferroni correction. P<0.05 was deemed significant for analyses of BCVA and CS.  
I have also reported the number of participants whose recordings have increased, 
decreased or stayed the same compared to the baseline value. This allows the 
reader to identify trends in change as well as identify outliers which may affect the 
overall mean. I then performed a sub-analysis of each group, reporting the results in 
the same manner as described above.    
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7.3.1 Best corrected visual acuity 
At month 6 there was no clinically meaningful change in mean BCVA (-0.5 letters) 
and this was statistically non-significant (p>0.20) (Table 7.5). Just as many subjects 
gained VA as compared to those who lost VA. Subgroup analysis revealed no 
clinically significant change in BCVA (-<1 letter) for both the early maculopathy and 
sight-threatening maculopathy groups, and this was not significant (p>0.20 for both 
comparisons).  
At month 12 the findings were very similar. There was no clinically meaningful 
change in BCVA (mean -0.4 letters) and this was not statistically significant (p≥0.50) 
(Table 7.5). Subgroup analysis revealed no clinically significant change in BCVA 
(mean -<1 letter) for both maculopathy groups though again this was not 
statistically significant (p>0.20 for both comparisons) 
7.3.2 Contrast sensitivity 
The results for Pelli-Robson contrast sensitivity performed with standardised visions 
by accredited optometrist observers are shown in Table 7.6.  
At month 6 there was a clinically insignificant change in CS (mean 0.2 letters) but 
this was not significant (p>0.50). Sub-group analysis revealed a clinically 
insignificant change in both maculopathy groups (mean <1 letter) but this was not 
significant (p>0.20 for both comparisons). 
At month 12 there was a clinically insignificant worsening in CS (mean -0.5 letters) 
but this was not significant (p>0.50). Sub-group analysis showed no particular 
pattern with slight improvement in the early maculopathy group (0.2 letters) but 
worsening in the sight-threatening maculopathy group (-0.7 letters). Both outcomes 
were clinically insignificant and the comparisons were not significant (p>0.20). 
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7.3.3 Microperimetry 
At month 6 there was a trend towards improved function across the whole group 
(p=0.02) (Table 7.7). Nearly two-thirds of subjects showed improved function 
(23/36, 64%). Sub-analysis revealed that each group showed improvement in 
function, though none of the groups demonstrated statistical significance, p>0.01 
for all comparisons. Subjects with sight-threatening maculopathy showed a greater 
mean improvement than subjects with early maculopathy (0.8 dB vs 0.3 dB).  
At month 12, mean sensitivity had significantly improved across the whole group 
(mean change of 1.7 dB, p<0.01) (Table 7.7). Over 80% (23/28) had shown an 
improvement in function. Sub-analysis revealed that each group showed an 
improvement. Subjects with sight-threatening maculopathy showed a significant 
mean improvement of 13% (1.9 dB, p<0.01). Subjects with early maculopathy 
showed a trend towards improved function of 10% (mean change of 1.6 dB, 
p=0.02). Paired t-test demonstrated similar p values. All but two of the sight-
threatening maculopathy group (11/13, 85%) and 75% (9/12) of the early 
maculopathy group showed an improvement.  
7.3.4 Multifocal electroretinogram central ring amplitude 
At month 6 there was a small but non-significant reduction in mean central ring 
amplitude in the whole group (mean -0.9 nV/deg2, p>0.20) (Table 7.8). This is 
reflected in that just over half (54%) showed improvement in amplitude whilst 46% 
showed worsening amplitude. Sub-group analysis revealed no specific pattern with 
a decrease in function in the early maculopathy group (mean change of -5.4 
nV/deg2, p>0.20) and a minimal improvement in the sight-threatening maculopathy 
group (mean change of 0.5 nV/deg2, p>0.50). Paired t-test was also non-significant 
(p>0.20 for all comparisons). 
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At month 12, amplitude worsened on average by 5.0 nV/deg2 though this was not 
statistically significant (p>0.10) (Table 7.8). Just under two-thirds of subjects 
showed a reduction in amplitude (20/31). Sub-group analysis revealed that all 
groups showed a mean reduction in amplitude though none of them reached 
statistical significance (p>0.10 for all comparisons). Decrease in amplitude was 
similar between the diabetic control (mean change of -8.3 nV/deg2, -15%) and the 
early maculopathy (mean change of -7.9 nV/deg2, -15%) groups. Subjects with sight-
threatening maculopathy showed a smaller reduction in amplitude (mean change 
of-3.3 nV/deg2, -7%). Paired t-test confirmed this reduction was statistically not 
significant (p>0.20 for all comparisons).  
7.3.5 Multifocal electroretinogram central ring implicit time 
At month 6, there was no change in mean mfERG implicit time (IT) in the group as a 
whole (mean 0.0 ms, p>0.50) (Table 7.9). Similar numbers of subjects showed either 
prolongation (36%) or improvement (43%) of implicit time. Sub-group analysis 
demonstrated prolongation in both the diabetic control group (mean change of 1.4 
ms, p>0.20) and the early maculopathy group (mean change of 0.9 ms, p>0.50), 
though none reached statistical significance. There was a mean improvement in 
implicit time in the sight-threatening maculopathy group, though this again did not 
reach statistical significance (mean change of -1.1 ms, p≥0.20). 
At month 12, there was an overall small increase in mfERG IT though this did not 
reach statistical significance (mean change of 0.4 ms, p>0.50) (Table 7.9). Just as 
many subjects showed prolongation of IT (42%) as those who showed an 
improvement (39%). Sub-group analysis showed a similar pattern to that at month 
6. Diabetic controls showed a small prolongation in IT (mean change of 0.4 ms, 
p>0.20), as did the early maculopathy group (mean change of 0.9 ms, p>0.20). 
There was an improvement in IT in the sight-threatening maculopathy group (mean 
change of -0.9 ms, p>0.50), though this did not reach statistical significance. 
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7.3.6 Oscillatory potential sum amplitude 
At month 6, there was an overall worsening of OP sum amplitude of 12%, though 
this did not reach statistical significance (mean change of -6.9 µV, p>0.10) (Table 
7.10). Just over half of subjects showed worsening amplitude (59%) with the rest 
showing an improvement. Sub-group analysis demonstrated worsening amplitude 
in all groups though none reached statistical significance. Early maculopathy group 
showed a mean worsening in amplitude of 22% (-14.9 µV, p>0.05). There was only a 
minimal worsening in amplitude of 2% in the sight-threatening maculopathy group 
(mean change of -0.8 µV, p>0.50).  
At month 12, there was a trend towards worsening amplitude of 11% for the whole 
group (mean change of -6.2 µV, p<0.05) (Table 7.10). Over two-thirds showed 
worsening amplitude (68%). Sub-group analysis revealed a similar worsening in 
amplitude of 9% and 10%, respectively, in both the early maculopathy (mean 
change of -5.6 µV, p>0.20) and the sight-threatening maculopathy group (mean 
change of -4.5 µV, p>0.05). The greatest decrease in function was seen in the 
diabetic control group with a mean reduction in function of 20% though this did not 
reach significance (mean change of -14.2 µV, p>0.20).Similar p values were seen in 
the paired t-test.  
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7.3.7 Oscillatory potential 1st peak implicit time 
At month 6 there was a minimal prolongation in OP IT which was statistically not 
significant (mean change of 0.1 ms, p>0.20) (Table 7.11). Over half (20/38) showed 
no change in their OP IT. Sub-group analysis revealed that all groups showed 
prolongation in OP IT though none reached statistical significance (p>0.20 for all 
comparisons). Both the early maculopathy group and the sight-threatening 
maculopathy group showed only a minimal prolongation of IT (mean change of 0.1 
ms). Diabetic controls showed the greatest prolongation (mean change of 0.6 ms). 
At month 12 there was an overall mean improvement in OP IT though this was not 
significant (-0.3 ms, p>0.50) (Table 7.11). Just as many subjects showed 
prolongation in IT (27%) as those who showed an improvement in it (23%), with half 
of all subjects demonstrating no change (15/30). Sub-group analysis revealed that 
the improvement in OP IT was driven by the early maculopathy group which 
showed a mean improvement of 1.0 ms, though this was not statistically significant 
(p>0.20).  The sight-threatening maculopathy group again showed a small 
prolongation in IT that was not statistically significant (mean change of 0.2 ms, 
p>0.50). Once again the greatest prolongation was in the diabetic control group, 
though this was not statistically significant (mean change of 0.8 ms, p>0.20). 
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7.3.8 Optical coherence tomography 
At month 6 there was an overall decrease in mean central subfield thickness (CSFT) 
though this was not significant (-11.1 µm, p>0.50) (Table 7.12). This decrease was 
predominantly driven by the sight-threatening maculopathy group, with a mean 
reduction in CSFT of 36 µm though this was not statistically significant (p>0.20). A 
non-statistically significant increase in CSFT was seen in both the diabetic control 
group (mean change of 6%, p>0.20) and the early maculopathy group (mean change 
of 4%, p>0.20). 
At month 12 there was an overall mean increase in CSFT of 8.2 µm though this was 
not statistically significant (p>0.50) (Table 6.12). Just over half of subjects (18/31) 
showed an increase in CSFT with the rest showing a decrease. Sub-group analysis 
demonstrated that increase in CSFT was seen in all groups though none reached 
statistical significance (p>0.20 for all comparisons). Diabetic controls had a mean 
increase of 2% in CSFT, early maculopathy group of 5%, and sight-threatening 
maculopathy group of 2%.  
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7.4 Correlating central macular function and structure 
I analysed the relation between OCT CSFT and central macular function to 
determine if change in thickness corresponded to change in function. I therefore 
performed a regression analysis using ANOVA to determine if there was any 
correlation (r) between change in CSFT and central macular function. P<0.05 was 
deemed significant. 
7.4.1 Microperimetry 
At both month 6 and month 12 there was no significant correlation between change 
in MP sensitivity and change in CSFT (p>0.10 for both comparisons) (Figure 7.2 a,b). 
At month 6 increased CSFT was non-significantly associated with improved MP 
sensitivity (r=0.11, p>0.50). At month 12 the trend was reversed with increasing 
CSFT non-significantly associated with decreasing MP sensitivity (r=-0.28, p>0.10). 
Figure 7.2: Analysis of mean change in CSFT (µm) compared to change in MP central 
ring sensitivity (dB) at a) month 6 and b) month 12. Data presented is of the group 
as a whole with the groups represented by different colours: blue = diabetic 
controls; green = early maculopathy; gold = sight-threatening maculopathy 
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7.4.2 Multifocal ERG central ring amplitude 
At both month 6 and month 12 there was no significant correlation between change 
in CSFT and mfERG central ring amplitude (p>0.20 for both comparisons) (Figure 7.3 
a,b). Non-significant improvement in amplitude was seen with increasing CSFT at 
both 6 months (r=0.09, p>0.50) and 12 months (r=0.21, p>0.20).  
Figure 7.3: Analysis of mean change in CSFT (µm) compared to change in mfERG 
central ring amplitude (nV/deg2) at a) month 6 and b) month 12. Data presented is 
of the group as a whole with the groups represented by different colours: blue = 
diabetic controls; green = early maculopathy; gold = sight-threatening maculopathy 
 
7.4.3 Multifocal ERG central ring implicit time 
There was no significant correlation between change in CSFT and change in mfERG 
central ring IT at both month 6 (r=-0.02, p>0.50) and month12 (r=-0.03, p>0.50) 
(Figure 7.4) 
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Figure 7.4: Analysis of mean change in CSFT (µm) compared to change in mfERG 
central ring implicit time (ms) at a) month 6 and b) month 12. Data presented is of 
the group as a whole with the groups represented by different colours: blue = 
diabetic controls; green = early maculopathy; gold = sight-threatening maculopathy 
 
 
7.4.4 Oscillatory potential sum amplitude 
There was no significant correlation between change in CSFT and change in OP sum 
amplitude at both month 6 and month 12 (Figure 7.5). At month 6, there was a non-
significant improvement in amplitude with increase in CSFT (r=0.20, p>0.20). At 12 
months there was no correlation at all (r=0.00, p>0.50). 
7.4.5 Oscillatory potential 1st peak implicit time 
There was no significant correlation between changes in CSFT and OP 1st peak IT 
(Figure 7.6). At month 6 improvement in OP IT was seen with increasing CSFT 
though this did not reach statistical significance (r=-0.27, p>0.10). A similar trend 
was seen at month 12 though once again this did not reach statistical significance 
(r=-0.22, p>0.20). 
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Figure 7.5: Analysis of mean change in CSFT (µm) compared to change in OP sum 
amplitude (µV) at a) month 6 and b) month 12. Data presented is of the group as a 
whole with the groups represented by different colours: blue = diabetic controls; 
green = early maculopathy; gold = sight-threatening maculopathy 
 
 
Figure 7.6: Analysis of mean change in CSFT (µm) compared to change in OP 1st 
peak implicit time (ms) at a) month 6 and b) month 12. Data presented is of the 
group as a whole with the groups represented by different colours: blue = diabetic 
controls; green = early maculopathy; gold = sight-threatening maculopathy 
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7.4.6 Best corrected visual acuity 
There was no statistically significant correlation between change in BCVA and 
change in CSFT at both month 6 and month 12 (Table 7.7). Non-significant 
improvement in BCVA was seen with increased CSFT at both month 6 (r=0.12, 
p>0.20) and month 12 (r=0.04, p>0.50) 
Figure 7.7: Analysis of mean change in CSFT (µm) compared to change in best 
corrected visual acuity (letters) at a) month 6; and b) month 12. Data presented is of 
the group as a whole with the groups represented by different colours: blue = 
diabetic controls; green = early maculopathy; gold = sight-threatening maculopathy 
 
 
7.4.7 Contrast sensitivity 
There was no statistically significant correlation between change in CSFT and 
change in CS (p>0.50 for both comparisons) (Figure 7.8). There was a non-significant 
improvement in CS with increasing CSFT at both month 6 (r=0.02, p>0.50) and 
month 12 (r=0.03, p>0.50). 
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Figure 7.8: Analysis of mean change in CSFT (µm) compared to change in contrast 
sensitivity (letters) at a) month 6; and b) month 12. Data presented is of the group 
as a whole with the groups represented by different colours: blue = diabetic 
controls; green = early maculopathy; gold = sight-threatening maculopathy 
 
7.5 Analysis of association and prognostic potential of central macular 
function  
In Chapter 6, I described and reported on predictive associations between central 
macular function and subjects with sight-threatening maculopathy. I used a similar 
approach to investigate prognostic associations of visual and central macular 
function could that may predict the requirement of treatment for diabetic 
maculopathy at both 6 months and 12 months.  
Of subjects with DM, 15 underwent treatment prior to the month 6 visit and a 
further three underwent treatment prior to the month 12 visit. The critical value for 
month 6 was calculated by determining the lower quartile of visual and macular 
function of the 15 subjects who underwent treatment plus the 39 subjects who 
completed month 6; for month 12, the critical value was determined by calculating 
the lower quartile of the 18 subjects who required treatment plus the 31 subjects 
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who completed the study. Association was calculated using the Fisher exact test; 
binomial confidence intervals were calculated using the Clopper-Pearson formula. 
The following indices were analysed: 
 Association: the significance that a subject with function worse than the critical 
value will require treatment 
 Sensitivity: the percentage of subjects requiring treatment that have function 
worse than the critical value 
 Specificity: the percentage of subjects who do not require treatment have 
function better than the critical value 
 Positive predictive value (PPV): the percentage of subjects with function worse 
than the critical value who require treatment 
 Negative predictive value (NPV): the percentage of subjects with function better 
than the critical value who do not require treatment 
In Tables 7.13 and 7.14 I present my results for month 6 and month 12, respectively. 
At month 6, there was a significant association between requirement for treatment 
and reduced function in BCVA, CS and MP. There was a trend towards reduced 
function using mfERG central ring amplitude.  
For functional measures that showed significant prognostic associations, sensitivity 
was fair (46.7-66.7%) and specificity was good (87.2-92.3%). There was a 
fair/moderate PPV (58.3-71.4%) and good NPV (81.0-83.7%). 
At month 12, only CS (p<0.01) and MP (p<0.03) remained significant and there was 
a trend towards reduced BCVA (p>0.05). None of the other investigations showed 
significance towards requirement for treatment (p>0.20 for all comparisons). 
For CS and MP, sensitivity was moderate (55.6% and 41.2%, respectively) and 
specificity was high (90.3% for both). Both PPV and NPV were moderate for both 
investigations (70.0-77.8 for all comparisons). 
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Table 7.13: Association of baseline visual and central macular function and subjects 
who subsequently required treatment for maculopathy by month 6. *p<0.05 
deemed significant. amp = amplitude; IT = implicit time; PPV = positive predictive 
value; NPV = negative predictive value. CI = confidence interval 
Investigation Critical 
value 
Association 
(p value) 
Sensitivity 
(%) 
(95% CI) 
Specificity 
(%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
BCVA 
(letters) 
≤79.0 <0.02* 46.7 
(21.3-73.4) 
87.2 
(72.6-95.7) 
58.3 
(27.7-84.8) 
81.0 
(65.9-91.4) 
CS (letters) ≤34.0 <0.01* 66.7 
(38.4-88.2) 
89.7 
(75.8-97.1) 
71.4 
(41.9-91.6) 
87.5 
(73.2-95.8) 
MP (dB) ≤12.6 <0.01* 50.0 
(23.0-77.0) 
92.3 
(79.1-98.4) 
70.0 
(34.8-93.3) 
83.7 
(69.3-93.2) 
mfERG amp 
(nV/deg2) 
≤34.1 0.06 42.9 
(17.7-71.1) 
84.6 
(69.5-94.1) 
50.0 
(21.1-78.9) 
80.5 
(65.1-91.2) 
mfERG IT 
(ms) 
≥41.2 1.00 28.6 
(8.4-58.1) 
71.8 
(55.1-85.0) 
27.3 
(7.8-55.1) 
73.7 
(56.9-86.6) 
OP sum amp 
(µV) 
≤38.2 0.18 46.2 
(19.2-74.9) 
74.4 
(57.9-87.0) 
37.5 
(15.2-64.6) 
80.6 
(64.0-91.8) 
OP IT (ms) ≥20.0 0.35 23.1 
(5.0-53.8) 
89.5 
(75.2-97.1) 
42.9 
(9.9-81.6) 
77.3 
(62.2-88.5) 
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Table 7.14: Association of visual and central macular function and subjects who 
subsequently required treatment for maculopathy by month 12. *p<0.05 deemed 
significant. amp = amplitude; IT = implicit time; PPV = positive predictive value; NPV 
= negative predictive value 
Investigation Critical 
value 
Association 
(p value) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV (%) 
BCVA 
(letters) 
≤79.0 0.07 38.9 
(17.3-64.3) 
87.1 
(70.2-96.4) 
63.6 
(30.8-89.1) 
71.1 
(54.1-84.6) 
CS (letters) ≤34.0 <0.01* 55.6 
(30.8-78.5) 
90.3 
(74.3-98.0) 
76.9 
(46.2-95.0) 
77.8 
(60.9-89.9) 
MP (dB) ≤12.6 <0.03* 41.2 
(18.4-67.1) 
90.3 
(74.3-98.0) 
70.0 
(34.8-93.3) 
73.7 
(56.9-86.6) 
mfERG amp 
(nV/deg2) 
≤34.1 0.30 35.3 
(14.2-61.7) 
80.6 
(62.5-92.6) 
50.0 
(21.1-78.9) 
69.4 
(51.9-83.7) 
mfERG IT 
(ms) 
≥41.2 1.00 29.4 
(10.3-56.0) 
71.0 
(52.0-85.8) 
35.7 
(12.8-64.9) 
64.7 
(46.5-80.3) 
OP sum amp 
(µV) 
≤38.2 0.35 43.8 
(19.8-70.1) 
71.0 
(52.0-85.8) 
43.8 
(19.8-70.1) 
71.0 
(52.0-85.8) 
OP IT (ms) ≥20.0 0.22 25.0 
(7.3-52.4) 
90.0 
(73.5-97.9) 
57.1 
(18.4-90.1) 
69.2 
(52.4-83.0) 
 
There have been no studies that have assessed the role of investigations of visual 
and central macular function in predicting the requirement for treatment as 
determined by a clinician. In my study, CS and MP central ring sensitivity may 
identify subjects who require treatment of their maculopathy at within both 6 and 
12 months, whilst BCVA may aid at 6 months. The other investigations of macular 
function have not been shown to be beneficial to identify those ‘at risk’. These 
findings are a reflection of current clinical practice in which reduction of visual 
 178 
 
acuity often prompts clinical treatment. The lack of significance with mfERG and OP 
may be due to the wide variations in amplitude and IT as described in Chapter 6. It 
is probable that there is a critical point in neuronal function beyond which 
microvasculopathy, and subsequently sight-threatening disease, develops. This may 
explain why subjects with early maculopathy showed a reduction in function in MP 
central ring sensitivity and mfERG amplitude (see Chapter 6) and all but one did not 
require treatment. 
As with the analysis of association for diagnosing sight-threatening maculopathy in 
Chapter 6, these results should be treated with caution. This study was not powered 
for such an analysis. In addition the short follow-up time and the use of local study 
protocols mean that the results may not applicable to determine predictability in 
the long-term and in a different cohort of patients, where the critical value may be 
different. 
7.5 Discussion 
7.5.1 Key results 
In this chapter the following statistically significant changes in visual function were 
seen in the group as a whole: 
 a 11% increase in MP central ring sensitivity at 12 months 
The following trends were seen in the group as a whole: 
 a 4% increase in MP central ring sensitivity at 6 months 
 a 11% decrease in OP sum amplitude at 12 months 
Sub-group analysis revealed the following significant changes in visual function: 
 a 13% increase in MP central ring sensitivity in the sight-threatening 
maculopathy group at 12 months 
Sub-group analysis revealed the following trends: 
 an increase in MP central ring sensitivity in sight-threatening maculopathy group 
at 6 months 
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 an increase in MP central ring sensitivity in early maculopathy group at 12 
months 
 a decrease in mfERG central ring amplitude across all groups at 12 months 
 a decrease in OP sum amplitude across all groups at 6 and 12 months 
Analysis of structure on OCT revealed no specific trend at 6 months, but there was 
an increase in thickness across all groups at 12 months. Change in CSFT was not 
significantly correlated to change in visual function. However increase in CSFT 
appeared to be non-significantly associated with improvement in visual function 
across all investigations apart from MP and OP sum amplitude at 12 months.  
CS and MP central ring sensitivity appeared to be prognostic for the requirement of 
treatment for maculopathy at both month 6 and month 12. BCVA appeared to be 
prognostic for requirement of treatment at month 6 but not month 12. 
7.5.2 Microperimetry 
In my study, there was an overall significant improvement in sensitivity of 1.7 dB 
(p<0.01) at month 12. There was an improvement in sensitivity at month 6, though 
this did not reach statistical significance (mean 0.6 dB, p<0.02). Sub analysis 
revealed that at month 12 there was a significant improvement in the sight-
threatening maculopathy group (mean 1.9 dB, p<0.01) and a trend towards 
improved sensitivity in the early maculopathy group (mean 1.6 dB, p<0.02). 
There has been one study that has assessed change in foveal sensitivity in subjects 
with DM. In a longitudinal study of 2 years, 25 subjects with DM and 20 healthy 
controls were assessed using BCVA, OCT and the Rarebit Fovea Test (RFT).215 The 
RFT records the success of detecting stimuli when fixating on a central fixation cross 
and is recorded as the mean hit rate (MHR). In this study MHR below 97% was 
recorded as subnormal and a test area that covered the central 4o of the macula 
was used. The authors reported that significantly more subjects with DM (12/25) 
stayed or became subnormal compared to healthy controls (2/20, p<0.01). One 
subject had mild maculopathy at baseline which had not altered clinically but there 
was a decrease in MHR and thinning on OCT. There was no significant difference in 
VA or OCT CSFT during the study. The authors also reported change in retinopathy 
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at four to six years from baseline with a third developing worsening; however there 
was no correlation to RFT at baseline.  
In my study subjects were followed up for only one year and we only analysed the 
central macula. The improvement in sensitivity probably reflects a learning effect 
and so a longer follow up would provide a more accurate reflection of longitudinal 
changes in retinal function. Also assessment of just the central macula may not 
accurately reflect changes in neuronal function, and analysis of the macula as a 
whole could be more beneficial. 
7.5.3 Multifocal electroretinogram 
In my study there was no significant difference in either amplitude or IT at both 
month 6 and month 12 for subjects with DM. There was an overall worsening in 
amplitude (mean -5.0 nV/deg2, p>0.10) at month 12 with all groups showing non-
significant worsening. There was a slight prolongation of IT at 12 month (mean 
0.4ms, p>0.50) though there was no specific pattern across the groups. 
Pescosolido et al (2015) stated that mfERG is beneficial in assessing early disease 
but is not suitable for follow-up studies, especially after treatment.216 This is due to 
wide inter- and intra-subject variability in mfERG, especially amplitude. They also 
state that structural assessments such as OCT and FA offer a more objective analysis 
of maculopathy progression. Other studies have stated that mfERG findings do not 
correlate with changes in retinal structure after treatment.217,218 
In my study I assessed change in central ring amplitude and IT over a year. However 
published literature has focused on development of vasculopathy in areas of 
reduced macular function and have not reported changes in actual values of these 
investigations.205,219 
In a study of 11 subjects with DR and 11 subjects without DR, mfERG IT was 
assessed to predict onset of development of DR.220 The authors utilised 103 
hexagons which were assessed for presence or absence of retinopathy and a Z-
score was determined for each hexagon. The authors reported that, over 1 year, 
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none of the subjects without DR developed DR and mfERG IT did not alter 
significantly. The authors concluded that retinal function remains stable over 1 year.   
In a further study by Han et al (2004)200 12 subjects with NPDR and 16 subjects with 
no DR were assessed over 1 year for development of new retinopathy. After 1 year, 
11/12 of the NPDR and 1/16 of the no DR groups developed new retinopathy. The 
authors performed a multivariate analysis using mfERG IT, duration of DM, presence 
of retinopathy and blood glucose level at baseline. The authors reported that this 
multivariate model had a sensitivity of 86% and specificity of 84%. However there 
was no report on development of maculopathy. 
Harrison et al (2011) assessed development of DR in 78 eyes of subjects with no DR 
over a mean follow up time of 3 years.221 Using a 103 hexagon array, the authors 
calculated 35 retinal zones and assigned a Z-score based on normative data. The 
authors reported that increased IT and reduced amplitude were more likely to 
develop macular oedema. The same group also reported that for every 0.9 ms 
increase in IT there was a 16% increased risk of developing retinopathy.147 The 
authors concluded that mfERG IT, after adjustment for confounders, is predictive 
for development of DR. However these findings were based on all macular loci 
whilst I focused on just the central macula. There was no quoted risk of developing 
macular oedema.  
Adams & Bearse Jr (2012) analysed 46 eyes of 23 patients over 2 years.222 They 
reported that only 5.2% of retinal zones and 35% of eyes developed DMO. Over half 
of these eyes developed CSMO. MfERG amplitude, IT, systolic blood pressure and 
gender were predictive for onset of DMO. Once again this study reported on all 35 
retinal zones of a 103 hexagon grid rather than just the central macula.   
In summary, mfERG amplitude in the central macula appeared to decrease over 12 
months in subjects with DM and there was a slight prolongation in IT. This may 
reflect ongoing neuronal disruption associated with DM though the significance of 
rate of such loss is yet to be established. Longer studies with a larger cohort are 
required to determine whether subjects with an increased rate of function loss are 
more likely to develop maculopathy.  
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7.5.4 Oscillatory potentials 
In my study, there was a trend towards an 11% reduction in OP sum amplitude over 
1 year (mean -6.2 µV, p=0.03). However there was no trend seen with IT. There was 
a 9-10% reduction in amplitude at 12 months for both the early and sight-
threatening maculopathy groups, though this was not significant (p>0.05). This 
suggests that OP function may decrease in the presence of maculopathy regardless 
of severity of disease. There are no previously published studies with which to 
compare these results. 
Like longitudinal studies of mfERG, studies in OP have been used to predict 
development of retinopathy. Vadala et al (2002) assessed OP amplitude in 80 
subjects with insulin-dependent DM and no DR over a period of 10 years.160 The 
authors reported that 35% of subjects developed DR. Of those who developed DR, 
less than half (46%) of subjects developed reduction in OP amplitude to subnormal 
levels; however decrease in OP amplitude was also noted in 25% of subjects in 
whom the fundi remained normal. Of those who developed retinopathy, 61% 
developed subnormal levels of amplitude prior to development of vasculopathy. 
However 39% developed reduced amplitudes concomitantly or after development 
of vasculopathy. The authors concluded that OP amplitude on its own may not 
predict onset of DR development.   
In summary, OP sum amplitude appears to decrease longitudinally in subjects with 
DM. With a similar finding in mfERG amplitude, this suggests continuing decline in 
neuronal function in the inner retina. It is possible that longitudinal assessment of 
both mfERG and OP amplitudes may aid in the identification of subjects at risk of 
developing diabetic maculopathy by determining rate of neuronal dysfunction. 
7.5.5 Contrast sensitivity 
In my study there was a clinically insignificant decrease in CS at 12 months (mean -
0.5 letters, p>0.50). There was no specific trend in subjects with maculopathy. 
There is no published literature with which to compare these findings. Therefore no 
specific conclusions can be drawn on the benefit of longitudinal assessment of CS in 
my cohort of subjects. 
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7.5.6 Subjects who received treatment 
Of the 87 subjects who completed the baseline visit, 15 (17%) underwent treatment 
for their maculopathy prior to the 6 month visit. A further three subjects underwent 
treatment for their maculopathy. Those who underwent treatment were found to 
have a higher HbA1c than those who had withdrawn from the study and those who 
had completed the study. In addition the treated group had worse BCVA and 
contrast sensitivity.  
The Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) has been 
described in Chapter 3. Important findings in the study included elevated HbA1c 
was associated with an increased risk of developing diabetic macular oedema and 
CSMO.69 The ACCORD Eye study also reported reduction in progression of DR in 
subjects treated with intensive glycaemic control.122 This fits in with our finding that 
those who received treatment had a greater HbA1c.  
There was no difference in serum cholesterol between those who were treated and 
those who were not treated. Zander et al (2000) reported that subjects with type 1 
DM, but not type 2, and maculopathy had significantly higher cholesterol levels.129 
The Early Treatment Diabetic Retinopathy Study (ETDRS) reported that subjects 
with elevated cholesterol were more likely to develop hard exudates and significant 
visual loss.119 The ACCORD Eye study and the FIELD study reported that subjects 
who received a lipid lowering agent demonstrated decreased rate of progression 
and reduced requirement for treatment of their maculopathy.122,123 However the 
United Kingdom Prospective Diabetes Study (UKPDS) demonstrated minimal benefit 
in development of microvascular complications following treatment of elevated 
serum cholesterol levels.125,134 
As with serum cholesterol, there was no significant difference in systolic and 
diastolic BP between those were treated and those who did not receive treatment. 
The UKPDS demonstrated that reduction in BP was associated with a reduced 
requirement for laser for maculopathy.125,134 However the ACCORD eye study 
demonstrated no significant difference in progression of retinopathy with intensive 
BP control.122 
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In my study, subjects who received treatment demonstrated no significant 
difference in BP or serum cholesterol. This could be because these subjects had 
worse systemic disease prior to entering the study and so had already received 
systemic treatment. All but one subject who received treatment had sight-
threatening maculopathy at baseline. In addition our baseline systemic findings may 
not accurately reflect prior systemic control. 
7.6 Limitations of the study 
Of the 89 subjects with DM recruited to the study, 61 (69%) were invited to follow 
up. Of these only 39 completed the 6 month visit and 31 completed the 12 month 
visit. The analyses performed above show that there was no significant difference in 
systemic risk factors between subjects who withdrew and those who completed the 
study at both 6 months and 12 months. This would have minimised any bias that 
may have been introduced by subjects being withdrawn. However the low number 
of subjects within each group makes comparisons within each group difficult. I will 
explore the reasons for low follow-up in Chapter 8 and how this may be addressed.  
Due to the short duration of follow up (12 months), the discrepancies in results of 
macular function may reflect the variations seen in the fluctuating appearance of 
retinal changes in diabetic retinopathy and maculopathy. A study of longer duration 
may better elucidate changes in function as more permanent microscopic and 
macroscopic changes in retinal structure take hold. 
No healthy controls were invited to take part in the longitudinal study. Therefore 
there is no comparison to determine whether longitudinal changes in function were 
due to DM alone. In future studies, the longitudinal assessment of healthy controls 
will be required to determine normative data for change in macular function 
longitudinally. This normative data could then be used to determine significance of 
rate in change in function in DM and other retinal conditions.  
In my study I focused on assessment of the central macula. My aim was to 
determine central macula function to identify risk of developing sight-threatening 
maculopathy. As a result I did not analyse a large portion of the macula. Analysing 
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the whole macula may provide a more comprehensive view of function, or 
dysfunction, in disease. 
There is wide variability in mfERG and OP recordings. Therefore, in small groups, 
any outliers are likely to make a significant change to mean values. For example, in 
the OP implicit time recordings, the early maculopathy group showed improvement 
at 12 months. That was because one subject showed an estimated improvement of 
8 ms compared to baseline.   
A recent study of 317 eyes of subjects with type 2 DM reported increased thickness 
of CSFT was significantly associated with an increased risk of developing clinical 
macular oedema.223 In addition, involvement of the inner and outer rings was 
associated with an increased risk of developing clinical macular oedema. The 
authors concluded that combining thickness of the outer and inner rings would 
offer a better characterisation of DMO. I did not analyse OCT CSFT with regards to 
risk of developing maculopathy. However, it may be likely that combining 
assessment of structure and function may offer a comprehensive way of predicting 
DMO formation.  
7.7 Summary 
In this chapter I have demonstrated that MP sensitivity appeared to improve 
longitudinally in the first year, especially in the sight-threatening maculopathy 
group. There appeared to be a trend towards reduction in mfERG and OP amplitude 
as this was seen in all groups, but no change in BCVA or CS, indicating possible 
progressive reduction in sub-clinical retinal function. The significance of rate of 
decrease in function is yet to be established. There does not appear to be any 
correlation between change in CSFT and central macular function. This may be due 
to different unknown mechanisms in action in which some subjects develop 
thinning of the retina whilst others develop thickening. Reduced function in MP 
retinal sensitivity and CS appear to be associated with need for treatment; this may 
reflect current clinical practice of treating subjects with visual dysfunction.  
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In Chapter 8 I will explore the role of investigations of macular function in the 
assessment, and their potential roles in their identification, of those at risk of 
developing diabetic maculopathy.    
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Chapter 8 Discussion 
Diabetes mellitus (DM) is a growing epidemic with diabetic eye disease, especially 
diabetic maculopathy, being a significant contributor to visual impairment. 
Screening programmes based around visible clinical findings have reduced, but not 
eliminated, the risk of developing visual impairment. Neuronal dysfunction of the 
macula in DM has been shown to occur prior to the development of 
microvasculopathy and has been studied in diabetic retinopathy (DR). My aim was 
to assess neuronal function, and dysfunction, to determine the role functional 
assessment of the central macula could play in determining severity of diabetic 
maculopathy.  In this chapter I explore the key results that I have described in 
Chapters 6 and 7 and I discuss the possible contributions of microperimetry (MP), 
multifocal electroretinography (mfERG), oscillatory potentials (OP) and contrast 
sensitivity (CS) to the management of diabetic maculopathy.  
8.1 Severity of maculopathy 
In my study, subjects with sight-threatening maculopathy showed significant 
reductions in central macular function across all parameters (mean visual acuity 
(VA), CS, MP, mfERG amplitude and implicit time, and OP). These associations were 
the main aim of my thesis and the study design was powered accordingly. I believe 
therefore that these biomarkers are valid for this population of patients. Subjects 
with early maculopathy showed trend reduction in function in some parameters 
(VA, CS, MP and mfERG amplitude).  
Measures of macular function other than BCVA are attractive as diagnostic 
biomarkers in early and moderate sight threatening maculopathy. In order for 
associations to be credible as diagnostic markers however a number of conditions 
need to be met including sufficiently high sensitivity, specificity, positive and 
negative predictive value and external validation.224 The sensitivities in my study 
were only moderate which can be explained by either them not having strong 
diagnostic potential or by the limited study size. Nonetheless my findings are 
biologically plausible and strengthen the research area. 
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The potential of the measures of macular function as diagnostic biomarkers could 
be strengthened with higher critical values. There may be a critical value for each 
type of function beyond which the likelihood of a subject having, or developing, 
sight-threatening maculopathy substantially increases. I selected a critical value 
based upon the lower quartile of all subjects with DM. The reason I used this cut-off 
was because there were no previous studies upon which to base a critical value. If I 
used a lower cut-off, for example 5%, this would have considerably reduced 
sensitivity and negative predictive value of each investigation. An alternative would 
be to base the critical value upon the healthy controls rather than subjects with DM. 
Critical values could be set at 10%, 20% and 50%. Sensitivity and specificity could 
then be calculated and the critical value associated with the highest sensitivity and 
specificity could be used for future studies. Another approach would be to set 
sensitivity to 80% and then calculate the critical value that leads to such sensitivity 
levels and calculate specificity and positive and negative predictive based on that. In 
my study I did not analyse sensitivity and specificity with outcomes adjusted for 
age; this would need to be performed in future studies. 
By identifying these critical values for each measure, it may be possible to stratify 
the risk of a subject developing diabetic macular oedema and/or ischaemic 
maculopathy. This risk stratification could have implications on follow-up, initiation 
of ophthalmic treatment and systemic treatment and form part of the 
individualised patient care which has become the new aim in healthcare. 
Another way of looking at the outcomes of each investigation of this study is the 
data presented in the boxplots in Chapter 6. In CS, MP and mfERG central ring 
amplitude and implicit time, one can see a small deterioration of function from 
diabetic controls to early maculopathy and then a steeper drop in function to sight-
threatening maculopathy. There may be a critical point at which a certain 
percentage of neurons are lost beyond which function deteriorates substantially. 
Through my study I have been unable to detect this critical point, though it is likely 
to be within the range of outcomes of subjects with early maculopathy as the 
greatest deterioration was between this and the sight-threatening maculopathy 
groups. In my study greatest mean reduction in function in the sight-threatening 
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maculopathy group was seen in mfERG amplitude compared to MP. Therefore, it is 
likely that mfERG amplitude could be more sensitive to picking up earlier 
deterioration in function and thus be useful in the detection of this critical point. 
8.2 Early maculopathy 
In my study, subjects with early maculopathy showed trends towards reduced 
function in the central macula for BCVA, CS, MP and mfERG amplitude compared to 
healthy controls. However these differences were not statistically significant and so 
it is difficult to determine the benefit of assessment of central macular function in 
early disease. 
Other studies have reported reduced function in early or no disease. However these 
studies have predominantly focused on assessment of the whole macula rather 
than the central macula. This suggests that in early disease analysis of the whole 
macula should be performed using functional assessments. Using a similar method 
described above, critical values based on outcomes of the whole macula could be 
determined. A threshold at the worst quartile (75%) could allow subjects with 
function worse than the critical value to undergo analysis of central macular 
function to determine severity of maculopathy.  This could lead to disease profiling 
or stratification to identify those at risk of developing visual impairment. 
Eventually, using the critical values, a chart or algorithm could be produced such 
that functional and structural outcomes could be combined with systemic risk 
factors to provide patients with an accurate risk of developing maculopathy and 
subsequently require treatment.  
8.3 Amplitude vs implicit time 
Amplitude represents strength of response to a stimulus while IT represents 
efficiency of response. In my study, amplitude in both mfERG and OP appeared to 
be more affected than IT in maculopathy.  As described in Chapter 3, several other 
studies have reported IT to be more sensitive than amplitude especially for mfERG. 
This discrepancy is likely due to differences in study protocol. As reported in 
Chapter 5 my study used a 19 hexagon array whilst most other previously published 
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studies used a 61 or 103 hexagon array to cover roughly the same area. Therefore 
each hexagon in my study covered a larger area of the macula and therefore 
generated greater amplitude compared to other studies. In addition, the central 
macula generates the greatest amplitude compared to other parts of the macula. 
Therefore, by focussing on the central macula, reduction in amplitude in disease is 
likely to be more meaningful using the 19 hexagon array. 
In my study mfERG IT appeared to be less sensitive than amplitude in assessing 
diabetic maculopathy and test of association was non-significant in the diagnosis of 
sight-threatening maculopathy. This is most likely due to my study protocol in which 
a stimulus is presented every 83.3 ms compared to 16.7 ms in other protocols. This 
delay in stimulus presentation allows the neurons time to repolarise to resting state 
and be ready for the next stimulus. Therefore, in early disease, any slight decrease 
in function may not be detected. Therefore, if decrease in IT is noted then there 
must be sufficient disease. 
However, these differences may also represent different structures of the retina 
being affected. Subjects with DMO show a wide variation of structural changes. It is 
therefore possible that different neuronal cells are affected and so there could be a 
variation in neuronal dysfunction between subjects with similar clinical diagnosis. 
By combining different assessments of macular structure and function, it may be 
possible to determine whether a subject has disease within a specific retinal layer or 
whether the whole retina is diseased.    
8.4 Oscillatory potentials 
OP sum amplitude was significantly reduced in sight-threatening maculopathy but 
not early maculopathy; for both groups there was no significant trend with OP IT. 
The reduction in function was less with OP than with mfERG. This may be because 
OP is an assessment of global retinal function. Therefore there would need to be 
significant retinal disease before reduced function is detected. This suggests OP 
would not be an adequate investigative tool for diabetic maculopathy. More 
recently, multifocal OP has been performed and shown to be useful in assessing 
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macular disease and may be an avenue to explore further in the analysis of diabetic 
maculopathy.  
8.5 Optical coherence tomography  
OCT has become an integral part of the assessment of diabetic maculopathy and 
monitoring response to treatment, often being used as a primary outcome. In my 
study, there was significant thickening in central subfield thickness (CSFT) in the 
sight-threatening maculopathy which is to be expected. There was no significant 
difference between healthy controls, diabetic controls and subjects with early 
maculopathy. This suggests that OCT CSFT is useful in more severe disease but not 
for early disease. However I only assessed the CSFT. Subjects with early 
maculopathy had features that did not meet the criteria for clinically significant 
macular oedema and so would have been outside the central subfield. This may 
explain why these subjects showed no significant changes. 
I did not correlate retinal function to CSFT, but there was no correlation between 
change in retinal function and change in CSFT in longitudinal analysis. Published 
studies have reported changes in OCT thickness in relation to maculopathy. 
However there appears to be some debate around what is abnormal. Some studies 
report retinal thinning to be indicative of DR whilst others have reported retinal 
thickening to be more indicative. The former is meant to represent neuronal loss 
whilst the latter represents microvascular leakage. Comparison of retinal function 
to retinal thickness has previously suggested that reduced function is associated 
with retinal thinning. In addition increased retinal thickness has been shown to be 
predictive of developing maculopathy. I recommend that both OCT and 
assessments of retinal function be used in analysis of maculopathy though more 
research is required in the correlation of function to thickness. 
8.6 Predicting disease progression 
Unfortunately my study showed no consistent trend in change in function over 12 
months with an improvement in MP but worsening of OP. This may be due to the 
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intra-subject variability in amplitude and IT that has been reported previously. 
Therefore change in function longitudinally may not be a useful approach. 
However there was an association between BCVA, CS and MP and requirement for 
treatment at 6 months, and between CS and MP and requirement for treatment at 
12 months. These outcomes reflect current clinical practice. Using the method 
previously described to determine critical values of each investigation, it was 
possible to determine likelihood of a subject requiring treatment over a set period 
of time. For example, in my study subjects with CS ≤34.0 letters at baseline had a 
76.9% likelihood of requiring treatment within 12 months.  
By altering the critical value using the method described above it may be possible to 
identify likelihood of requiring treatment based upon mfERG amplitude over 12 
months. However neuronal dysfunction is reported to appear before microvascular 
disease. Therefore, in my study, neuronal dysfunction was likely to be already 
established and so association was not significant. A higher critical value, for 
example 50% quartile, would be required and the subjects studied for longer to 
determine whether mfERG is useful for identifying likelihood of requiring treatment. 
8.7 Novel clinical endpoints 
The scientific community and the pharmaceutical industry are keen to develop new 
biomarkers and clinical endpoints as surrogates and/or predictors of vision 
impairment providing a more accurate and repeatable assessment of retinal 
function. Interventional studies in diabetic maculopathy currently use best 
corrected visual acuity (BCVA) as the primary outcome measure, driven primarily by 
the requirements of the regulatory agencies, especially the FDA. This reliance on 
BCVA to demonstrate clinical efficacy has hampered the development of several 
therapeutic options with notable examples of failed phase 3 studies from the 
DIRECT study and the PKCbeta therapy programme. BCVA is subjective and has 
reproducibility in various studies at best of +5.5 letters, and more typically of 
around 10 letters. 
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In my study, functional assessments appeared to be more severely affected in early/ 
moderate disease, even in subjects with unaffected BCVA. These assessments may 
offer a more objective measure of treatment response; the EUROCONDOR study 
has used mfERG as a primary efficacy measure rather than BCVA. Future studies 
could assess why some subjects respond well to treatment while others show no 
significant benefit. It may be possible that subjects who respond inadequately to 
treatment have severe neuronal dysfunction; therefore any further treatment may 
be unlikely to offer significant benefit. 
Preclinical detection of disease does carry certain disadvantages. There are likely to 
be false positives resulting in more referrals to specialist services, and so more 
demand on resources. The associated costs of increased testing may divert funding 
or resources from other clinical services; though it could be argued that there may 
be cost-savings through the potential prevention of significant visual impairment. 
Some patients with DM may undergo more frequent clinical appointments 
unnecessarily. It is likely that those with minimally reduced function may be 
subjected to unnecessary investigations and even treatments. False negatives may 
result in patients at risk of developing visual impairment being missed or not 
assessed appropriately. 
8.8 Multimodal imaging 
For my study I developed a method of comparing structural and functional 
assessments. Due to the use of different imaging and data recording platforms this 
was challenging. However such a method is required to obtain an accurate 
comparison between structure and function. This allows for interpretation of 
specific retinal loci to develop a more comprehensive picture of disease and 
monitor changes across each investigation. 
One disadvantage of combining several investigations is the extensive volume of 
data generated. This data can be overwhelming and therefore difficult to interpret. I 
focused on the central macula as I wanted to assess function in the region that is 
predominantly associated with visual function. As can be seen in Chapter 5, the MP 
grid was designed such that stimuli could be localised to specific hexagons of mfERG 
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and quadrants of OCT. It would therefore be possible to assess part or whole of the 
macula. However this time consuming process may be impractical in clinical practice 
using current technology. For an investigation to be clinically useful it has to have an 
easily generated outcome. One recommendation could be to assess part of the 
macula, for example the nasal macula in the first instance. The nasal macula has 
previously been shown to be susceptible in early diabetic retinopathy. Combining 
outcomes form the central and nasal macula may provide more data on macular 
function than just the central macula alone. Another concern of using larger 
amounts of data is the risk of dilution of outcomes. If a large area of the macula is 
analysed simultaneously, then any normal functioning retina included in the 
analysis would minimise the effect seen by the abnormal retina. Therefore subjects 
with abnormal central macular function may be mislabelled as normal.       
8.9 Recruitment and follow-up 
One limitation of my study was the time taken to recruit subjects to the study and 
the subsequent drop out during follow-up. The time taken to recruit meant that 
fewer subjects were invited to follow up and this weakened the longitudinal results. 
It also meant that follow up was limited to one year during analysis.  
I pre-screened over 280 subjects for this study. However many potential subjects 
declined to take part, citing multiple appointments, time constraints and ill-health 
as the main reasons. It is important to remember that DM is a systemic disorder 
that can be life-consuming for patients and carers. Therefore any study which 
requires multiple, long appointments may not appeal to the very people whom the 
study would offer most benefit.  
Once recruited, many subjects dropped out for similar reasons. To encourage 
continued participation I organised all investigations to be performed in one day 
and provided flexibility for study visits, such as allowing subjects to arrive later in 
the morning.  
Despite my best efforts, each study visit took a minimum of five hours, and usually 
took as long as six to seven hours. I would recommend that any study should 
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consider a maximum of four hours to avoid participant fatigue and reduce dropout 
rates. Ideally, if the study visit could be combined with a clinic visit then that would 
most likely encourage better participation. Limiting the number of investigations 
and using a shortened protocol would also help to speed up the day. Based on my 
results I would recommend contrast sensitivity, microperimetry and multifocal 
electroretinography to be incorporated within clinical assessment of diabetic 
maculopathy along with VA and OCT. In my experience through this study this was 
achievable within four hours though it would require someone to co-ordinate the 
process and ensure maximal utilisation of the investigations. 
It is still to be established how frequently these tests should be performed, though I 
would suspect no more than annually in clinical practice. As experience and 
understanding with these investigations improve the frequency of these tests could 
be altered depending on severity of ophthalmic and systemic disease.  
8.10 Concluding remarks and future studies 
Assessments of neuronal function, such as contrast sensitivity, multifocal 
electroretinography, microperimetry, and oscillatory potential, offer the clinician 
added information on severity of diabetic maculopathy, especially in the presence 
of central macular ischaemia. The outcomes of my study demonstrate a reduction 
in central macular function in sight-threatening maculopathy across all parameters 
and a trend towards reduced function in some parameters in presence of early 
maculopathy which is biologically plausible. Microperimetry and mfERG appear to 
be more sensitive in early maculopathy than OP. These findings add strength to 
existing data on mfERG and MP as well as provide novel findings of OP and CS in 
diabetic maculopathy. Exploratory analysis of diagnostic potential adds further 
strength to the role of tests of functional assessment as potential biomarkers and 
provides as an alternative to visual acuity for maculopathy analysis. I believe that 
my data, in conjunction with other published data, should allow for the design of 
clinical trials in which functional assessments could be used as primary outcomes to 
study disease progression or effect of an intervention.    
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Of the functional biomarkers assessed, I feel that MP and mfERG amplitude offer 
the best potential for diagnosis of diabetic maculopathy. MfERG is an objective 
assessment and so may offer more reliable recordings; however it requires greater 
resources (equipment, time, clinic space and personnel) than MP and so would not 
be practical in a clinical setting. MP is easier to perform and analyse and so could be 
more easily incorporated into clinical practice. In current clinical practice, MP could 
potentially offer further information in determining the need for treatment. 
However, this is a reflection of clinical judgment being based upon treatment of 
reduced visual function. MfERG and OP amplitude may potentially provide further 
information on sub-clinical progression and therefore identify need for treatment 
prior to development of visual impairment. However further studies are required to 
determine the difference between physiological and pathological change in retinal 
function longitudinally.   
My study is limited by exclusion of subjects with DR but no diabetic maculopathy. 
This group was excluded as our aim was to assess macular function with respect to 
diabetic maculopathy, rather than retinopathy, and to limit type 1 errors that may 
be seen with having a larger dataset.  In addition I focused on only the central 
macula and therefore excluded a substantial proportion of the macula in my 
analysis. Future studies should include subjects with DR but no diabetic 
maculopathy to determine effect of maculopathy itself on macular function. 
Analysis of the whole macula, and not just the central macula, should be performed 
to determine whether the extra information generated provides a more significant 
assessment of diabetic maculopathy. A longitudinal study of healthy controls should 
also be performed to develop normative data on change in function with which to 
compare.  
A study with a larger cohort and use of different thresholds to determine the critical 
values for each investigation may aid in risk stratification. I believe this is where 
assessments of macular function would offer most advantage in the management of 
diabetic maculopathy. 
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